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 Modeling and Simulation Approach to Characterize the Magnitude and Consistency of 
Drug Exposure using Sparse Concentration Sampling  
Yan Feng, PhD 
University of Pittsburgh, 2006
 
Population pharmacokinetic (PK) and pharmacodynamic (PD) modeling using a mixed effect 
modeling (MEM) approach has been widely used for various drug classes during development. 
The MEM approach provides a significant advantage when analyzing large scale clinical trials 
and special population where only a few samples are available per subject.   
 
The aims of this thesis are to explore the applications and advantages of MEM approach 
in the analysis of target populations (e.g., late-life depression, intensive care unit patients) from 
various aspects.  
1): To characterize the sources of variability and evaluate the impact of patients’ specific 
characteristics on SSRIs disposition using hyper-sparse concentration data. This study 
demonstrated that age and weight are significant covariates on citalopram clearance and volume 
of distribution. The age effect persists across the entire age range (22 to 93 years). Thus elderly 
subjects may need to receive different dose of citalopram based on their age. The other late-life 
depression study shows that weight and CYP2D6 polymorphisms significantly impact on 
maximal velocity (Vm) of paroxetine elimination. Thus, female and male subjects with different 
CYP2D6 genotypes may receive different dose based on their metabolizer genotype.  
2): To optimize a dosing strategy for general medical and intensive care unit (ICU) 
patients receiving enoxaparin by continuous intravenous infusion. The study suggests that dose 
should be individualized based on patients’ renal function and weight. It is also found that 
patients in the ICU tend to have higher exposure, thus should receive lower dose than those in 
the general medical unit. 
3): To evaluate the consistency of exposure using the deviation between model-predicted 
and observed concentrations (Cpred/Cobs ratio) and assess the stability and robustness of using 
 iv 
the ratio in reflecting erratic adherence patterns. The simulations demonstrate that ratio could be 
used as the indicator of the extreme adherence conditions for both long and short-half life drug.  
 
The knowledge gained in the thesis will contribute to the understanding the sources of 
variability in target population, including subjects specific characteristics, enzyme genetics and 
adherence, under conditions of highly sparse concentration sampling. This provides a basis 
whereby the magnitude and consistency of exposure can be examined in conjunction with the 
maintenance response of subjects in a future study as response data become available. 
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CHAPTER 1 INTRODUCTION 
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 1.1 OVERVIEW 
Pharmacokinetic (PK) studies aim to study the time course of absorption, distribution, 
metabolism and elimination of a drug, which is considered as ‘what the body does to the drug’.1-3 
Pharmacodynamic (PD) studies aim to study the time course of the drug concentration and link 
this to the time course of pharmacologic effects, which is considered as ‘what the drug does to 
the body’.4 An integration of the determined relationship of concentration-time (PK) and 
concentration-effect (PD) is generally used to predict the temporal pattern of drug’s 
pharmacologic effect and thus to optimize an effective dosage. It is commonly observed in the 
clinical studies that subjects receiving the same dose of a drug can respond differently, where 
some patients have ineffective therapy whereas some patients experience toxicity. The 
population approach is the analysis which attempts to understand PK/PD difference among 
population subgroups and attempt to determine and classify sources and hierarchies of variability.  
 
Population approach has been widely used in various drug classes during drug 
development, such as anticoagulants 5-8, anti-cancer drugs 9,  CNS drugs 10, 11 and antibacterial 
drugs12. The ultimate objective of a population analysis is to provide information that can be 
applied to develop guidelines for individualizing drug dosage regimens. Thus understanding the 
sources of variability and its impact on drug disposition is very important for rational drug 
pharmacotherapy in the target population. Moreover, increasing the magnitude of random 
variability may possibly cause decreased efficacy and safety of a drug.  
 
The sources of variability which influence the observed data can be categorized as 
measurable (fixed effect or attributable) and unobservable variability (random effect or non-
attributable) (Figure 1). Traditional PK approaches (e.g., Naïve pooled data (NPD) and standard 
two-stage (TS) analysis) used in population analysis, usually involves intensive sampling in 
small homogenous population (e.g., 6-12 healthy volunteers). NPD approach pools the data from 
all individuals neglecting the differences between individuals and fits an individual’s model for it. 
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The estimation of variability from NPD approach is typically overestimated since all sources of 
random variability (inter- and intra-individual variability) are pooled together. 13-15  Thus NPD 
analysis is unable to provide information that allows an adequate characterization of the sources 
of variability and its implication for drug therapy. Standard TS method is able to work fairly well 
in the situations where there is intensive data per individual. The random inter-individual 
variability from TS approach can be overestimated, which is related to both true biological 
variability and the uncertainty of the individual parameter estimate. 13, 14 However, this problem 
is unlikely to be important for the traditional well-defined PK study with intensive sampling 
measurements and a simple model structure. The other approach for population analysis is the 
mixed effect modeling (MEM) approach, which is ideally suited for analyzing data from large 
clinical trials (e.g., phase II and phase III study) and data from special populations (e.g., 
geriatrics, pediatrics and critical care unit patients), where only a few samples are available for 
each subject due to the ethical and/or medical concerns.10 The MEM approach can also be 
applied in combined data analysis, which can be used to stabilize the population analysis with 
prior information.16  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fixed effect  
(Biological variability) 
Random effect  
(Statistic variability) 
Sources of variability  
Measurable factors Unobserved factors 
Subject’s demographic 
condition (e.g., age, 
weight, sex, genetics); 
Concomitant medical 
information; disease 
status (e.g., renal 
function, hepatic 
disease) 
Inter-individual 
variability  
Residual error (e.g., 
intra-individual 
variability, measurement 
error, model 
misspecification) 
 
Figure 1: Sources of variability 
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Population PK analysis (mixed effect modeling approach) has many advantages over 
traditional PK approach.10 Unfortunately, the drug dosing history is often poorly recorded and 
the extent of non-adherence is usually underestimated, which leads to biased parameter estimates. 
17-23 In clinical trials, it is reported that the average adherence rate is only 43-78% among 
subjects receiving chronic treatment. 24, 25 There are many other similar terminologies used in the 
literature to describe adherence, such as compliance, concordance and alliance. 26, 27 In this thesis, 
adherence is defined in two ways: the percentage of prescribed doses taken and the percentage of 
days of therapy when the medication was taken appropriately. Thus we focus on the continuous 
middle “execution” phase of drug intake that concerns the pattern that occurs before the 
discontinuation phase.28 Adherence, a major concern for many chronic disease therapies (e.g., 
hypertension, diabetes and depression), is a widespread phenomenon causing decreased efficacy, 
relapse and recurrence during treatment.29, 30 Many studies have suggested that adherence is 
related to the clinical outcomes. 29-33  It is a challenging area of investigation for the clinical 
settings. A 100% reliable indirect measure for adherence doesn’t exist to date. Medication Event 
Monitoring System (MEMS)34 is a microprocessor-based method for continuous monitoring of 
adherence, which provides more accurate information than simple adherence measurement (e.g., 
self-report, direct interrogations, tablet estimates or prescription count). Adherence can also be 
measured by evaluating the stability of plasma level / dose (L/D) ratios. 30, 35 However, L/D ratio 
requires exquisitely precise timing of the last dose as well as the sample measurement. In the 
population PK analysis, the poorly recorded dosing history can cause biased estimation, which 
can mislead the decision making in clinical trials and drug pharmacotherapy.17-23 Utilization of a 
prior established PK model may allow one to utilize these biases by evaluating the deviation 
between the prior model predicted and the observed drug concentrations. The deviation may be 
used to infer consistency of drug exposure and the erratic consistency of exposure can be used to 
reflect the adherence patterns.  
 
The work discussed in the thesis explores the advantages of MEM approach in the 
analysis of sparse data sampling situation from several perspectives, including 1): the evaluation 
of the covariate effect on selective serotonin reuptake inhibitor (SSRI) disposition in late-life 
depression using highly sparse sampling measurement (Chapter 3 and 4); 2): the evaluation of 
the consistency of the exposure using the ratio of predicted versus observed concentrations, 
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which was then applied to reflect the erratic adherence pattern (Chapter 5); and 3): the dosage 
optimization using modeling and simulation approach for an anticoagulant drug (Chapter 2).   
 
In the following sections, the traditional PK analysis (Standard TS approach) and MEM 
approaches are discussed first, and then the advantages and disadvantages of the two methods are 
compared. After that, the base model development is discussed which shows how to select a base 
model and what constitutes the inter-individual variability. The covariate model development is 
discussed after the base model section, which include the criteria for covariate selection and 
formulation of covariate model. Different model validation and evaluation methods are then 
discussed. Finally, the model-based simulation is addressed. 
1.2 POPULATION ANALYSIS APPROACH 
Population PK analysis is able to obtain typical PK parameter estimates, and identify sources of 
and correlations of variability in plasma concentrations between individuals for a specific dose 
across a number of individuals.36 Population PKs is widely used in drug safety and efficacy 
evaluation. Population PK modeling can be done using different approaches, such as NPD, 
standard TS method, and a MEM approach.37, 38 In the section below, we are focusing on the 
standard TS approach and parametric MEM approach. 
 
1.2.1 Standard Two-Stage approach 
In the 1st stage, the individual PK parameters are calculated separately from a dense data 
set, using classical fitting procedures (e.g., Weighted Least Squares) as shown below.  
OBJ (Pi) = (C∑
=
n
i 1
obs j – Cpred j)2 × Wij     (1) 
Where Pi is the PK parameters for ith individual, Wij is the weight of jth observation in ith 
individual. The weighted least squares assume a heteroscedastic error structure, where the 
random error is assumed to be some function of the observed concentrations, such as Wij=1/Cobs j 
which assumes the variance is proportional to the concentrations. 
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In the 2nd stage, the population mean and standard deviation (SD) of the PK parameters 
are calculated for the study population. The relationship between the covariates and the PK 
parameters across subjects can be evaluated using regression analysis. The population parameters 
(mean and variance) across the subjects can be calculated as below: 
Arithmetic mean and variance: 
 Mean = ∑  P
=
n
i 1
j / N     (2) 
 Variance = ∑  (P
=
n
i 1
j –mean)2 / N    (3) 
The TS approach is simple and usually generates unbiased mean parameter estimates. 
However, the random inter-individual variability from TS approach can be overestimated, which 
is associated with both true biological variability and the uncertainty of the individual parameter 
estimate.13, 14 The traditional two-stage method requires intensive sampling measurements at 
appropriate time to obtain accurate parameter estimate in stage 1, and it is generally not 
applicable in the highly sparse data sampling situation (e.g., 1-2 sample per subject), since 
estimating the individual parameters is out of the question.  
 
1.2.2 The mixed effect modeling approach 
The MEM approach is a one stage analysis approach, which considers the population 
study sample, rather than the individual, as a unit of analysis for the estimation of the distribution 
of parameters and their relationship with covariates within the population. The word “mixed” 
refers that the method evaluates both fixed and random effects. 
The MEM approach is ideally suited for analyzing data from large clinical trials, where 
only a few samples are available for each subject.10 This technique identifies individual-specific 
characteristics that impact the disposition of a drug. In addition, the results are more 
generalizable than those of the traditional methodology because a greater number of subjects are 
evaluated.39 MEM can identify both individual specific and overall population PK parameters 
based on sparse data sampling, and use each data point to inform the entire analysis. 10, 38, 40 
In the population analysis, it is natural to fit the data into a hierarchical modeling 
structure, which allows the variability in concentrations to be separated into inter- and intra-
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individual variability. In the 1st stage, the data of a particular individual is modeled conditioned 
on individual parameters, and the relationships between individuals are modeled in the 2nd stage. 
The hierachical structure in the two stages is described below: 
 
1st Hierarchy:  
Each subject has a set of drug concentrations, and the predicted concentration (h1(θi, tij, 
di)) is defined as below: 
 Yij = H1(θi, tij, di)+εij                          (4) 
With εij independent and identically distributed as ε ~ N(0, σ2). Yij is the jth observed 
concentration in the ith individual; h1 is the functional form of PK model, h1(θi, tij, di) is the jth 
predicted concentrations in ith individual; di is the dosing history, including amount of dose and 
the time of administration for ith individual; θi is the value of the ith individual’s PK parameter. 
 
2nd Hierarchy:  
The model used in second stage is defined as below: 
θi = H2(µ, Covi)+ ηi                                     (5) 
With ηi independent and identically distributed as η ~ N(0, ω2). Covi represent the 
covariates for the ith individual and µ is the population parameter. The predicted values of PK 
parameters for the ith individual at time tij are defined by H1 in equation 4. H2 is a function, which 
describes the relationship between ith individual’s covariates and ith individuals’ PK parameters.  
 
Stages 1 and 2 of the hierarchy explicitly partition the variability in the observed data into 
two variance components. These are called intra- (sometimes also called residual unknown 
variability) and inter-individual variability. The objective of population modeling is to identify 
covariates which are responsible for between-individual variability and to quantify the remaining 
variability. 
 
1.2.2.1 Model definition 
The population PK model is a combination of three basic components:  
● The structural PK model component, which defines the PK parameters and describes the 
plasma concentration-time profile 
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● The statistical PK model component, which comprises both intra- and inter-individual 
variability. The residual error model component describes the underlying distribution of the error 
in the measured PK variable and the inter-individual error model component describes the inter-
individual variation in PK parameters after correction for fixed effects 
● The covariate model component, which describes the influence of fixed effects (i.e., 
demographic factors) on PK parameters 
The description for each model component is presented below. 
 
1.2.2.1.1 Base model development 
Structure of the PK model 
The structure of the PK model represents the best description of the data without 
considering the effect of subject’s specific covariates. Structural PK models usually are 
expressed by using primary PK parameters such as clearance (CL) and volume of distribution (V) 
rather than rate constants, which can generate primary PK parameters in combination forms. 
Using primary PK parameters allows us to assess the impact of covariate on these parameters 
e.g., age, weight, sex, race or genotypes which may alter plasma concentration. The two-
compartment linear model with oral administration is shown below: 
 
 
 
 
 
 
Ka 
Depot 
Compartment 
Central 
Compartment 
Peripheral 
Compartment 
Q 
CL 
 
Figure 2 General form of the two-compartment model  
 
In the diagram above, Ka is the absorption rate constant, Q is the inter-compartment 
clearance, and CL is the oral clearance. The mass balance equations are given by: 
1
1 AKa
dt
dA ×−=       (6) 
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33
2
2
1
2 )(
V
AQ
V
AQCLAKa
dt
dA ×+×+−×=    (7) 
3
3
2
23
V
AQ
V
AQ
dt
dA ×−×=      (8) 
Where V2 is the volume of the central compartment, V3 is the volume of the peripheral 
compartment, A2 is the amount of drug in central compartment and A3 is the amount of drug in 
peripheral compartment. Equation and model above describes a linear PK drug, where AUC is 
proportional to dose and clearance is a constant regardless of drug concentrations.  
If AUC of a drug is non-linear by dose group e.g., paroxetine, clearance changes with 
concentration. The structural model should be reflected by a non-linear model, where the typical 
values such as Vmax and Km should be evaluated. The Michaelis - Menten equation is applied 
for clearance estimation in a non-linear model as shown below: 
2
2
max
V
AKm
VCL
+
=       (9) 
Where Vmax is the maximum rate, Km is the Michaelis - Menten constant, which is 
equal to substrate concentration at half of the maximal velocity. 
 
Inter-individual variability 
In this model component, the individual parameter estimates are modeled as a function of 
typical value for the population and individual random deviations. The inter-individual 
variability of the PK parameters can be described as below: 
Exponential:  CL= TVCL × EXP(ETACL)             (10) 
Additive:  CL= TVCL + ETACL                      (11) 
Proportional:  CL = TVCL ×(1 + ETACL)             (12) 
Where, TVCL is the typical value of clearance for the population; CL is the individual 
parameter estimate; ETACL is the inter-individual variability term on CL, representing the 
difference between the individual parameter estimate and the population mean. The random 
effects of inter-individual variability are assumed normally distributed, with a mean of zero and 
 9 
variance of ω2. In the exponential form, the distribution of parameter is skewed to the right 
which is commonly observed for the PK parameter distribution.    
 
Intra-individual variability 
The difference between the predicted concentration and observed concentrations is 
defined as residual variability, which is comprised of but not limited to intra-individual 
variability, experimental errors, and process noise and / or model misspecifications. It can be 
modeled using additive, proportional and combined error structure as described below: 
Additive error: ijijij yy ε+= ˆ       (13) 
Proportional error: )1(ˆ ijijij yy ε+×=     (14) 
Combined additive and proportional error: ')1(ˆ ijijijij yy εε ++×=  (15) 
Where  is the jijy
th observation in the ith individual,  is the corresponding model 
prediction, and 
ijyˆ
ijε  (or 'ijε ) is a normally distributed random error with a mean of zero and a 
variance of σ2.  
The additive error (constant absolute error) model is applied when the variance is 
assumed to have a constant absolute magnitude and independent for all measurements. The 
proportional error (constant coefficient of variation error) model is applied when the 
measurements to be modeled have heteroscedastic property and the error represents a constant 
proportion of the observed data. In the case of PK concentrations, where wide range of 
concentrations is measured, the error in measurement based on the analytical method is usually a 
combination of additive and proportional error. Use of a combined error model would improve 
predictions at lower limit of assay precision where variance may be assumed a constant and a 
proportional error model at higher concentration range. 
 
1.2.2.1.2 Covariate model development 
An important objective of a population PK analysis is to identify the sources of variability 
from observable covariates and their correlation with the individual PK parameters, which can 
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explain part of the inter-individual variability besides the part which has been explained by 
random effect in the base model. As mentioned in the overview section, many factors in the 
biological system can potentially contribute to variability such as age, sex, weight, renal function, 
polymorphic enzymes and concomitant medication. Quantitative assessment of the relationship 
between covariates and PK parameters is important for drug development because it provides 
information on whether the special dosage is necessary for a subgroup of patients.  
 
Covariate identification and its selection criteria - The effect of subjects’ specific covariates 
e.g., age, weight, and gender is tested on PK parameter during the final model development. The 
covariate models can be developed by a forward inclusion / backward elimination using the 
likelihood ratio test. Covariates that are significant at the 0.05 level are retained in the model (χ2, 
∆OFV=-3.84, df=1). Once all the covariates that are significant at the 0.05 level have been 
included in the model, a backward elimination process is conducted. A significant level of 0.01 is 
used for the backward elimination (∆OFV=-6.63, df=1). The backward elimination process is 
repeated until all remaining covariates are significant (p<0.01). Covariate influence on inter-
individual variability and goodness of fit is also examined. Covariate factors should also have 
clinical or physiological relevance. Thus, if the magnitude of covariate effects if less than 20% of 
the parameter estimates for the typical subjects, the covariates may not be considered clinically 
relevant and may not be included into final model despite reductions in the objective function 
value (OFV).6  
 
Incorporation of covariate - The covariates can usually be classified as continuous covariate like 
age, weight, height and discrete covariates include: sex, race, and enzyme genotypes. 
These two types of covariates can be incorporated into the model as described below:  
   
Example for continuous covariate 
The incorporation of a continuous covariate for the parameter CL: 
    (16) CovCovCL MedCovTVCL
θθ )/(+=
    (17) CovCovCL MedCovTVCL
θθ )/(×=
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 ))(1( CovMedTVCL CovCovCL −×+×= θθ   (18) 
CL = TVCL × EXP(ETACL)                           (19) 
where TVCL is the population estimate of CL for individuals having a specific covariate; 
θCL is the population estimate for CL without a covariate effect; Cov is the continuous covariate 
that is affecting CL; θCov is constant describing association between covariate and typical value of 
parameter estimates; and MedCov is the median value of Cov; CL is the individual estimate of 
clearance, which is the population estimate for clearance incorporating the covariate and inter-
individual variability; ETACL is the inter-individual variability term for CL. 
 
Example for discrete covariate 
The incorporation of a discrete covariate involves assigning a numeric value to the 
covariate (e.g., sex, male = 0, female = 1). The equations below show sex as a discrete covariate 
in an exponential, a proportional, and an additive form respectively on the parameter CL.   
TVCL = θCL + Sex × EXP(θSex)   (20) 
TVCL = θCL × (1+Sex × θSex )   (21) 
TVCL = θCL +  Sex × θSex    (22) 
 CL = TVCL × EXP(ETACL)    (23) 
When sex is male, TVCL equals θCL since numeric value for male = 0 causing a zero 
multiplier for the covariate effect. For female, the θSex term is added to the population estimate of 
CL to modify it.  
 
If discrete covariate had more than two groups, for example the categorical variables are 
assigned to each of the three CYP2D6 phenotype groups (i.e, Poor metabolizers (PMs) = 1, 
Intermediate metabolizers (IMs)  =2, Extensive metabolizers (EMs) = 3), the incorporation of this 
covariate is shown below:  
IF (PHENOTYPE.EQ.1) TVCL= θPMs  (24) 
IF (PHENOTYPE.EQ.2) TVCL= θIMs  (25) 
IF (PHENOTYPE.EQ.3) TVCL= θEMs  (26) 
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Missing covariate value - In subjects without a recorded covariate value, it is better to 
impute the missing covariate values for these subjects than to exclude them from analysis which 
will decrease the sample size and lose information. The simple imputation approach can be 
applied, including mean estimation and predicting missing values from regression. Mean 
estimation method is to replace missing data with the median or mean covariate value calculated 
from non-missing subjects in the population dataset. To predict missing values from regression is 
to impute each independent variable on the basis of other independent variables in model using 
regression analysis. Simple imputation does not reflect the uncertainty about the predictions of 
the missing data, thus the standard deviation and standard errors are underestimated since there is 
no variation in the imputed values.41 The other attractive method is multiple imputation (MI) 
approach proposed by Rubin, which replaced each missing data with a set of plausible values 
with representation of the uncertainty about the right value to impute. 42, 43   MI requires the 
assumption of independency and missing at random, meaning that the probability that some data 
are missing does not depend on the actual values of the missing data, or missing completely at 
random, meaning the probability of an observation being missing does not depend on observed 
or unobserved measurements. The basic process of MI include: 1): impute missing values using 
an appropriate model that incorporates random variation; 2): do this m times, which produce m 
complete data sets; 3): analyse the m complete data sets using standard methods, e.g., 
Expectation Maximization method and Markov Chain Monte Carlo method; 4): combine the 
results from the m complete data sets and the point estimates from the MI and the standard errors 
can be calculated as below:  
Point estimate: 
∑
=
=
m
i
jQm
Q
1
1       (27) 
The variance estimate: (Total variance = within variance + between variance) 
⎥⎦
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Where m is the number of sets imputed and analyzed, Qi is the estimate from analyzing the ith 
data set, and vi is the variance estimate from analyzing the ith data set. The advantages of MI are 
that it introduces random error into the imputation process which reduces the probability of 
introducing biased estimate of all parameters than that in simple imputation method 
(deterministic imputation), it also allows one to obtain good estimates of the standard errors. 
However, there are often strong reasons to suspect that the data are not missing at random, where 
even accounting for all the available observed information, the reason for observations being 
missing still depends on the unseen observations themselves. 
 
In summary, the intra-subject model and the inter-subject model specifications together 
complete the model formulation for the population analysis with the non-linear mixed effects 
modeling approach.  
 
1.2.3. Estimation method and software 
Objective function and likelihood - The best model should provide the best model fit 
across all subjects through fitting. These ‘best’ parameter estimates in the model are typically 
obtained by minimizing or maximizing some objective function (OBJ), such as ordinary least 
squares, weighted least squares and extended least squares. The objective functions are shown 
below: 
Ordinary Least Squares:    (29) ∑
=
−=
n
i
edObs ii
YYOBJ
1
2
Pr )(
Weighted Least Squares: [ ]∑
=
×−=
n
i
iedObs WYYOBJ ii
1
2
Pr )(   (30) 
Extended Least Squares: ∑
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 (31) 
 
Where vari models the variance of the observation, Yobs i are the observed concentrations 
and Ypred i are the predicted concentrations. W is the weight which reflects the relative 
uncertainty attached to the individual estimate. The extended least square is designated as a 
maximum likelihood if the random effects assume to be normally distributed. 
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The objective function quantifies the difference between observed and predicted data for 
a given parameter set. The estimation method commonly used in nonlinear mixed effect 
modeling is the maximum likelihood approach, which is an alternative of the least square 
objective function (extended least squares). In the nonlinear mixed effect modeling, all the 
parameters are estimated simultaneously. The likelihood for the population parameters are shown 
below:  
})](  ,[{) ,(
1
∏
=
==
N
i
ii xParameterModelypModelYFL  (32) 
Where L is likelihood, F represents some function of the observations and the model, and 
p is the probability of observation occurs at a given parameter set.  
The likelihood is the product of probabilities for each individual observation (i) to occur, 
given the respective model and parameters. Since the parameters are selected to maximize the 
probability, the greater the likelihood of the model means the large the probability of the 
dependent variable to occur, therefore, the better the model describes the data.  
 
Software - All software alternatives and approaches are based on the hierarchical 
nonlinear mixed effect modeling methods described above. The programs can be categorized 
into three groups: parametric maximum likelihood, nonparametric maximum likelihood and 
Bayesian. The programs using parametric methods are NONMEM, NLME in S-plus, 
WinNonMix, Kinetica 2000, MCPEM in S-ADAPT (a version of ADAPT II) and NLINMIX in 
SAS. The programs using nonparametric methods are NPML, NPEM and NLMIX. The 
difference between non-parametric and parametric method is that parametric approach has the 
assumption of specific distribution of the random effect. The programs using Bayesian 
approaches include BUGS/WinBUGS, and JAGS (Just Another Gibbs Sampler), which require 
the specification prior and hyper-prior information of the parameter in the estimation. The 
computer program NONMEM® developed by Beal and Sheiner in 1980 at UCSF is the first 
computer program available for sparse data analysis in a PK setting and has been widely used in 
population analysis. The NONMEM software is used as the analysis platform in all population 
PK analyses in the thesis projects and is also the focus in the following sections. 
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Estimation in NONMEM – In the compartment model, the flow between compartments 
can be defined by a series of linear differential equations, which yields a concentration time 
model as described in stage 1 of H1 (equation 4), a nonlinear function with unknown parameter. 
Due to the nonlinear dependency of the observations on the random variability of the η and ε, the 
integrals in likelihood cannot be evaluated analytically. Therefore, some form of approximation 
is needed.  
 
In NONMEM, the first order (FO) method estimates the typical value for each parameter, 
ω2 and σ2. FO method linearizes nonlinear model via a first order Taylor series expansion and is 
evaluated at the expected value of the random effects at 0. The detailed description about the 
approximation for FO method has been reported.44 The FO method provides the population 
parameter estimates. The individual parameter estimates can be obtained using the POSTHOC 
option in NONMEM program using empirical Bayes methods to estimate η values for each 
individual. The first-order conditional method (FOCE) method is more time consuming than 
using FO method, because the individual estimate are determined for every iteration of the 
regression. The FOCE method also linearizes the nonlinear model via a first order Taylor series 
expansion about the value of individual η (with the assumption that the eta is not very different 
from zero but is potentially non-zero) instead of 0. 45, 46 The FOCE with interaction (FOCEI) 
option in NONMEM assumes the interaction between η and ε. FOCEI differs from FOCE 
without interaction, which assumes the homoscedastic intra-individual variability across 
individuals. Applying FOCE and FOCEI methods are more time consuming for computation 
than that of FO method, but these methods have a more accurate approximation to the likelihood 
than the FO method. The Laplacian method uses a second-order Taylor series expansion about 
the η values. In the higher nonlinear model e.g., Emax model, logistic model, using Laplacian 
method can obtain more accurate parameter estimates than that of FOCE method. 45 
 
1.2.4. Model building criteria 
The adequacy of the developed structure models is evaluated using both statistical and 
graphical methods. The likelihood ratio test is used to discriminate between alternative (nested) 
models. The likelihood ratio test is based on the property that the ratio of the NONMEM 
objective function values (-2 log-likelihood) is asymptotically χ2 distributed. A reduction of the 
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objective function by 3.84 units is considered significant (χ2 P<0.05 df=1). For comparison 
between non-nested models, the Akaike Information Criterion (AIC) can be applied, 47 which is 
AIC equals to objective function value plus 2 times the number of parameters. 
 
1.2.5. Model evaluation 
Model validation/evaluation aims to determine whether the model is a good description 
of the validation data set. The model validation approach can be different based on the objective 
of the population analysis and the question that needs to be addressed. Not all population models 
need to be validated. Model validation can be classified as internal (e.g., bootstrap, data splitting 
and cross validation) and external (e.g., data from new studies) validation based on the sources of 
the data applied for validation.  
External validation is the most stringent type of validation. However, it needs external 
data from the new study, which is usually not available in most situations. Internal validation 
methods are commonly used, which rely on the analysis of the subsets from the total data with 
the majority of data used in model building. Data splitting method involves randomly dividing 
data into an index data set and a test data set, where the index data set (e.g., 2/3 of the original 
data set) is used to develop the model and the test data set (e.g., 1/3 of the original data set) is 
used to evaluate the model performance. Cross over validation method is a ‘leave-one-out’ or 
‘leave-some-out’ validation approach. Data is divided into m subsets. Fit the models from m-1 
data set and each of the m-1 estimation subsets is used to predict the unused subset. The mean 
prediction error (Ypred – Y obs) calculated for each of these m models is used as measure of 
accuracy and mean absolute prediction error is used for precision measurement.  Bootstrap 
analysis 48 is a widely used internal validation approach. It is a re-sampling methodology that 
provides a nonparametric assessment of the variances and confidence intervals without requiring 
asymptotic assumption on the distribution of parameters. This is a general technique for 
estimating sampling distribution. New “virtual” datasets are created by selecting patients at 
random. The model is re-run or parameters re-estimated for each of these datasets (e.g., 1000 
times). The results provide a good measure of model stability, confidence intervals, variances 
and parameter distributions. The characteristics of the confidence intervals reflect how well or 
how poorly the model captured the parameters given the available dataset. The other model 
evaluation method is predictive performance check. It is based on comparing meaningful 
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statistics of observed data, with corresponding statistics calculated from data simulated under a 
model. Statistics of the data which are meaningful depend on the objectives of the modeling 
analysis and are specified as a prior. Briefly, empirical distributions of these statistics under a 
model are constructed from data generated by Monto Carlo simulation. The validity of a model is 
assessed by determining the probability of obtaining the value of a statistic calculated from 
observed data given the simulated empirical distribution of the statistic. 49 
 
1.3 MODEL-BASED SIMULATION 
Simulation has been widely used in various areas, such as engineering, economics, marketing 
and statistics. In the field of drug development, model-based simulation approach has been 
shown to be a very useful tool to facilitate dose selection by evaluating and understanding the 
consequences of different study designs.6, 7 50 Simulation reveals the effect of input variables and 
assumptions on the results of a planned population analysis. Monte Carlo simulation is a widely 
used simulation approach.51-53 The ultimate objective for a simulation study is to determine the 
factors affected the virtual subjects’ response and thus provide the related information to the new 
clinical trial design. The beauty of a clinical trial simulation is to test various assumptions and 
hypotheses based on the prior information obtained from the previous studies, before conducting 
a real study. For example, simulation can be used to address the question on what would the 
‘best dose’ for target population if the random variability is reduced by 50% after formulation 
modification, what is the efficacy/safety outcome would possibly look like if subjects receive 
half of the recommended dose, or if they receive two times the recommended dose. Except for 
the advantages discussed above, simulated data lacks the complexity of real data generated by 
clinical trials. Covariate data is hard to mimic through simulation, especially for time-varying 
covariates. 
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1.4 OBJECTIVES OF THE THESIS 
The thesis explores the usefulness of MEM approach in several aspects for the clinical studies 
under sparse data sampling situation, including 1): the evaluation of the covariate effects on 
SSRIs disposition in the late-life depression using highly sparse sampling measurement (Chapter 
3 and 4); 2): the assessment of the deviation between the model-predicted and observed 
concentrations (Cpred/Cobs and Cipred/Cobs) in reflecting the erratic adherence patterns 
(Chapter 5); and 3): the dosage optimization using modeling and simulation approach in 
anticoagulant drug where a dynamic marker is measured (Chapter 2). The aims for each study 
are described below: 
 
Chapter 2: To determine an appropriate dosage for patients receiving continuous 
intravenous infusion of enoxaparin  
● To describe the PK for subjects administrated enoxaparin by continuous intravenous 
infusion using population analysis 
● To optimize a dosage strategy for subjects receiving CII enoxaparin using model-based 
simulation approach 
 
Chapter 3: To assess covariate affecting exposure to drug with linear PK characteristics 
given highly sparse sampling measurements  
● To describe PK parameters of selective serotonin reuptake inhibitor (citalopram) with 
linear PK characteristics using highly sparse sampling measurements in a depressed population  
● To evaluate the impact of covariates, including age, weight, race, and sex on citalopram 
PK parameters in late-life depression 
 
Chapter 4: To assess CYP2D6 genotype effects on PK of a drug with nonlinear 
pharmacokinetic characteristics  
● To describe PK parameters of selective serotonin reuptake inhibitor (paroxetine) with 
nonlinear PK characteristics using limited sampling measurements in late-life depression  
● To evaluate the impact of covariates, including CYP2D6 genotypes, race, age, sex, 
weight, on paroxetine PK parameters in late-life depression 
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.  
Chapter 5: To identify erratic adherence pattern by evaluating the consistency of drug 
exposure using a simulation approach 
● To evaluate the overall distribution of the deviation between model predicted and 
observed concentrations (Cpred/Cobs and Cipred/Cobs ratio) across the adherence patterns (high 
adherence rates to extremely low adherence rates) for both long and short half-life drugs under 
the situation when the subjects’ correct dosing history (negative control) and when the incorrect 
dosing history (positive control) is applied in population analysis  
● To evaluate the association between ratio and the rate under positive control 
● To evaluate the bias and precision of parameter estimates under negative and positive 
controls 
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CHAPTER 2 OPTIMIZATION OF DOSE SELECTION USING BIOMARKER 
RESPONSE WITH SPARSE DATA 
 
 
 
 
 
 
 
 
 
This chapter is based on the following paper: 
Yan Feng, Bruce Green, Stephen B. Duffull, Sandra L. Kane, Mary B. Bobek, Robert. R. Bies. 
Development of a dosage strategy in patients receiving enoxaparin by Continuous Intravenous Infusion 
using modeling and simulation. British Journal of Clinical Pharmacology. 2006  
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Abstract 
Objective: To develop an appropriate dosing strategy for continuous intravenous infusions 
(CII) of enoxaparin by minimizing the percentage of steady state anti-Xa concentration (Css) 
outside the therapeutic range of 0.5 -1.2 IU/ml.  
Methods: A nonlinear mixed effects model was developed with NONMEM® for 48 adult 
patients who received CII of enoxaparin with infusion durations that ranged from 8 to 894 h at 
rates between 100 and 1600 IU/h. Three hundred and sixty three anti-Xa concentration 
measurements were available from patients who received CII. These were combined with 309 
anti-Xa concentrations from 35 patients who received subcutaneous enoxaparin. The effect of 
age, body size, height, sex, creatinine clearance (CrCL) and patient location (Intensive Care Unit 
(ICU) or general medical unit) on pharmacokinetic (PK) parameters were evaluated. Monte 
Carlo simulations were used to 1) evaluate covariate effects on Css; and 2) compare the impact 
of different infusion rates on predicted Css. The best dose was selected based on the highest 
probability that the Css achieved would lie within the therapeutic range. 
Results: A two-compartment linear model with additive and proportional residual error for 
general medical unit patients and only a proportional error for patients in ICU provided the best 
description of the data. Both CrCL and weight were found to significantly affect clearance and 
volume of distribution of the central compartment, respectively. Simulations suggested that the 
best doses for patients in the ICU setting were 50 IU/kg/12h (4.2 IU/kg/h) if CrCL<30 ml/min; 
60 IU/kg/12h (5.0 IU/kg/h) if CrCL was 30-50 ml/min; and 70 IU/kg/12h (5.8 IU/kg/h) if CrCL> 
50 ml/min. The best doses for patients in the general medical unit were 60 IU/kg/12h (5.0 
IU/kg/h) if CrCL < 30 ml/min; 70 IU/kg/12h (5.8 IU/kg/h) if CrCL was 30-50 ml/min; and 100 
IU/kg/12h (8.3 IU/kg/h) if CrCL>50 ml/min.  These best doses were selected based on providing 
the lowest equal probability of either being above or below the therapeutic range and the highest 
probability that the Css achieved would lie within the therapeutic range. 
Conclusions:  The dose of enoxaparin should be individualized to the patients’ renal function 
and weight.  There is some evidence to support slightly lower doses of CII enoxaparin in patients 
in the ICU setting. 
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Introduction 
Venous thromboembolism is a common cause of morbidity and mortality. Low molecular 
weight heparins (LMWHs) are as effective and safe as unfractionated heparin (UFH) for the 
treatment of deep vein thrombosis (DVT)  and pulmonary embolus (PE).54-57 LMWHs are also 
superior to and as safe as unfractionated heparin for acute coronary syndromes.58-60  When 
compared to UFH, LMWHs have superior bioavailability,61 a more predictable anticoagulation 
response, and a lower incidence of heparin-induced thrombocytopenia and osteoporosis with 
long term treatment.62  
Enoxaparin is one of the most widely used LMWHs in Europe and the US,63, 64 with anti-Xa 
activity widely used as a marker of enoxaparin concentration. 5, 6, 65 It is predominantly 
eliminated by the kidney. 66Studies suggest that renal dysfunction leads to increased anti-Xa 
concentrations, 5, 67, 68which in turn is associated with bleeding complications. Therefore, dosage 
adjustment based on renal function is suggested to decrease the risk of adverse bleeding events. 7, 
69, 70 
      Compared with general medical unit patients, critically ill patients have more medical 
complications due to pre-morbid and surgical conditions, invasive treatments, and prolonged 
immobility.71 Cook et al.72 found that Intensive Care Unit (ICU) patients with multiple 
predisposing factors have a high risk of venous thromboembolism and PE, which may result in a 
higher risk of mortality. Moreover, a range of organ dysfunction in ICU patients may result in 
more variable exposure to drugs and thus response. 73Investigators at the University of Buffalo 74  
have observed substantial variability in anti-Xa concentrations measured in multiple trauma 
critically ill patients.  Unreliable and extensive variable anti-Xa concentrations were found in 
these trauma critically ill patients when the standard recommended dose and route of 
administration (subcutaneous (SC)) of enoxaparin for the prevention of venous 
thromboembolism was applied. This has led the group to examine alternate means of 
administration (intravenous infusion) to attempt to reduce variability in the observed anti-Xa 
concentrations after enoxaparin administration in trauma critically ill populations. Under the 
circumstance where patients were reported to have substantial variability 74 (e.g. intensive care 
unit patients) in the observed anti-Xa concentrations with SC enoxaparin,  intravenous infusion / 
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CII could be utilized as a possible approach to reducing the variability.  Therefore, it is desirable 
to attempt to understand these factors and attempt to control exposure to drug more closely.   
      The modeling and simulation work presented here represents a pilot examination of 
enoxaparin administered via continuous intravenous infusion and provides a first look at the 
nature of the inter-individual variability (including covariate examination) for this administration 
method.  
Dosing strategy and extensive population pharmacokinetic analysis for patients receiving 
enoxaparin by continuous intravenous infusion (CII) has not been reported in the literature. The 
purpose of this study was to describe the pharmacokinetics (PK) for CII enoxaparin by 
developing a population PK model. This model was then used to guide a dosing strategy for CII 
enoxaparin.  
 
Subjects and Methods 
Subjects  
Anti-Xa concentrations were available from two studies. Patient characteristics for the two 
studies are shown in Table 1. The first study was conducted at the Cleveland Clinic 
Foundation.75  In the CII study, patients who received enoxaparin from January 1997 to 
December 1998 were identified, and a retrospective chart review was completed subsequent to 
institutional review board approval. The study provided 48 patients (23 male) with 363 anti-Xa 
concentrations with an average (Mean±SD) age and weight of 60.3±17.7 years, 73.9±14.6 kg, 
respectively. Patients were located in both general medical unit (n=29) and the ICU (n=19) and 
initially received enoxaparin 100 IU/kg/12h (8.3IU/kg/h) by CII. Routine monitoring of anti-Xa 
concentration was determined by chromogenic assay of LMWHs. 76 
The second study, reported by Green et al., provided detailed subject information for the 
subcutaneous (SC) use of enoxaparin.7 The study included 35 patients with 309 anti-Xa 
concentrations. The patients’ age, weight and CrCL were (Mean±SD): 75.1±10.5 years, 
67.7±15.5 kg, 39.2±21.6 ml/min respectively. 
The Brater equation 77 was used to calculate the CrCL for individuals with unstable serum 
creatinine (SCr) in the CII study when two SCr concentrations measured over 12 hours apart were 
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different by more than 0.2 mg/dL. CrCL for individuals with stable SCr concentrations was 
calculated using the Cockcroft and Gault (CG) equation in the CII and SC study, using ideal body 
weight (IBW) as a body size descriptor. 78 
 
Population PK analysis 
The population PK analysis for the combined data set was performed by using NONMEM® 
(version V, GloboMax, Hanover, MD)79 with the subroutine ADVAN4, TRANS4. The first 
order conditional estimation with interaction (FOCEI) method was used to estimate parameters. 
The likelihood ratio test was used to discriminate between alternative models. An 
objective function decrease of 3.84 units was considered significant (χ2 P<0.05 df=1). The 
covariates age, height, sex, CrCL and body size [total body weight (weight),  body surface area 
(BSA), body mass index (BMI), IBW, lean body weight (LBW), adjusted body weight (ABW), 
and percent ideal body weight (%IBW)6, 80] were introduced into each parameter one by one. The 
continuous covariate weight on clearance (CL) was incorporated into the model in several ways.  
These are shown as below: 
 
TVCL=θ1+(weight/ Medweight)θ weight 
TVCL=θ1*(weight/Medweight)θ weight 
CL=TVCL*exp(ηi CL) 
 
TVCL is the typical value for the population and ηi is the random effect representing the 
difference of the ith patient from the population mean.  The random effects of between subject 
variability were assumed to be log-normally distributed, with a mean of zero and standard 
deviation of ω. Weight is the total body weight in kilograms and Medweight is the median total 
body weight. Weight and other body size descriptors were included in the analysis to help 
examine whether the departure from the normal body size affected disposition.          
      CrCL (creatinine clearance in L per h) was included in CL as below:  
      TVCL=θ1+(CrCL/4.8)* θCrCL
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CL=TVCL*exp(ηi CL) 
     The non-renal component of clearance (θ1) was evaluated in this model as a fixed 
parameter (0.229) reported by Green et al,7 as well as being directly estimated by NONMEM. If 
CrCL was missing, then TVCL= θmissing was used. A sensitivity analysis was used to evaluate the 
impact on the other parameter estimates if θ1 was fixed. The reported parameter estimates for θ 
NR (non-renal clearance component) and θCrCL (renal component clearance) were 0.229 and 0.681 
respectively in the literature.7 To assess how the previously published parameters (see above) 
would impact on the analysis, θ NR was fixed to the published value of 0.229.  The fixed value 
for θ NR was then changed in 10% increments over a range of ±50% to assess whether or not this 
affected the other parameter estimates. 
Residual variability was modeled using additive, proportional and combined error structures.  
Graphical assessment of Bayesian individual parameter estimates versus covariates was 
evaluated to help identify possible covariate relationships. Covariates were retained in the model 
if inclusion in the model decreased the objective function value (OFV) by 3.84 (χ2 P<0.05 df = 1). 
The model improvement was assessed by the OFV values and parameter estimates. In addition, 
the significance of the covariates was assessed using a randomization test with Wings for 
NONMEM.81, 82 This approach provided a calibration for the changes in OFV versus p-value for 
determination of statistical significance.  In addition, graphics of goodness of fit were utilized to 
assess model robustness.83 
 
Simulation of steady state anti-Xa concentration  
Two types of simulations were performed; the first was a deterministic simulation which 
assessed the impact of covariate effects on predicted Css. Anti-Xa concentrations were simulated 
using mean model parameters obtained from the final covariate model with random effects fixed 
to zero. This was done to more clearly evaluate covariate effect on Css. The calculation of Css is 
shown below: 
CL
RCss 0=   (1) 
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The second simulation set used a Monte Carlo approach 51-53to identify an appropriate dose 
for CII enoxaparin. The final covariate model was used as the input-output model to predict 
concentrations. The final model and parameter estimates obtained from the final model were 
used for the Monte Carlo simulations. The distribution of PK parameters was set to a log-normal 
distribution. Simulations were conducted to compare the percentage of the predicted Css values 
that were outside of the therapeutic range for the general medical unit and ICU patients receiving 
enoxaparin at infusion rates of 8.3, 5.8, 5.0, 4.2 IU/kg/h. The lowest infusion rate (4.2 IU/kg/h) 
was selected based on the best dose suggested by Green et al 7 for renal dysfunction patients 
receiving SC enoxaparin. The highest infusion rate (8.3 IU/kg/h) is the current dosing strategy of 
enoxaparin administrated by SC administration. A unique covariate distribution model was 
developed for general medical unit and ICU patients.  The model constituted a joint distribution 
of weight and CrCL based on the ICU and the general medical unit patients in CII study. The 
correlation of weight and CrCL in the covariate distribution model was 0.33 for general medical 
unit patients and 0.30 for ICU patients in the CII study.75 One thousand general medical unit 
patients and 1000 ICU patients were simulated from the joint distribution model. Two hundred 
simulations of 2000 patients were performed for each infusion rate using NONMEM®. For twice 
daily SC administration, the therapeutic range of anti-Xa is 0.5 IU/ml – 1.2 IU/ml.76, 84-88  This 
therapeutic range was applied as the target range for dose selection in simulation study for CII. 
The percentage of predicted Css which was higher than 1.2 IU/ml or which was lower than 0.5 
IU/ml was calculated for each simulation using code written by the researchers in True-BASIC® 
(developed in 1965 by John Kemeny & Thomas E. Kurtz). The mean, 5th and 95th percentiles 
(90% predicted interval (PI)) were calculated from 200 simulations for the percent of predicted 
Css falling out of therapeutic range at each infusion rate. The patients were classified into 3 
categories (CrCL<30ml/min; CrCL: 30-50 ml/min; CrCL>50 ml/min) prior to the simulation 
study, which was based on the severity of kidney impairment. These probabilities were then 
calculated for patients with varying degrees of renal function (CrCL<30 ml/min; CrCL: 30-50 
ml/min; CrCL>50 ml/min), and the percentile of the mean, 5th and 95th (90% PI) is represented 
graphically. The best dosing regimens were selected based on the highest probability that the 
achieved concentrations would fall within the desired therapeutic range.  
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Results 
Patient Characteristics  
Eight patients in the CII study had unstable SCr; three of them were general medical unit 
patients and five were ICU patients. The CrCL for twenty seven patients in the CII study was 
unavailable. The duration of infusion for the 48 patients ranged from 8 to 894 h (138±158 h) and 
infusion rates ranged from 100 to 1600 IU/h (500±210 IU/h).  
 
Population PK modeling  
A two-compartment linear model with exponential inter-individual variability on clearance 
(CL) and volume of distribution of central compartment (V2) adequately described the data. The 
basic PK parameters of CL, V2 and volume of distribution of peripheral compartment (V3), 
absolute bioavailability (F1) and absorption rate constant Ka (for SC study) are shown in Table 2.  
The residual error model accounted for differences in the residual error variance between the 
general medical unit and ICU patients. The residual error model was a combined additive and 
proportional model for general medical unit patients and proportional only for ICU patients. 
Allowing the residual error variance to partition based on location of the patient improved the 
OFV by 62.6 units (P<0.005).  
The best residual error was described by the equation: 
For general medical unit patients:  Yij = IPREDij*(1+εij1) + εij2  
For ICU patients:  Yij = IPREDij*(1+εij3) 
     where IPREDij represents the jth predicted concentration for the ith individual, Yij is 
the observed anti-Xa concentration, and ε are the i.i.d. normally distributed random effects with 
normal distribution with a mean zero and standard deviation σ. ε1 and ε3 are the proportional 
component, and ε2 is the additive component.  
      Visual inspection of individual empirical Bayes estimates of clearance showed a 
systematic change with CrCL.  Thus CrCL was chosen for inclusion in the model as below:  
      CL=θNR+(CrCL/4.8 )* θCrCL *exp(ηi CL) 
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The θ NR and θCrCL are non-renal and renal clearance components, respectively.7  The 
reported parameter estimates for θ NR and θCrCL were 0.229 and 0.681 respectively in the 
literature.7 From the sensitivity analysis, the CV% of all other parameter estimates, including 
mean parameter estimates (CV%: 0.4%-2.5%), inter-individual (CV%: 3.4% (ωcl); 3.0% (ωv2)) 
and intra-individual variability (CV%: 0.1% (σ1); 0.2%(σ2); 1.2%(σ3)), was less than 10% as a 
result of changing the value of θ NR with one exception. θCrCL, which is correlated with the θNR 
value, had a larger change in value (CV%: 19%) than all the other parameters in the analysis. 
However CV% of total CL estimates were less than 10%, which may explain the compensatory 
change of θCrCL with θNR value. Therefore, fixing θ NR to 0.229 did not affect the estimation of 
other parameters (mean parameter estimates, inter- and intra-individual variability), based on the 
sensitivity analysis. We left this value fixed at 0.229 as it was estimated under a much more 
robust experimental design and thus more likely to be an accurate reflection of non-renal 
clearance. 7 
CrCL was the most significant covariate on CL (∆OFV =-10.1; P<0.005). Weight was the 
most significant covariate on V2 (∆OFV=-11.8; P<0.005). After incorporating the effect of CrCL 
on CL, weight was the most significant covariate on V2 (∆OFV=-21.56; P<0.005). The final 
model included CrCL on CL and weight on V2.   The critical values of the delta OFV, according 
to the randomization test, to accept CrCL and weight were 2.6 and 2.3 respectively. The final 
model for CL and V2 was therefore: 
CL= 0.229 + (CrCL/4.8)*θCrCL *exp(ηiCL) 
V2=θ2*(weight/70) *exp(ηi V2) 
where θ denotes the fixed effects, η denotes random effects with log normal distribution 
with zero mean and standard deviation ω, 0.229 (L/h) is the fixed value for non-renal clearance 
component, 80 ml/min (4.8 L/h) is considered as the cut-off value for normal renal clearance. 89, 
90 
The final PK parameter estimates are shown in Table 2. Population predicted anti-Xa 
concentrations versus observed anti-Xa concentrations are shown in Figure 1. ICU patients had 
an approximately 2 fold higher proportional residual variability than those general medical unit 
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patients. Inter-individual variability of CL and V2 decreased by 38% and 53% respectively in the 
covariate model compared to the base model.  
Upon inspection, the 48 patients in the CII study, ICU patients had a lower CL (0.79±0.40 
L/h) than general medical unit patients (0.99±0.39 L/h), which is consistent with our previous 
results.75, 91  The individual dosage adjustment was calculated using individual estimates from 
NONMEM®. To achieve a target concentration of 0.5 IU/ml anti-Xa concentration, the infusion 
rates for typical ICU and general medical unit patients with weight of 70 kg were 5.6±2.7 
IU/kg/h and 7.0±2.7 IU/kg/h, respectively.  
 
Simulation of steady state anti-Xa concentrations  
Assessing significant covariates that affect anti-Xa concentrations: Since weight and CrCL 
were significant covariates for PK parameters, simulations were applied to evaluate their impact 
on target anti-Xa concentration at steady state with weight varying from 30 to 120 kg and CrCL 
varying from 10 to 120 ml/min. Steady state anti-Xa concentrations were simulated using a 2-
compartment model with parameters fixed to the final parameters under the covariate model and 
all random effects set to zero.   
Anti-Xa concentration at steady state was calculated by equation 1. The effect of weight and 
CrCL on Css when administering enoxaparin at a rate of 100 IU/kg/12h by CII, is shown in 
figure 2. Clearance increased from 0.6 to 0.9 L/h when CrCL increased from 30 to 80 ml/min. As 
CrCL decreased and weight increased, predicted Css increased. This was particularly 
pronounced, when CrCL was below 30 ml/min.  
 
Comparing the percent of predicted Css outside of therapeutic range at infusion rates 
of 8.3, 5.8, 5.0 and 4.2 IU/kg/h:  CrCL was simulated using the covariate distribution model. 
The distribution of the covariates in patients with simulated values was comparable to that of 
general medical unit and ICU patients in the CII study. The final PK model with covariates was 
used as the input-output model. The percent for a predicted Css higher than 1.2 IU/ml or lower 
than 0.5 IU/ml was calculated for each simulation when general medical unit and ICU patients 
received infusion rate at 8.3, 5.8, 5.0 and 4.2 IU/kg/h respectively.  
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The percentage of predicted Css outside of therapeutic range (mean, 5th and 95th percentiles) 
at each infusion rate for general medical unit and ICU patients was shown in Table 3. The 
percentage of predicted Css outside of therapeutic range at each infusion rate for these subjects 
with different renal function was shown in Table 4. For both general medical unit and ICU 
patients, when the infusion rate decreased, the percentages of the predicted Css that were higher 
than 1.2 IU/ml decreased and the percentages of the predicted Css that were lower than 0.5 IU/ml 
increased (Figure 3a, 3b, 4a, 4b). General medical unit patients achieved the lowest total 
percentage (with an equal probability of either being above or below the therapeutic range) of the 
predicted Css falling outside of therapeutic range at an infusion rate of 8.3 IU/kg/h, while ICU 
patients achieved the lowest total percentage at 4.2 IU/kg/h.  
Figure 3, Figure 4 and Table 4 illustrate the percentage of patients’ predicted Css falling out 
of therapeutic range for ICU and general medical unit patients.  These figures reflect that, given 
an optimization of dosage to result in an equal probability of being either above or below the 
therapeutic range, general ward unit subjects achieved the lowest total percentage of Css falling 
outside of therapeutic range at infusion rate of 5.0 IU/kg/h if CrCL<30 ml/min, 5.8 IU/kg/h if 
CrCL was 30-50 ml/min and 8.3 IU/kg/h if CrCL>80 ml/min, while ICU subjects achieved the 
lowest total percentage of Css falling outside of therapeutic range at infusion rate of 4.2 IU/kg/h 
if CrCL<30 ml/min, 5.0 IU/kg/h if CrCL was 30-50 ml/min and 5.8 IU/kg/h if CrCL>80 ml/min. 
The difference between different dosing strategies is shown graphically in Figure 3a, b and 
Figure 4a, b. If the current dosing guideline (100 IU/kg/twice a day) of enoxaparin administrated 
SC were used for patients with CrCL<30 ml/min receiving CII, 64.6-68.1% of ICU patients and 
52.1-60.9% of general medical unit patients would have anti-Xa concentration > 1.2 IU/ml 
(Figure 3b, 4b). This can be reduced to 24.1-29.2% for ICU patients when dosing is decreased to 
4.2 IU/kg/h and to 21.4-28.3% for general medical unit patients when the dosing decreased to 5.0 
IU/kg/h. When using the revised dosing strategy, simulated ICU and general medical unit 
patients with a CrCL<30 ml/min experienced a 28% and 22% (Table 4) decrease in the 
percentage of the total predicted Css falling out of therapeutic range respectively, when 
compared with the patients receiving 8.3 IU/kg/h of enoxaparin.  
In some situations, the best dose selected based on the total percentage of Css outside of the 
therapeutic range was found to be indistinguishable from other doses (change of total % Css 
outside of the therapeutic range less than 10%). For example, if ICU patients, with CrCL<30 
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ml/min that received enoxaparin at infusion rate of 5.0 IU/kg/h, the total percent Css outside of 
therapeutic range was reduced by 3% compared to the situation when the best dose of 4.2 
IU/kg/h was applied. This is also true for general medical unit patients with CrCL< 30 ml/min, 
the total percentage of Css falling outside of therapeutic range at infusion rate of 5.0 IU/kg/h was 
48% and became 49% at the rate of 5.8 IU/kg/h. However, in the “best dose” situations, patients 
have a similar probability of being either above or below the therapeutic range (Figure 3c, 4c). If 
the change of the total % Css outside of the therapeutic range was less than 10% when dose other 
than best dose was applied, the dose was considered to be indistinguishable from the best doses 
suggested above. Thus the range of dosage at each of the patient types were indicated, where the 
total probability of being outside the therapeutic range was indistinguishable: for general medical 
patients 4.2-5.8 IU/kg/h if CrCL<30 ml/min, 5.0 – 8.33 IU/kg/h if CrCL was 30-50 ml/min and 
5.8-8.33 IU/kg/h if CrCL>50 ml/min;  for ICU patients, 4.2-5.0 IU/kg/h if CrCL<30 ml/min, 4.2 
– 5.8 IU/kg/h if CrCL was 30-50 ml/min and 5.0-5.8 IU/kg/h if CrCL>50 ml/min. However, the 
clinician will have to consider the risks to a particular patients associated with the relative 
probability of that patients being either above or below the range when tailoring the actual dose 
administered to the patient. 
  
Discussion 
Dosing strategies developed by many SC enoxaparin studies were based on weight and renal 
function, which may help to reduce bleeding complications, 65, 67, 68, 84and these changes are 
amplified in complicated patient populations that are present in critically ill multiple trauma 
patients74.  Highly variable and unreliable anti-Xa concentrations were observed when the 
standard dose of enoxaparin for prevention of venous thromboembolism was applied. In this 
study, the bioavailability estimation for general medical unit patients in SC study was 0.94. 
Whether the extensive variability of anti-Xa concentrations in critically ill patients from Dr. Haas 
74study is due to the variable bioavailability for SC enoxaparin is unknown. Applying CII 
enoxaparin is one approach to evaluate this issue and may reduce the variability observed after 
SC administration in critically ill patients.   This has led some investigators to begin examining 
the continuous IV administration of enoxaparin to examine this issue.  Despite this, no extensive 
population pharmacokinetic analysis or dosing adjustment suggestions have been reported for 
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enoxaparin given by CII. This is the first study to evaluate factors affecting anti-Xa 
concentrations following CII administration of enoxaparin. This information is used to develop a 
dosing guideline based on the percentage of the predicted steady state anti-Xa concentrations 
falling out of the therapeutic range with CII using Monte Carlo simulations. 
In previous population data analyses, combined data sets were used to help stabilize 
estimations.16 In our study, combining additional data from the SC study with the CII data 
allowed us to better describe and characterize the PK parameters for CII.  Compared with the CII 
data analysis alone, there was a 50% decrease of standard error of estimation for CL and V2 in 
the combined data analysis. Moreover, the inter-individual variability of CL and V2 decreased 
37% and 47% respectively, compared with the CII data analysis alone. 75 
Approximately half of the subjects in CII study were from ICU. This may contribute to 
additive PK complexity as those patients were prone to have fluid shifts, organ dysfunction, and 
drug binding alteration.71, 92 Different PK parameters (CL) were found in ICU and general 
medical unit patients in this study and our previous report. 75The different clearance between 
ICU and general medical unit patients was also found by Priglinger et al.,73 where they 
demonstrated that SC administration of LMWH may not work well in critically ill patients due to 
different PK behavior as compared with general medical unit patients. Simulations suggest that 
an infusion rate of 5.6±2.7 IU/kg/h for ICU patients and 7.0±2.7 IU/kg/h for general medical unit 
patients were needed to achieve lower limit of therapeutic range of 0.5 IU/ml anti-Xa 
concentration. The model for ICU patients showed a higher proportional residual error than that 
from general medical unit patients. This may be a function of model misspecification in the 
highly dynamic ICU population compared to the more stable general medical unit patients  
Similar to previous reports of SC administration of enoxaparin,7, 68 this study showed that 
enoxaparin CL increased with increasing CrCL.  One study in 96 obese patients reported by 
Green et al.6 demonstrated that LBW is a significant covariate on CL and weight on V2. After 
including CrCL on CL and weight on V2, no body size descriptor other than weight was found as 
a significant covariate on PK parameters. Green et al 7 reported a series recommended dosing 
regimens based on the glomerular filtration rate (GFR) estimated using CG equation , where 
dose of 0.4 mg/kg/12h was suggested to subjects with GFR less than 30ml/min. A simulation 
study for CII administration found that CrCL had a higher impact on Css in patients with renal 
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dysfunction (CrCL<30 ml/min) than in patients with moderate renal impairment and normal 
renal function patients. Results from 200 simulations at each infusion rate (8.3, 5.8, 5.0, 4.2 
IU/kg/h) demonstrated that general medical unit patients achieved the lowest total percent of 
predicted Css outside of the therapeutic range at 8.3 IU/kg/h (90% PI: 48.0%-56.8%), while ICU 
patients achieved the lowest total percent at 4.2 IU/kg/h (90% PI: 47.7%-54.2%) (Table 3). 
Furthermore, if CrCL was less than 30 ml/min (renal dysfunction), the best doses for patients in 
the ICU and general medical unit were 4.2 IU/kg/h and 5.0 IU/kg/h, respectively; 5.0 IU/kg/h 
and 5.8 IU/kg/h, respectively, if CrCL is between 30 and 50 ml/min (moderate renal impairment). 
For ICU and general medical unit patients with CrCL greater than 50 ml/min, the best dose was 
5.8 IU/kg/h and 8.3 IU/kg/h respectively (Table 4). Based on these results, most patients will 
achieve expected steady state anti-Xa concentrations between 0.5 IU/ml and 1.2 IU/ml, if a): 
ICU patients with CrCL > 50 ml/min receive enoxaparin at 5.8 IU/kg/h, and general medical unit 
with CrCL > 50 ml/min receive enoxaparin at 8.3 IU/kg/h infusion rate; 2): ICU patients with 
CrCL between 30 to 50 ml/min receive enoxaparin at 5.0 IU/kg/h, and general medical unit 
patients with CrCL between 30 to 50 ml/min receive 5.8 IU/kg/h; and 3): ICU patients with 
CrCL< 30 ml/min receive enoxaparin at 4.2 IU/kg/h and medical unit patients with CrCL< 30 
ml/min receive enoxaparin at 5.0 IU/kg/h. These best doses also represented the optimal solution 
where the probability of being above the therapeutic range is not different from being below the 
range (Figure 3c, 4c). Given different therapeutic risks in the clinic, it was felt that this would 
provide a starting point. The additional information on the total risk of being outside the 
therapeutic range can then be considered in concert with this information tailoring to the patient 
with respect to whether or not it is worse for that patient to be above or below the range. Given 
the equal total probabilities of being outside the range for multiple dosage levels, we have 
provided a range of dosages where that total probability is indistinguishable across groups can be 
determined from Table 4. However, the clinician will have to consider the relative probability of 
above or below the range when tailoring the actual dose administered to the patient. 
CII administration of enoxaparin had been used in the treatment of acute pulmonary 
embolism.93, 94    Patients with acute pulmonary embolism received an i.v bolus of 0.5 mg/kg 
enoxaparin and followed by an initial dosage of 2-3 mg/kg/day CII enoxaparin. Anti-Xa 
concentrations were measured daily. The dosage was adjusted to maintain anti-Xa concentration 
between 0.2 – 0.6 IU/ml. 93, 94No deleterious hemorrhagic side effects were found during the 
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treatment of acute pulmonary embolism.94  This might be due to the dosage adjustment by daily 
measurements of anti-Xa and anti-IIa concentrations, which lead to more constant level of 
anticoagulation. The dosing adjustment recommended in this paper can be applied when CII is 
used in clinical practice to patients with varying renal function, which is not available in 
literature yet.  
Unfortunately, the limitations of a retrospective study are the availability of documented data 
in a medical unit record review. Even with the electronic laboratory information, SCr 
concentrations were unavailable in twenty seven patients in the CII study. The need to evaluate 
SCr was at the discretion of the physician since this was an observational evaluation. We 
acknowledge the small sample size of patients with available SCr in the CII study and accounted 
for this by combining data in the PK analysis with additional patients from a second study. This 
approach has been discussed previously.16   Combining datasets assisted in identifying CrCL as a 
significant covariate of CL. 75 
 
Conclusion 
This study evaluated the pharmacokinetic profile and defined a dosage strategy for 
administering enoxaparin by continuous intravenous infusion in patients with varying renal 
function. CrCL was identified as a significant covariate on CL and total body weight on V2. 
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Table 1: Patient characteristics for the two studies 
 
SC  CII  Combined Demographics 
General medical unit General medical unit ICU  
Sample size 35 29 19 83 
Age (years) 75.1  
(44-86) 
60.9 
(16-90) 
59.3 
(23-77) 
66.6  
(16-90) 
Weight (kg) 67.7  
(32-95) 
74.1  
(46.5-108) 
73.3  
(46.5-97.5) 
71.0  
(32-108) 
Height (cm) 164.0  
(147-184) 
168.7 
(152-182) 
166.2 
(151-177) 
166.0  
(147-184) 
Gender 
(Male/Female) 
17/18 16/13 7/12 40/43 
CrCL 
(ml/min) 
39.2  
(14.9-95.7) 
63.5  
(31.1-128.3) 
26.8 
(7.6-49.6) 
45.0  
(7.6-128.3) 
 
 
Abbreviations: SC: subcutaneous, CII: continuous intravenous infusion, CrCL= Creatinine Clearance.  
* Twenty seven patients in the CII study did not have a serum creatinine (SCr) concentrations.  
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 Table 2: PK parameter estimates for two compartment model 
 
Parameters Base model SE% Parameters Final model     SE% 
CL (L/h) 0.693 9.5 CLmissing (L/h) 0.972         10.5 
θNR N/A N/A θNR (L/h) 0.229 N/A 
θCrCL N/A N/A θCrCL (1 /4.8 CrCL) 0.744 18.7 
V2 (L) 7.07 22.5 V2 (L/ 70 kg weight) 6.78 19.2 
V3 (L) 5.99 25.4 V3 (L) 6.19 24.9 
Q  (L/h) 0.494 27.9 Q  (L/h) 0.429 24.7 
Ka (/h) 0.428 29.0 Ka (/h) 0.476 27.3 
F1 1 1.1 F1  0.94 9.7 
ωcl% 65.5 44.1 ωcl% 40.7 23.8 
ωv2% 61.9 31.3 ωv2% 29.4 82.2 
σ1% 22.6 28.4 σ1% 12.1 100 
σ2 (IU/L) 75.4 36.6 σ2 (IU/L) 132 44.7 
σ3% 43.1 26.0 σ3% 44.0 26.3 
  
Abbreviations: CL=clearance, CrCL=creatinine clearance, IU=international units, SE=standard error, 
weight=total body weight, V2=volume of distribution of central compartment, V3=volume of distribution 
of peripheral compartment, ω=coefficient of variation of inter-individual variability, σ1=proportional 
coefficient of variation of residual error for general medical unit patients, σ2=additive coefficient of 
variation of residual error for general medical unit patients, σ3= proportional coefficient of variation of 
residual error for ICU patients; N/A: not available, θNR = 0.229 (fixed), Unit of weight=kg, Unit of 
CrCL=L/h, F1: absolute bioavailability 
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 Table 3: Percent of predicted anti-Xa Css higher than 1.2 IU/ml or Percent of predicted anti-Xa Css 
lower than 0.5 IU/ml when general medical unit and ICU patient receiving enoxaparin at different 
infusion rates of 8.3, 5.8, 5.0 and 4.2 IU/kg/h 
 
General medical unit Patients ICU Patients 
Infusion rate 
 (IU/kg/12h) 
Percent of 
Css <0.5IU/ml 
Percent of 
Css >1.2IU/ml 
Percent of 
Css<0.5IU/ml 
Percent of 
Css>1.2IU/ml 
 Mean       90%PI Mean       90%PI Mean       90%PI Mean       90%PI 
8.3 18.1        16.7-20.7 33.9       31.3-36.1 5.8            4.5-6.8 61.1       59.4-63.9 
5.8 35.8        33.8-38.2 17.0      15.0- 19.0 13.8         12.5-15.1 41.4       40.4-43.5 
5.0 44.9        42.5-47.1 11.9      10.3-13.5 20.5         19.2-22.2 31.0       30.3-33.3 
4.2 55.2        52.5-57.5 7.50       6.40-8.70 28.3         26.5-29.8 22.7       21.2-24.4 
 
 
Abbreviations: ICU = intensive care unit, Css = steady state anti-Xa concentration, h= hour, PI=predicted 
interval 
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 Table 4: Percent of predicted anti-Xa Css higher than 1.2 IU/ml or Percent of predicted anti-Xa Css 
lower than 0.5 IU/ml when general medical unit and ICU patient receiving enoxaparin at different 
infusion rates of 8.3, 5.8, 5.0 and 4.2 IU/kg/h for subjects at each renal function group (1: CrCL< 30 
ml/min; 2: CrCL 30-50 ml/min; 3: CrCL> 50 ml/min).  
 
 
Infusion rate 
(IU/kg/12h) 
CrCL 
(ml/min) 
General medical unit Patients 
Mean percent of     Mean percent of 
Css <0.5IU/ml        Css >1.2IU/ml 
ICU Patients 
Mean percent of     Mean percent of
Css <0.5IU/ml        Css >1.2IU/ml 
8.3 <30 6.74 54.4 4.1 65.8 
 30-50 11.9 42.7 7.4 55.5 
 >50 22.4 28 13.3 44 
5.8 <30 16.6 32.3 10.97 46.1 
 30-50 28.2 21.6 16.8 36.2 
 >50 43.8 11.6 25.8 22.9 
5.0 <30 23.7 24.3 16.8 35.1 
 30-50 36.8 15.3 24.2 26.4 
 >50 53.3 7.59 36.8 14.5 
4.2 <30 32.8 16.3 24.1 26.4 
 30-50 47.4 9.93 32.4 18.4 
 >50 63.8 4.47 48.0 9.13 
 
Abbreviations: ICU = intensive care unit, Css = steady state anti-Xa concentration, h= hour 
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 Figure 1: population predicted anti-Xa concentrations versus Observed for the two-compartment 
model with CrCL and weight covariates in the model. Individual data points were shown as dots 
and the unity was shown as a solid line. 
 
 
 
Predicted anti-Xa concentrations (IU/L)
O
bs
er
ve
d 
an
ti-
X
a 
co
nc
en
tra
tio
ns
 (I
U
/L
)
0 500 1000 1500 2000 2500 3000
0
50
0
10
00
15
00
20
00
25
00
30
00
 
 
 
 
 40 
 Figure 2: Three-D surface showing the relationship between CrCL, weight and predicted Css. 
The surface shows how the Css changes with both weight and CrCL simultaneously. 
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 Figure 3: The percentage of predicted Css falling out of therapeutic range at different infusion 
rate (8.3, 5.8, 5.0, 4.2 IU/kg/h) for ICU patients with different renal function (1: CrCL< 30 
ml/min; 2: CrCL 30-50 ml/min; 3: CrCL> 50 ml/min). Dash lines represent the 5th and 95th 
percentiles (90% PI).  
a): Percentage of predicted Css which is lower than 0.5 IU/ml 
b): Percentage of predicted Css which is higher than 1.2 IU/ml  
(Rhombus ◆: 4.2 IU/kg/h; Square ■: 5.0 IU/kg/h; Triangle ▲:5.8 IU/kg/h; Dot ●: 8.3 IU/kg/h) 
c): Percentage of predicted Css falling out of therapeutic range (0.5-1.2 IU/ml) when patients 
with CrCL<30ml/min received enoxaparin at 4.2 IU/kg/h infusion rate and CrCL between 30 and 
50 ml/min received enoxaparin at 5.0 IU/kg/h infusion rate and CrCL> 50 ml/min received 
enoxaparin at 5.8 IU/kg/h infusion rate. 
 (Square ■: > 1.2 IU/ml; Dot ●: < 0.5 IU/ml) 
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 Figure 4: The percentage of predicted Css falling out of therapeutic range at different infusion 
rate (8.3, 5.8, 5.0, 4.20 IU/kg/h) for general medical unit patients with different renal function (1: 
CrCL < 30 ml/min; 2: CrCL 30-50 ml/min; 3: CrCL > 50 ml/min).  
Dash lines represent the 5th and 95th percentiles (90%PI).  
a): Percentage of predicted Css which is lower than 0.5 IU/ml 
b): Percentage of predicted Css which is higher than 1.2 IU/ml  
(Rhombus ◆: 4.2 IU/kg/h; Square ■: 5.0 IU/kg/h; Triangle ▲:5.8 IU/kg/h; Dot ●: 8.3 IU/kg/h) 
c): Percentage of predicted Css falling out of therapeutic range (0.5-1.2 IU/ml) when patients 
with CrCL < 30 ml/min received enoxaparin at 5.0 IU/kg/h infusion rate and CrCL between 30 
and 50 ml/min received enoxaparin at 5.8 IU/kg/h infusion rate and CrCL>50 ml/min received 
enoxaparin at 8.3 IU/kg/h infusion rate. 
(Square ■: > 1.2 IU/ml; Dot ●: < 0.5 IU/ml) 
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CHAPTER 3 DETERMINATION COVARIATE EFFECTS ON EXPOSURE OF 
DRUG WITH LINEAR PHARMACOKINETIC CHARACTERISTICS GIVEN HIGHLY 
SPARSE DATA 
 
 
 
 
 
 
 
 
 
This chapter is based on the following paper: 
Bies, Robert R, Feng, Yan, Lotrich, Francis E, Kirshner, Margaret A, Roose, Steven P, Kupfer, David J, 
Pollock, Bruce G. Utility of sparse concentration sampling for citalopram in elderly clinical trial subjects.  
Journal of Clinical Pharmacology, 2004, 44(12):1352-1359. 
The supplemented results from the further study after publication were also presented. 
 
 
Copyright has been assigned to Sage Publications. The permission of using the full article in the 
thesis had been granted from the copyright owner (Sage Publications). 
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 ABSTRACT 
Objective: To evaluate whether the disposition of the selective serotonin reuptake 
inhibitor, citalopram, could be robustly captured using 1 to 2 concentration samples per subject 
in 106 patients participating in two clinical trials.   
Methods:  Nonlinear mixed effects modeling was used to evaluate the pharmacokinetic 
parameters describing citalopram’s disposition. Both a prior established 2-compartment and a de-
novo 1-compartment pharmacokinetic model were used. Covariates assessed were concomitant 
medications, race, sex, age (22-93 years) and weight. Covariates affecting disposition were 
assessed separately and then combined in a stepwise manner.   
Results: Pharmacokinetic characteristics of citalopram were well captured using this 
sparse sampling design. Two covariates (age and weight) had a significant effect on the 
clearance and volume of distribution in both the one and two compartment pharmacokinetic 
models. Clearance decreased 0.23 L/hr for every year of age and increased 0.14 L/hr per kg body 
weight. 
Conclusions: Hyper-sparse sampling designs are adequate to support population 
pharmacokinetic analysis in clinically treated populations.  This is particularly valuable for 
populations such as the elderly, who are not typically available for pharmacokinetic studies. 
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INTRODUCTION: 
Selective serotonin reuptake inhibitors (SSRIs) such as citalopram are commonly used to treat 
depression in geriatric patients.95 There are limited data on the variability and exposure characteristics of 
these compounds once in general clinical use.  Elderly patients are not easily studied using the intensive 
concentration sampling required for classical pharmacokinetic (PK) analysis approaches. These data are 
potentially available using a sparse-sampling approach to measuring concentration exposure.  
 The limitation of traditional PK studies with small numbers of healthy volunteers is in the ability to 
extrapolate the results to clinical populations. For certain drugs, such as citalopram, large differences in 
PK/PD profiles may be found across individuals. Mixed effects population PK methods are better suited 
for evaluating inter-individual and intra-individual random effects in large-scale clinical trials, and only 
require a few samples per patient in a large number of patients.96 Moreover, covariate effects, when 
evaluated using this methodology, are supported by all data in the analysis.  Thus, systematic error is 
reduced when compared to classical PK approaches.97   
Despite this, there have been no studies evaluating in a continuous manner, the nature of PK changes 
for citalopram in clinically treated populations, particularly with regard to age.  Age-related differences 
in citalopram pharmacokinetics have been reported as general differences between groups of young and 
elderly individuals.98, 99  For example, Frederiscon Overo et al 98 measured citalopram PK in 11 elderly 
patients aged 73 to 90 years, and Gutierrez and Abramowitz 99 similarly examined citalopram 
disposition in 24 healthy elderly volunteers aged 65 to 77 years. Both of these studies found a reduction 
in clearance in the elderly group, with Frederiscon Overo et al showing a range of clearance from 4.8 to 
18 L/hr in the elderly and approximately 24 L/hr in the young.98 In 2 other studies utilizing data from 
therapeutic drug monitoring, age was correlated with drug concentrations 100 or with dose/concentration 
ratios,101 although specific pharmacokinetic parameters were not assessed. However, there is a need to 
quantitatively evaluate differences in PK for drugs used in the elderly across a range of ages and to 
account for the role of other individual specific characteristics that may impact exposure to drug. 
This study evaluated the performance of nonlinear mixed effects modeling in capturing exposure to 
citalopram as well as individual specific characteristics affecting that exposure with very limited 
sampling in a large number of psychiatric patients from two clinical trials.  We quantitatively explored, 
using nonlinear mixed effects modeling, the relationships between clearance, weight, age sex, race and 
concomitant medications as well as the degree of inter-individual variability in drug exposure. 
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METHODS: 
General Design  
Two clinical trials   (see below) provided a total of 199 plasma concentration samples for citalopram 
from 106 subjects (Table 1).  The subjects were started at a dose of 20 mg citalopram daily. The subjects 
received an average daily citalopram dose of 30±15 mg in study A and 15 ±5 mg in study B. 
Population PK analyses were performed using de-identified data. De-identified data does not allow a 
link to be made between patients and their individual personal and psychiatric information.  Both studies 
were approved by the appropriate institutional review boards and all subjects gave informed consent to 
participate. 
 
Subject selection 
Study A was a multi-site (5 academic medical centers in the U.S, with University of Pittsburgh as the 
coordinating center) open label study to assess citalopram as treatment for depression in patients with 
bipolar disorder.102  The subjects had a diagnosis of DSM-IV bipolar I or II depression.  Patients were 
excluded for mania, rapid cycling, mixed or psychotic forms of depression, any other axis I diagnosis, 
history of alcohol or substance abuse in the last three months, unstable or untreated medical disorder, 
and women who were pregnant or breastfeeding or of childbearing potential not on contraception. 
Subjects were treated with citalopram in 2 phases, an initial 8-week response phase followed by a 
16-week continuation phase for responders. Citalopram was started at 20 mg daily, and could be 
increased by 20 mg every 2 weeks based on response to a maximum of 60 mg or reduced to a minimum 
dose of 10 mg based on the appearance of adverse drug reactions.  A detailed history of dosage changes 
was available for the purposes of modeling citalopram pharmacokinetics. Plasma samples were obtained 
at baseline, week 1, week 8 and the end of study.  A histogram showing the distribution of sampling 
times (time after dose) is shown in Figure 1.  The concentration measurements were not scheduled for 
any particular time as the mixed-effects modeling approach could account for this as long as the last 
dosage time and the sampling time were known.  The dosage times were noted for inpatient subjects and 
were supplied as self-report from outpatients.  Concomitant medications were noted at each of the clinic 
visits. A total of 45 patients entered this study with 40 of these patients providing 85 citalopram 
concentration samples. 
Study B was a multi-site (10 academic medical centers in the U.S. with Columbia University as the 
coordinating center) randomized, double-blind study of the treatment of depression with citalopram or 
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placebo in subjects at least 75 years of age.103, 104  Subjects had a DSM-IV diagnosis of major depressive 
disorder with duration of the episode of greater than four weeks at baseline.  Subjects were excluded if 
they had other axis I disorders, dementia, acute severe or unstable medical illness or if they had a mini-
mental status examination score of less than 18. 
Citalopram was given at an initial dose of 20mg daily with the option to increase to 40mg daily for 
weeks five through eight.  Dosages could be reduced to 10 mg daily if there were significant side effects.  
Plasma samples for citalopram were obtained at baseline, week 4, and week 8 or upon termination, if 
early termination occurred.  No specific timing was scheduled for the citalopram concentration sampling.  
The distribution of sampling times is shown in Figure 1.  The time of last dosage was noted by self-
report and the dosage history was available for PK modeling.  The clinical trial site recorded the timing 
of the plasma sample collection for citalopram.  A total of 66 patients provided 114 concentration 
samples. 
 
Citalopram Analysis 
Citalopram and metabolites were measured by HPLC with UV detection using a method developed 
in our laboratory.105  This assay has been validated with a lower limit of detection of 3ng/mL and 
coefficients of variation ranging form 3.1% (220ng/mL) to 9.4% (15ng/mL).  All concentration 
measurements were analyzed in the Geriatric Psychopharmacology Laboratory at the University of 
Pittsburgh using the same analytical protocol. 
 
Pharmacokinetic modeling 
A prior nonlinear mixed effects model describing citalopram pharmacokinetics was used to evaluate 
the data from the two studies described above.106, 107  In addition, a new model search was performed 
evaluating 1 and 2-compartment models. The focus of the modeling was to examine the impact of the 
covariates weight, age, race, sex and concomitant medications on the oral clearance (CL/F) and volume 
of distribution (V/F) of citalopram.  NONMEM (Globomax Corporation, Hanover MD) was used for the 
analysis using both ADVAN2 TRANS2 and ADVAN4 TRANS4.  An exponential error model for inter-
individual variability (equation 1) on the pharmacokinetic parameters was used along with an additive 
and proportional residual error model (equation 2).  In equation 1, CL/Fi is an individual patient’s oral 
clearance value, TVCL/F is the population average oral clearance for an individual of particular age and 
weight and η is the inter-individual variability shown in exponential form.  In equation 2, Y is the 
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observed concentration value and G is the individually predicted concentration value. ERR(1) and 
ERR(2) are the residual error terms. Model building and assessment were done initially using the first 
order estimation method and confirmed using the first order conditional estimation method. 
CL/Fi = TVCL/F*exp(ηCL/F)   (1) 
Y = G*(1+ERR(1))+ERR(2)    (2) 
Initially, covariate relationships were evaluated using XPOSE,108 comparing the individual 
deviations for the parameters to the covariates of interest.  Four covariates (weight, age, sex, and race) 
were evaluated in this way.  For Study A, concomitant medication was assessed as an additional 
covariate. 
Covariates were evaluated in the mixed effects PK model in a stepwise fashion.  Initially, each 
covariate was assessed individually and then incorporated into the model in a stepwise fashion.  Both a 
stepwise addition with backward removal and a backward removal with forward addition method were 
utilized for covariate identification.  The difference in objective functions (∆-2 times the log likelihood 
(-2LL)) was used to compare alternative models.  As the log likelihood difference approximates a χ2 
distribution, the incorporation of a covariate resulting in an objective function decrease of 7.88 units (χ2, 
P<0.005, df=1) was considered significant.    Weight was incorporated as: 
TVCL1/F = θ1*(WT/MedWT) θ2  (3) 
where TVCL1/F is the population clearance, θ1 and θ2 are the coefficient and exponent 
surrounding the centered weight term, WT is weight in kilograms and MedWT is the median weight.109, 
110  The importance of each covariate was compared based on decreasing of objective functions (∆-2LL) 
when the model including a covariate and increase of ∆-2LL when the model excluding a covariate.  The 
most important covariate was retained in the model and then the second included after correction of the 
first.  Age was incorporated in model after inclusion of the weight covariate as shown below where 
TVCL/F is the population clearance including the age covariate, TVCL1/F is the weight normalized 
population oral clearance value and the age covariate is centered about the median age in the study (60 
years): 
 
 TVCL/F=TVCL1/F*exp((age-60)* θ3)  (4) 
In each run, the 95% confidence intervals (CI) of point estimates were determined from the standard 
errors of estimates (SE) as follows: CI point estimate ± 1.96×SE. If the covariate step was unsuccessful, 
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the 95% CI was determined by bootstrapping (sampling with replacement) method.111 This method 
consisted of repeatedly fitting the model to 200 bootstrap replicates of the data.  The 95% CI of 
bootstrap parameters were calculated by taking as the 2.5th to 97.5th inter-percentile range of the 200 
replicates. 
RESULTS:  
Although the prior 2-compartment model was used as an initial test model for this analysis,106, 107 the 
population PK model that was supported robustly by these data was the 1-compartment linear PK model. 
The 1-compartment PK model with exponential interindividual variability on both oral clearance and 
volume of distribution was determined to be the most robust based on both the Akaike information 
criterion (AIC)47 and the confidence intervals around the estimates (AIC = 1562, 1-compartment; AIC = 
1569, 2-compartment). 
The estimates of oral clearance averaged 6.34 L/h in the older patients (aged 75-93 years) and 16.49 
L/h in the younger patients (aged 22-65 years). The oral clearance values ranged from 2 L/h for the 
eldest patient (aged 93 years) in the study to approximately 19.5 L/h in the youngest subjects (aged 22-
29 years). This is consistent with studies using intensive PK sampling in limited numbers of subjects, in 
which oral clearance was approximately 4 L/h in the elderly group and 24 L/h in the young.112  
Details of the model-building process with the first-order (FO) and first-order conditional estimation 
(FOCE) methods are discussed below and also shown in Table 2. The incorporation of weight and age as 
covariates on CL/F and V/F resulted in significant changes in the objective function. The final models 
for CL/F and V/F were as follows:  
 
TVCL1/F = θ1*(WT/80) θ2
TVCL/F= TVCL1/F*exp((AGE-60)* θ3) 
CL/F = TVCL/F*exp(η1) 
TVV1/F= θ4*(WT/80) θ5 
TVV/F = TVV1/F*exp((AGE-60)* θ6) 
V/F= TVV/F*exp(η2) 
 
Beginning with a basic model not incorporating age or weight, a series of four additional models 
were tested using both FO and FOCE methods.  The best model for both FOCE method and FO method, 
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showed that weight and age were statistically significant covariates on both CL/F and V/F (Base Model 
OFV=1680, Best model with Covariates OFV=1567, FOCE).  After incorporation of weight as a 
covariate on CL/F and V/F, the incorporation of age as a covariate on CL/F and V/F further improved 
model fitness (FO: ∆=-102.3; FOCE: ∆=-36.93, P<0.005).  Observed versus model population predicted 
plots for the one-compartment model with both covariates using FOCE are shown in Figure 2.  This 
latter model effectively described twice the inter-individual variability on CL/F and V/F than the model 
without covariates.  A 2-compartment model was also evaluated.  Although the 1-compartment model 
had more robust parameter estimates, both models showed an age and weight effect on CL/F and V/F 
(see above for AIC values).  The parameters for the 1-compartment model are listed in Table 3.  Figure 
3 shows the relationship between the post-hoc predicted oral clearance versus weight and age as a 3-
dimensional response surface.  In the covariate free model, oral clearance increases while weight 
increases.  A similar relationship (although in the opposite direction) was seen in comparing the post-
hoc predicted oral clearance to age (Figure 3).  Notably the oral clearance decreased as age increased 
across the entire weight range.  Covariate plots generated by XPOSE of oral clearance versus age given 
weight and oral clearance versus weight given age also illustrated these inter-relationships (data not 
shown).     
In determining the individual specific PK parameters, we also calculated the dose-normalized AUC0-
24 to compare the relative exposure per milligram of drug dosed across age.  As age increased the 
average exposure increased. The average dose-normalized AUC (+/-SD) values were 69.7(+/-28.9) 
ng/mL*hr and 189.9(+/-78.4) ng/mL*hr for the 22-65 year and the 75-93 year old groups respectively 
(Figure 4).  The standard deviation in the old elderly group (75-93years) was more than two times 
greater than that in the younger group (aged 22-65, although the %CV is similar).  Consistent with the 
higher dose-normalized AUC observed in elderly subjects, the averaged dose was less than half than that 
used in younger adults (13+/-5 mg vs. 29+/-14 mg daily, respectively).  Subjects ultimately receiving 
less than 20mg (i.e., less than the initial dose both protocols) had lower CL/F values. 
 
DISCUSSION: 
In this study, we successfully implemented a population PK analysis in the spirit of Krecic-Shepard 
et al113 and Kang et al114 using a small number of samples per subject in a large number of subjects to 
determine the oral clearance and volume of distribution in patients ranging in age from 22 to 93 years.  
Specifically, our estimates of oral clearance averaged 6.34 L/hr in the older patients (75-93 years of age) 
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and 16.49 L/hr in the younger patients (aged 22-65 years of age).  The oral clearance values ranged from 
2L/hr for the eldest patient in the study to approximately 27 L/hr in the younger subjects. This is 
consistent with studies using intensive PK sampling in limited numbers of subjects, where oral clearance 
was approximately 4 L/hr in the elderly group and 24 L/hr in the young.98, 115 
The two metabolites of citalopram measured are typically present at lower concentrations than the 
parent compound and do not readily cross the blood brain barrier.  In our case, the concentrations for the 
demethyl-citalopram metabolite were less than or equal to those of the parent and the concentrations of 
the didemethyl-citalopram were less than 50% of the citalopram level.  This, in combination with EC50 
values that are three (demethyl-citalopram) to 15 times (didemethyl-citalopram) lower than that for 
citalopram, lead us to assume the metabolites do not significantly contribute to response.116  However, 
we did evaluate the metabolite concentrations versus the predicted clearance for citalopram. This 
showed no relationship between observed concentration and citalopram or its metabolites (data not 
shown).  This arises from the fact that samples were taken at random across the dose-concentration time 
profile.95   
This study allowed us to evaluate the covariate (body weight, age, race, sex, concomitant 
medications) effects on the PK parameters. When weight was included in the description the CL/F and 
V/F parameters, the model fit improved greatly both in the numeric indicator (objective function) and 
visually. This was anticipated as the volume of distribution is dependent on body weight due to the 
direct relationship between total body water and body size109, 110.  Also, the clearance (if solely a flow 
dependent process) is also related to the body weight with a hyperbolic function (usually BW0.75).109, 110, 
117  Age was also a highly significant covariate in this analysis.  In our study, using the covariate free 
model, oral clearance decreased from 19.50 L/h (age range: 22 to 29 years) to 2.05 L/h (age: 93 years). 
This decrease was consistent across the entire age range. Thus, age was included as a covariate affecting 
oral clearance (after weight), greatly decreasing the objective function by 70.53 (FO) units (P<0.005) 
and 57.10 (FOCE) units (P<0.005).  Other covariates tested were not significantly associated with the 
PK parameters. 
Although minimal samples were acquired for each patient (1 - 2 samples per patient), the results are 
consistent with findings from analyses from intense and therapeutic drug monitoring datasets.98-101  Our 
study was able to extend these findings by demonstrating a continuous relationship between age and 
clearance of citalopram, as well as simultaneously account for the effect of weight on the 
pharmacokinetics of citalopram. Clearance decreased 0.23 L/hr for every year of age and increased 0.14 
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L/hr for every kg of body weight. We were also able to assess for additional potential covariate effects, 
however, none showed a significant association with the PK parameters. 
Both dose-normalized magnitude of exposure and the absolute variability of that exposure increased 
dramatically as age increased. The largest magnitudes and variabilities per milligram of drug exposure 
occurred in the 75-93 year old subjects. Interestingly, there may have been a natural adjustment based on 
tolerability of the medications. Despite the fact that the dose titration protocols were similar across all 
ages, the final average dose in the older group was lower. In particular, the average dose was lower in 
individuals with lower clearance. 
In conclusion, our findings may have implications for how nonlinear mixed effects modeling 
approaches can glean useful information from sparsely sampled populations (ie, elderly, children, 
adolescents) not typically accessible in clinical trials. This information would be important in 
understanding both the magnitude and the variability of the exposure, as well as the specific factors 
that contribute to inter-individual differences in this exposure. 
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SUPPLEMENTAL RESULTS: 
Rationale for the supplemental study  
In the published article, the final model was developed using FOCE method. Age and 
weight were significant covariates on PK parameters (CL and V). The covariate selection criteria 
were based on significant reduction of OFV value, reduction of inter-individual variability and 
improvement of goodness of fit in diagnostic plots. The diagnostic plot in the previous study 
suggested that the model can adequately describe the data. However, the parameter estimate (V/F) 
didn’t agree with the PK parameter reported from the previous PK studies112, 118, 119, where V/F 
of citalopram was typically greater than 1000 L, due to its highly lipophilic property. In order to 
obtain physiological meaningful PK parameter estimates, further model development was 
performed. 
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 Supplemental Results  
The further model development was performed using FOCE with interaction (FOCEI) 
method. The variance of the inter-individual variability of Ka was fixed to 1, which helped to 
stabilize the NONMEM model run. Nonparametric bootstrap methods were applied as an 
internal model validation approach. The detailed covariates selection during model development 
was shown in Table 4. The parameter estimate and the 90% CI from bootstrap (n=1000) analysis 
were showed in Table 5. The observed citalopram concentrations versus population predicted 
citalopram concentrations diagnostic plot are shown in Figure 5.  
 
One of the major aims of this study was to assess covariate effect on PK parameters. Age 
was the most significant covariate on CL, with reduction of OFV by 62.7 units (p<0.005) and 
reduction of inter-individual variability on CL by 30%. After incorporation of age on CL, the 
incorporation of weight on CL further improved model fitness. Comparing to the model with age 
on CL, OFV reduced by 15.8 units (p<0.005) and inter-individual variability on CL reduced by 
10% after incorporation both age and weight on CL. The OFV values were further reduced when 
including sex or race on CL (M10 and M11), weight on V (M12) in the model with age on CL, 
and when including age on V (M13), sex or race on CL (M14 and M15) in the model with age 
and weight on CL. However, none of them reduced the inter-individual variability. The 
improvement of goodness of fit was not noticeable in the diagnostic plot as well. Thus none of 
the covariates were included in the final model (M9).  
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 Figure 1: Frequency histogram showing the sampling distribution for citalopram plasma 
concentration measurements. The x-axis is broken into two-hour bins. Several individuals were 
sampled past 30 hours (n=18 samples, <10% of all measurements, sampling times 31-178 hours 
after dose). The y-axis shows the proportion of samples taken in each interval. 
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 Figure 2: Population predicted (PRED) versus observed (DV)  citalopram concentration values 
for the one-compartment model used with weight and age covariates in the model.  Individual 
data points are shown as diamonds and the unity is shown as a solid line. 
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 Figure 3: Three-dimensional surface showing the relationship between age, weight and predicted 
clearance. The shading shows the exponentiated relationship for both weight and age across the 
entire range of these covariates. The surface shows how the clearance changes with both weight 
and age simultaneously. 
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 Figure 4: Dose normalized AUC in ng/mL*hr versus age in years. The AUC was calculated from 
the individual specific post-hoc predicted pharmacokinetic parameters. 
 
 
0
100
200
300
400
500
20 40 60 80 100
AGE (years)
A
U
C
0-
24
 n
g/
m
L*
hr
 
 60 
Figure 5: Observed citalopram concentrations versus population predicted citalopram 
concentrations plot of citalopram with 1-compartment model using FOCE interaction method. 
The solid line was the unity line. 
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Table 1:  Patient characteristics and data available from the Bipolar Depression and the Elderly 
Depression studies. 
 
Patient data Study A Study B 
N 40 66 
# of observations 85 114 
Sex Male:36; Female: 4 Male:33; Female: 33 
Race White:26; Black:14 White:62; Black:4 
Age range (years) 22-70 75-93 
MEAN±SD Age (years) 43.32±11.43 79.80±4.09 
MEAN±SD Weight (kg) 86.79±8.34 72.28±14.45 
MEAN±SD Dose (mg) 29.18±14.41 13.33±4.90 
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Table 2: Population model development (FOCE method) 
 
Covariate  Model -2LL ∆-2LL P value 
1 Base model 1693.136   
2-1     
CL(WT) M1 1650.527 -42.609  6.685e-11 
CL(AGE) M2 1601.486 -91.65 0 
CL(RACE) M3 1669.3 -23.836  1.047e-06 
CL(SEX) M4 1661.315 -31.821 1.691e-08 
2-2     
V(WT) M5 1680.49 -12.646 .00047027 
V(AGE) M6 1678.371 -14.765  .00012177 
V(RACE) M7 1686.147 -6.989  .00820122 
V(SEX) M8 1678.769 -14.367 .00015042 
3-1     
CL(AGE, WT) M9 1589.255 -12.23 .00047027 
CL(AGE, SEX) M10 1607.927 6.44 1 
CL(AGE, RACE) M11 1610.617 9.131 1 
3-2     
CL(AGE),V( WT) M12 1603.299 1.813 1 
CL(AGE),V( RACE) M13 1610.547 9.061 1 
CL(AGE),V( SEX) M14 1596.939 -4.547 .03297648 
4-1     
CL(WT, AGE), V(AGE) M15 1578.504 -10.75 .00104279 
CL(WT, AGE), V(SEX) M16 1593.99 4.735 1 
CL(WT, AGE), V(WT) M17 1581.881 -7.374 .00661736 
4-2     
CL(WT, AGE), V(AGE, WT) M18 1567.299 -11.2  .00081797 
 
∆-2LL was the objective function value from the covariate model minus the covariate-free model. -2LL values in 2-1 
and 2-2 were compared with base model; -2LL values in 3-1 and 3-2 were compared with M2; -2LL values in 4-1 
were compared with M9 and values in 4-2 was compared with M15. LL, log likelihood; WT, weight, Age (60 years) 
and WT (80 kg) were median values. 
Models: base model: TVCL/F= θ1, TVV/F= θ2; M1: TVCL/F= θ1*(WT/80)*θ4, TVV/F= θ2; M2: TVCL/F= θ 
1*EXP((AGE-60))*θ4, TVV/F= θ2; M3: TVCL/F= θ1+(1-Race)*θ4, TVV/F= θ2; M4: TVCL/F= θ1+(1-Sex)*θ4, 
TVV/F= θ2; M5: TVCL/F= θ1, TVV/F= θ2*(WT/80)*θ4; M6 TVCL/F= θ1, TVV/F= θ2*EXP((AGE-60))*θ4; M7: 
TVCL/F= θ1, TVV/F= θ2+(1-Race)*θ4; M8: TVCL/F= θ1, TVV/F= θ2+(1-Sex)*θ4; M9: TVCL/F=( θ1*EXP((AGE-
60))*θ4) *(WT/80)*θ5 , TVV/F= θ2; M10 TVCL/F=( θ1*EXP((AGE-60))*θ4) +(1-Sex)*θ5 , TVV/F= θ2; M11: 
TVCL/F=( θ1*EXP((AGE-60))*θ4) +(1-Race)*θ5 , TVV/F= θ2; M12: TVCL/F=( θ1*EXP((AGE-60))*θ4), TVV/F= 
θ2*(WT/80)*θ5; M13: TVCL/F=( θ1*EXP((AGE-60))*θ4), TVV/F= θ2+(1-Sex)*θ5; M14: TVCL/F=( θ1*EXP((AGE-
60))*θ4), TVV/F= θ2+(1-Race)*θ5; M15: TVCL/F=( θ1*EXP((AGE-60))*θ4) *(WT/80)*θ5 , TVV/F= θ2*EXP((AGE-
60))*θ6; M16: TVCL/F=( θ1*EXP((AGE-60))*θ4) *(WT/80)*θ5 , TVV/F= θ2+(1-Sex)*θ6; M17: 
TVCL/F=( θ1*EXP((AGE-60))*θ4) *(WT/80)*θ5 , TVV/F= θ2*(WT/80)*θ6; M18: TVCL/F=( θ1*EXP((AGE-60))*θ4) 
*(WT/80)*θ5 , TVV/F= θ2*EXP((AGE-60))*θ6*(WT/80)*θ7. 
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Table 3: PK parameter estimates for one compartment model. 
 
Parameters Cov-free model 95%CI Final model 95%CI 
Oral Clearance (L/h) 7.09 6.95-7.23 10.2 5.41-75.1 
V/F (L) 1.23 0.995-1.47 157 0.00306-2000 
Ka 0.00574 -0.851-0.862 0.0088 0.00156-5 
WT (θwt-CL) N/A N/A 0.663 0.0659-1.7 
AGE (θage-CL) N/A N/A -0.0285 -0.0416-0.0368 
WT (θwt-Vd) N/A N/A 3.61 0.0005-94.9 
AGE (θwt-Vd) N/A N/A -0.131 -0.946-1.25 
ωcl% 80.4 80.15-80.65 57.7 19.3-229.7 
ωv2% 450.5 448.6-452.5 279 0.0006-4582 
ωka% 94.9 93.1-96.7 45.1 0.00009-8700 
σ1% 17.37 -2.57-37.31 40.5 N/A 
σ2 (ng/mL) 4.39 3.49-5.29 3.46 N/A 
 
CI=confidence interval, WT=weight, V/F=volume of distribution, ω=coefficient of variation of inter-
individual variability, σ=coefficient of variation of residual error, N/A: not available 
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Table 4: Population Pharmacokinetic Model Development (1-compartment using FOCEI method) 
 
Covariate  Model -2LL ∆-2LL P value 
1 Base model 1664.743   
2-1    
CL    
WT M1 1636.694 -28.049 0.005
AGE M2 1602.017 -62.726 0.005
RACE M3 1658.054 -6.689 0.05
SEX M4 1648.254 -16.489 0.005
2-2    
V    
WT M5 1663.543 -1.2 > 0.05
AGE M6 1658.25 -6.493 0.05
RACE M7 1663.205 -1.538 0.05
SEX M8 1664.702 -0.041 0.05
3-1    
CL, V     
CL(AGE,WT) M9 1586.19 -15.827 < 0.005
CL(AGE, SEX) M10 1591.258 -10.759 < 0.05 
CL(AGE, RACE) M11 1597.967 -4.05 < 0.05 
CL(AGE),V(WT) M12 1599.33 -2.687 > 0.05
3-2    
CL and V     
CL(WT, AGE), V(AGE) M13 1577.613 -8.577 < 0.05 
CL(WT, AGE, SEX) M14 1578.305 -7.885 < 0.05 
CL(WT, AGE, RACE) M15 1581.042 -5.148 < 0.05 
 
 
<  
<  
<  
<  
 
 
  
<  
>  
>  
 
 
 
 
  
* WT=weight; CL=clearance, V=volume of distribution of central compartment; ∆-2LL was objective function 
value (OFV) form the covariate model minus the base model; -2LL values in 2-1 and 2-2 were compared with 
base model; -2LL values in 3-1 were compared with model M2; while values in 3-2 were compared with 3-1 
M9.  
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Table 5: PK parameter estimates from one-compartment model (FOCEI method) and bootstrap 
analysis 
 
 Final model result Bootstrap results 
Parameters Parameter estimate SE% Median 95% CI 
CL/F (L/h) 10.1 5.0 10.0 9.1-11 
V/F (L) 4520 47.6 3525 63.6-9673 
Ka (/h) 1.55 81.3 1.74 0.003-19445 
Age (θAge-CL) -1.1 12.5 -1.1 -1.36-0.89
WT- (θWT-CL) 0.829 25.6 0.85 0.471.22 
ωcl% 41.0 16.2 40.3 34.2-46.
ωv2% 89.5 30.5 79.4 0.0004-254
σ1% 20.5 35.5 20.4 12.8-25.
σ2 (ng/mL) 10.4 44.9 9.9 4.1-14.1 
 
2 
 
9 
  
* Abbreviations: CL=clearance, SE=standard error, weight=total body weight, V=volume of distribution of 
central compartment, ω=coefficient of variation of inter-individual variability, σ =coefficient of variation of 
residual error, WT=weight, Unit of weight=kg, Unit of age=year, 95% CI: 95% confidence interval. 
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 Abstract 
Objective: To develop a population pharmacokinetic (PK) model using sparse sampling of 
long-term treatment with paroxetine in elderly depressed subjects, incorporating CYP 2D6 
genotype as well as other covariates.   
Methods: Elderly subjects (age 70) with non-psychotic, non-bipolar major depressive 
disorder from the inpatient and outpatient clinic were treated with paroxetine in a five-year 
clinical trial investigating “Maintenance Therapies in Late-Life Depression” (MTLD-2). Plasma 
concentrations were collected during regular visits. CYP 2D6 genotype was determined using 
polymerase chain reaction (PCR) for each individual. A nonlinear mixed-effects model was 
developed with NONMEM
≥
® for those subjects who received 10 to 40 mg/day of paroxetine 
during treatment. One and two compartment models with linear and nonlinear elimination 
(Michaelis- Menten) were evaluated. Pharmacokinetic parameters as well as inter-individual and 
residual variability were estimated. The effect of age, weight, sex, race and CYP2D6 genotypes 
on the pharmacokinetics of paroxetine was evaluated.  
Results: One hundred and seventy one  subjects with a mean age of 77 years (range 69-95) 
and a mean weight of 72.0 kg (range 32.9-137.0), were enrolled in the MTLD-2 clinical trial. A 
total of 1970 paroxetine concentrations were available for population PK analyses. 
Approximately ten samples were taken per subject. A two-compartment nonlinear PK model 
with additive and proportional error provided the best base model for description of the data. 
Weight and CYP2D6 polymorphisms were found to have a significant effect on maximal 
velocity (Vm), where as sex had an effect on volume of distribution of the central compartment. 
The Vm estimates in each of the CYP2D6 phenotypic groups were: 125 µg/h in poor metabolizer 
(PM) (n=1), 182 µg/h in intermediate metabolizers (IMs) (n=28), 454 µg/h in extensive 
metabolizers (EMs) (n=36), and 3670 µg/h in ultra-rapid metabolizers (UMs) (n=5).  
Conclusions:  The population PK model adequately described paroxetine data in this elderly 
depressed population. The data indicate that female and male subjects with different CYP2D6 
polymorphisms have different elimination rates, and therefore may need to be dosed differently 
based on metabolizer genotype.  
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Introduction 
Selective serotonin reuptake inhibitors (SSRIs) are the first-line antidepressants used in 
primary care and psychiatric practices. The response rate after the first drug administration can 
be as low as 60% in the general adult population and 39% in the geriatric population.120 Large 
inter-individual variability (IIV) has been found in pharmacokinetic (PK) parameters such as 
clearance (CL), half-life, area under the curve (AUC) and pharmacodynamic (PD) parameters 
such as time to response, recurrence, and side effects. 10, 121-125  This represents a significant 
clinical problem in the treatment of psychiatric illness in geriatric subjects. Some studies have 
suggested that the PKs of SSRIs were associated with drug effect.126, 127  Thus, understanding the 
IIV in PKs is important for a PD study. 
 
Paroxetine, one of the most potent SSRIs, is widely used in the treatment of depression and 
anxiety.120 A wide range of IIV was observed for the PK parameters of paroxetine.128-131 
Following single or multiple administration of paroxetine at doses of 20 to 50 mg, the mean 
elimination half-life for healthy subjects was approximately 24 hours, with a range of 7 to 65 
hours having been reported.124 Elderly subjects taking paroxetine have higher plasma 
concentrations and slower elimination than younger subjects.124, 131 Although plasma 
concentrations have not yet been correlated with paroxetine response or adverse events, these 
results suggested the initial dosage in the elderly subjects should be reduced.  
  
Paroxetine was mainly metabolized by CYP2D6.124, 130 More than 80 allelic variants have 
been identified for the CYP2D6 gene among different ethnic populations.132 These 
polymorphisms result in variable enzymatic activity and drug-metabolizing phenotypes which 
can be classified as poor (PMs), intermediate (IMs), extensive (EMs) and ultra-rapid (UMs) 
metabolizers.133, 134 A limited number of studies have reported an association between CYP2D6 
polymorphism and paroxetine PKs. Two studies investigated the differences in paroxetine PK 
between EMs and PMs.129, 130 A seven-fold difference in the median AUC0-inf was found for 
healthy subjects receiving a single dose of 30 mg of paroxetine, and a 2-fold difference in the 
median AUC at steady state (AUCss) after multiple 30 mg doses.129 The other study found a 3-
fold difference in median steady-state concentration (Css) after multiple 30 mg doses.130 Some 
studies suggest that the distribution of CYP2D6 activity in EMs also displays substantial IIV. 
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Ozdemir135 found a 2-fold higher median Css in healthy heterozygous EMs when compared to 
healthy homozygous EMs receiving paroxetine (20 mg/day). No PMs were included in this study.  
Factors that contribute to the variability of paroxetine PK parameters in geriatric depressed 
population have not been reported.  The association between CYP2D6 polymorphisms and 
paroxetine PK in the geriatric population after chronic paroxetine treatment is unknown.  To 
investigate this association, we applied a nonlinear mixed-effect modeling approach  to 
characterize paroxetine pharmacokinetics in a placebo-controlled study (the “MTLD-2 trial) of 
the efficacy of paroxetine in preventing recurrence of major depressive episodes in people aged 
70 and above. Mixed effect population PK approach is the study of the sources and correlates of 
variability in plasma concentrations between individuals,36 which is currently widely used in 
evaluation of drug safety and efficacy. Compared with the traditional pharmacokinetic approach, 
population pharmacokinetics is more suitable for analyzing large scale clinical trials, where only 
a few samples are available per subject.  
The purpose of this study was a): to apply a nonlinear mixed effect modeling approach to 
describe paroxetine PK parameters using limited sampling in a large number of geriatric subjects 
from the MTLD-2 clinical trial, and b): to evaluate the impact of covariates including age, 
weight, sex, race, and CYP2D6 polymorphisms on the PK parameters. 
 
Subjects and Methods 
Subject 
The Maintenance Therapies in Late-Life Depression (MTLD-2) study 136  assessed  
paroxetine as a maintenance treatment for prevention of recurrent episodes of major depression 
in geriatric subjects.  Subjects (aged 70 or older) were included if they met the diagnostic criteria 
from the Structured Clinical Interview for DSM-IV Axis I disorders (SCID) for a current episode 
of major depressive disorder, non-bipolar, non-delusional, and not actively suicidal. Subjects 
also were required to score 15 or above on the 17-item Hamilton Rating Scale for Depression 
(HAMD-17) and 18 or higher Folstein Mini-Mental State Exam (MMSE).  All the study sites 
were located in Pittsburgh. The study was approved by institutional review committee of the 
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University of Pittsburgh and the written informed consent to participate in this study was 
obtained from each subject.  
 
There were three phases of paroxetine treatment.  Subjects were treated during an initial 
acute phase (which could last up to 26 weeks) to assess for response, followed by a 16-week 
continuation phase for those subjects who responded.  Subjects with a continued response 
(recovered based on the 16 week continuation phase) entered the two-year maintenance phase 
and were randomly assigned to a placebo group or to paroxetine.  A responder was defined by a 
HAMD-17 score of less than 10 for three consecutive weeks. Recovery was defined as being free 
of significant depressive symptoms for 16 weeks of continuation treatment.  Recurrence in 
maintenance treatment was defined by a HAMD-17 score over 15 for at least 2 consecutive 
weeks and meeting SCID criteria for syndromal major depressive episode, confirmed by an 
independent senior geriatric psychiatrist. The acute and continuation phases were open-label, and 
the maintenance phase was double-blind. Subjects visited the clinic weekly during acute 
treatment, twice monthly during continuation treatment, and monthly during maintenance 
treatment. Plasma paroxetine samples were taken at each visit for concentration measurement. 
No specific timing was scheduled for the paroxetine sampling.  The dosage time was noted for 
inpatient subjects and was self-reported by outpatients. 
 
Paroxetine was started at 10 mg daily and could be titrated to a higher dose based on 
response. Subjects received paroxetine doses ranging from 10 mg to 40 mg daily.  De-identified 
data were applied in a population pharmacokinetic analysis, where the identification (ID) number 
for each subject was changed by replacing the original ID numbers by a randomly generated 
number.  
 
Analytical Procedures 
Paroxetine plasma concentrations were determined by HPLC technique, as previous 
described.137  Briefly, plasma was extracted using ethyl acetate and heptane (1:4, v/v) and back 
extracted into 0.025 M potassium phosphate, pH 2.4. Separation was achieved using a Beckman 
Ultrasphere C18 (150 mm×2 mm) column. Detection wavelength was 205 nm and flow rate was 
0.35 ml/min. Fluoxetine hydrochloride was used as the internal standard. The limit of 
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quantitation was 5 ng/ml. The linear range was 5 to 500 ng/ml with inter-assay variability 
ranging from 3.4% to 5.4% for spiked controls.  
 
CYP2D6 Genotyping  
After separating lymphocytes from whole blood using BD Vacutainer CPTTM tubes, DNA 
was extracted using the standard procedure.138, 139 Genomic DNA fractions were stored at -20°C.  
A polymerase chain reaction (PCR)-based allele-specific analysis previously described,140 
was used to determine whether individuals were carrying duplicated CYP2D6 genes (CYP2D6 
*XN), and long PCR was used to amplify a fragment spanning the potential crossing-over 
sites.140, 141  An allele-specific long PCR method developed by Steen et al 141, 142 was used to 
detect CYP2D6 *5 (gene deletion). Nested PCR was performed to detect CYP2D6*2, *4, *10 
and *17 by amplifying the entire CYP2D6 gene (5 kb).140, 143-145 After amplification of the entire 
gene, subsequent internal PCR was performed to identify the presence of the CYP2D6*2 
(C2938T), *4 (G1934A), *10 (G4286C) and *17 (C1111T) allele. When no mutations were 
found, the allele was defined as CYP2D6 *1. The specific primers, restriction enzyme, restriction 
pattern, and agarose gel for these alleles were shown in Table 1.  
 The allelic frequency was calculated using the equation: 
 Allelic frequency for the variant allele 
 = (Homozygous alleles × 2 + Heterozygous alleles) / (Total subjects × 2) 
 
     CYP2D6 genotype was classified into one of four phenotype groups (Table 2) based on the 
phenotype-genotype relationship reported in the literature.146, 147 Subjects carrying two 
nonfunctional alleles (*0/*0) were assigned to the PM group. Subjects carrying one normal or 
reduced functional allele and one reduced or nonfunctional allele were assigned to the IM group. 
Subjects carrying two normal functional alleles were assigned to the EM group and subjects 
carrying one *XN allele were assigned to the UM group.  
 
      Population Pharmacokinetic Analysis 
      The population PK analysis includes the base model and final (covariate) model development. 
The base model defines the PK parameters and describes the plasma concentration-time profile. 
The final model describes the influence of fixed effects (i.e., demographic factors) on the PK 
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parameters. Analysis platform, minimization methods, model building criteria and model 
validation were described below.  
 
Analysis Platform  
Non-linear Mixed Effects Modeling was used for the population PK analysis using 
NONMEM computer program (Version 5, level 1.1, Globomax, Hanover, MD). 40, 79  The 
models consisted of a structural model that described the disposition of the drug following oral 
administration, and a pharmaco-statistical model that described the inter- and intra-individual 
variability. Diagnostic graphics, exploratory analyses, and post-processing of NONMEM outputs 
were performed using S-PLUS (Version 6.2, Insightful, Seattle, WA). 
 
Minimization Methods and Model Building Criteria 
The first order estimation method (FO) was used for model building. The adequacy of the 
developed structural models was evaluated using both statistical and graphical methods. The 
likelihood ratio test was used to discriminate between alternative models. The likelihood ratio 
test was based on the property that the ratio of the NONMEM objective function values (OFV) (-
2 log-likelihood) were asymptotically χ2 distributed. An objective function decrease of 3.84 units 
was considered significant (χ2 p < 0.05 df=1). Standard errors for all parameters were obtained 
using the covariance option in NONMEM.  
 
Base Model Development     
Structural PK Model: The structural PK model represents the best description of the data 
without considering the effect of subject-specific covariates. The population PK analysis was 
performed using NONMEM® 40, 79 with the subroutine ADVAN9, ADVAN2 TRANS2 and 
ADVAN4 TRANS4. Various structure models were tested, including one and two compartment 
model, model with linear, nonlinear elimination (Michaelis - Menten) and combination nonlinear 
with linear elimination.  
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Inter-individual Variability: It was assumed that the IIV of the PK parameters was log-
normally distributed. The relationship between a PK parameter (P) and its variance could 
therefore be expressed as shown below: 
PePP TVj
η×=           
where, Pj was the value of PK parameter for the individual j, PTV was the typical value of P for 
the population, and ηP denoted the difference between Pj and PTV, independently, which was 
identically distributed with a mean of zero and variance of ωP2. 
 
Intra-Individual Variability: The residual variability, which was comprised of, but not 
limited to, intra-individual variability, experimental errors, process noise and /or model 
misspecifications, was modeled using additive, proportional and combined error structures as 
described below: 
Additive error: ijijij yy ε+= ˆ  
Proportional error: )1(ˆ ijijij yy ε+=  
Combined additive and proportional error: ')1(ˆ ijijijij yy εε ++=  
where  was the jijy
th observation in the ith individual,  was the corresponding model 
prediction, and 
ijyˆ
ijε  (or 'ijε ) was a normally distributed random error with a mean of zero and a 
variance of σ2.  
 
Final Model Development 
The final model was developed by testing the effect of subject specific covariates, 
including age, weight, sex, race, and CYP2D6 polymorphisms on PK parameter estimates. The 
two types of covariates, including continuous covariates (e.g., age and weight) and discrete 
covariates (e.g., sex, race and CYP2D6 polymorphisms) were introduced into each parameter in 
a stepwise fashion.  The following example showed the effect of a continuous covariate on Vm 
(maximal rate): 
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Cov
CovVm MedCovTVVm
θθ )/(×=  
TVVm was the typical value for the population; The random effects of between-subject 
variability were assumed to be log-normally distributed, with a mean of zero and standard 
deviation of ω. Cov was the continuous covariate that was affecting Vm; and MedCov was the 
median Cov.  
 
The following example shows the effect of a discrete covariate (sex) on Vm: 
SexVm SexTVVm θθ ×−+= )1(  
When sex was female (male=0, female=1), TVVm equals θVm since numeric value for (1-
female) = 0 resulting in a zero multiplier for the covariate effect. For male subjects, the θSex term 
was added to the population estimate of Vm to modify it.  
      Categorical variables were assigned to each of the four CYP2D6 phenotype groups 
and for the subjects without CYP2D6 phenotype information (i.e, PMs = 1, IMs =2, EMs = 3, 
UMs=4, Missing=0). The incorporation of this covariate was shown here for the parameter Vm 
below: 
IF (PHENOTYPE.EQ.0) TVVM= θVm
IF (PHENOTYPE.EQ.1) TVVM= θPMs
IF (PHENOTYPE.EQ.2) TVVM= θIMs
IF (PHENOTYPE.EQ.3) TVVM= θEMs 
IF (PHENOTYPE.EQ.4) TVVM= θUMs 
ieTVVMVmi
η×=         
The graphical assessment of POSTHOC parameter estimates versus covariates was 
evaluated to help identify possible covariate relationships using S-PLUS 6.2. In addition, 
goodness of fit plots were utilized to assess model robustness.83 The covariate was retained in the 
model if it decreased the objective function value (OFV) by 3.84 (χ2 p < 0.05 df = 1). Covariate 
influence on inter-individual variability and goodness of fit was also examined. In cases where 
the covariate value was not recorded at any time during the study for the subject, the median 
value calculated from the population dataset was used.  
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Results 
Patient Characteristics  
The MTLD-2 clinical trial included 171 elderly subjects (58 males) who provided 1970 
paroxetine concentrations. Subjects had an average (mean±SD) age and weight of 77.1±5.7 years, 
72.0±16.4 kg, respectively (Table 3). With the exception of three subjects who were 69 years of 
age, subjects aged 70 years or older were included in the MTLD-2 study.  The majority of the 
subjects were Caucasian (CA) (n=156) and only fifteen subjects were African - American (AA).  
The distribution of paroxetine sampling time (time after dose) was shown in Figure 1. 
 
CYP2D6 Genotyping  
CYP2D6 genotype was classified into one of four phenotype groups (Table 2) based on 
phenotype-genotype relationship reported in the literature, as described in methods section.146, 147  
Among the 171 subjects, whole blood was available from 68 subjects for CYP2D6 genotyping 
analysis. Of these 68 subjects, 4 were AA and 64 were CA. Five subjects were identified as UMs, 
36 subjects were EMs, 26 subjects were IMs, and one subject was a PM.  
The frequency of each CYP2D6 alleles was summarized in Table 4.  The CYP2D6 *17 
allele, an African and African-American specific allele found in previous studies, 134, 148 was 
found in only 25% of the AAs in this study.  CYP2D6 *2N was only found in CA subjects.  
 
Population PK modeling  
 Base Model       
The population PK analysis was performed by using NONMEM® (version V, GloboMax, 
Hanover, MD) 40 with the subroutine ADVAN9. A two-compartment nonlinear model with 
exponential inter-individual variability on Vm, the Michaelis-Menten constant (Km), and volume 
of distribution of the central compartment (V2) adequately described the data. The best residual 
error model was a combined additive and proportional model. The basic PK parameters of Vm, 
Km, V2, volume of distribution of the peripheral compartment (V3) and absorption rate constant 
Ka were shown in Table 5.   
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A two-compartment model was determined to be the robust, based on the Akaike 
information criterion (AIC) 47 (AIC = 17265.0, one-compartment; AIC = 17149.9, two-
compartment). Moreover, the decrease in residual error (50% decreased in additive residual error) 
and bias of data fitting were also observed. Nonlinear elimination model improved OFV by 
114.0 units (p < 0.001) compared to the linear elimination model. Combination of linear and 
nonlinear elimination model did not further improve model fitness or reduce the OFV value 
(∆OFV = -3.2, p > 0.05).   
 
Final Model 
CYP2D6 phenotype was the covariate on Vm that resulted in the largest reduction in 
objective function value (∆OFV=-137.9; P<0.005). Weight was a significant covariate on V2 
(∆OFV =-69.64; P<0.005). After incorporating the CYP2D6 phenotypic effect on Vm, sex was a 
significant covariate on V2 (∆OFV=-107.1; P<0.005). After incorporating the CYP2D6 
phenotype on Vm and sex on V2, the incorporation of weight on Vm further improved model 
fitness by reducing OFV 62.66units (P<0.005). The detailed covariates selection during model 
development was shown in Table 6. The final model Vm and V2 was: 
 
IF (PHNO.EQ.0) TVVM=θ1
IF (PHNO.EQ.1) TVVM= θ7
IF (PHNO.EQ.2) TVVM= θ8
IF (PHNO.EQ.3) TVVM= θ9
IF (PHNO.EQ.4) TVVM= θ10 
11)75/(*1 θWTTVVMTVVM =  
   VM=TVVM1*EXP(ETA(1)) 
   TVV2= θ3 + (1-SEX)* θ12
   V2=TVV2*EXP(ETA(3)) 
 
The final PK parameter estimates were shown in Table 5. Diagnostic plots were shown in 
Figure 2, including observed paroxetine concentrations versus population predicted paroxetine 
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concentrations (Figure 2a); observed paroxetine concentrations versus individual predicted 
paroxetine concentrations (Figure 2b); weighted residual error (WRES) versus population 
predicted concentrations (Figure 2c); and WRES versus time (Figure 2d).  Compared to the base 
model, proportional and additive residual error was reduced by 12.5% and 20.4% respectively, in 
the final model. The inter-individual variability on Vm and V2 both decreased by 41.9%. The 
standard error (SE) of IIV estimation of Vm was reduced by 66.1% and SE of IIV estimation of 
V2 was reduced by 92.6%. The SE of Vm, Km, and V3 estimates were also decreased in the final 
model.  However, the estimation of IIV on Km and the SE of IIV of Km increased.  
The order of magnitude for the Vm estimates by CYP2D6 phenotype was: UMs > EMs > 
IMs > PMs (Figure 3), which corresponded to the functional allele of the CYP2D6 gene.  The 
population mean (%SE) of Vm estimates in the final model for each CYP2D6 phenotype group 
were: 125 µg/h (48.8%) in PM, 182 µg/h (19.4%) in IMs, 454 µg/h (49.5%) in EMs, and 3670 
µg/h (34.6%) in UMs. The 95% confidence intervals (CI) of Vm in each phenotype group were: 
64.41-444.09 µg/h in IMs, 191.35-895.96 µg/h in EMs, and 2073.70-7006.30 µg/h in UMs, 
(95%CI is unavailable for PM group with n=1). The estimates of V2 in male subjects were: 
461.30 ± 259.75 L and in female subjects were: 346.41 ± 255.81 L. 
Age did not affect paroxetine disposition in this study, although the Vm estimates in 
subjects aged 80 or older appeared to be lower than subjects younger than 80 years. The median 
(25th and 75th percentile) of Vm estimates in subjects aged 80 or older was 275 µg/h (198 µg/h 
and 468 µg/h); in subjects with age less than 80 years was 419 µg/h (291 µg/h and 620 µg/h). 
Race was a significant covariate on paroxetine PK if CYP2D6 phenotype was not 
included in the PK model (Table 3).  However, once the CYP2D6 phenotype was included in the 
model, race did not significantly impact on paroxetine PK parameters.  
 
Discussion 
The molecular basis of the CYP2D6 polymorphism has been intensively studied, and 
more than 80 allelic variants, including nonfunctional, normal, reduced or increased functional 
alleles, have been identified for the CYP2D6 gene among different ethnic populations.132, 134 
These polymorphisms result in variable enzymatic activity and drug-metabolizing phenotypes, 
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which can be classified as PMs, IMs, EMs and UMs metabolizers.133, 134 Paroxetine is mainly 
metabolized by CYP2D6 enzyme. However, the relationship between CYP2D6 genotype and 
paroxetine PKs in the geriatric population has not been reported. This is the first study to assess 
the impact of CYP2D6 genotype as well as other factors (e.g., weight, sex, age, and race) on 
paroxetine PKs by using a population modeling approach in a geriatric depressed population 
with small number of samples per subjects.  In addition, we have captured the individual specific 
drug exposure magnitude over time.  This provides a basis where the magnitude of exposure can 
be examined in conjunction with the maintenance response of subjects in this study in a future 
study as response data become available. 
Both one and two-compartment nonlinear PK models demonstrated that CYP2D6 
polymorphisms and weight were significantly related to paroxetine Vm and sex significantly 
impacts V2.  The two-compartment PK model was a better description of the data than the one-
compartment model, based on the significantly reduced OFV value and a better goodness of fit. 
The Vm estimates in each CYP2D6 phenotype groups showed that UMs had the highest Vm 
than other CYP2D6 phenotype groups, while PMs had the lowest Vm population estimate. The 
order of magnitude for Vm estimates by CYP2D6 phenotype was: UMs > EMs > IMs > PMs and 
the Vm estimates were: 125 µg/h in PM, 182 µg/h in IMs, 454 µg/h in extensive metabolizers 
(EMs), and 3670 µg/h in ultra-rapid metabolizers (UMs). The order of magnitude of the Vm 
estimate was consistent with the CYP2D6 functional alleles, where the UM phenotype could be 
caused by alleles carrying multiple 2D6 gene copies134, 143 and the PM phenotype was the result 
inheriting of any 2 nonfunctional (null) alleles (genotype *0/*0). The IM phenotype was the 
result of both heterozygosity for a null allele and homozygous for two alleles with impaired 
function (e.g *9, *10, *17). Moreover, the model was able to differentiate IMs and PMs groups. 
Comparing the differences of Vm estimates between CYP2D6 genotype groups, Vm estimates 
between PMs (125 µg/h) and IMs (182 µg/h) was similar, which agreed with the suggestion from 
several studies that the IM phenotype was of clinical importance because drug PKs in IMs could 
be more similar to the PMs than to the normal EMs, especially after chronic treatment.147 The 
Vm for subjects without having CYP2D6 genotype information was 474 µg/h, which is similar 
to the estimation of Vm in the EMs (454 µg/h), since EMs is the most frequent genotype in both 
the CA and AA populations.  
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Nonlinear pharmacokinetics of paroxetine was found in EMs in the study of Sindrup et al. 
129, 130   One explanation of this finding was saturation of CYP2D6 metabolic capacity, where 
CYP2D6 enzyme activity seems readily to saturate as paroxetine dose increase, as demonstrated 
by Sindrup et al130 and Preskorn.149  Another  possibility relates to the self-inhibition of 
paroxetine metabolism, since paroxetine itself can inhibit CYP2D6 enzyme activity.130, 150 
Without considering self-inhibition, the model with nonlinear elimination (Michaelis-Menten) 
could under-predict paroxetine concentrations.  However the result of MTLD-2 data analysis did 
not support the self-inhibition mechanism, as no bias or under-prediction was found in the 
diagnostic plots of the weighted residual verse predicted paroxetine concentrations and the 
weighted residual versus time. Moreover, the model was tested with different elimination 
mechanisms (e.g., simple noncompetitive inhibition and uncompetitive inhibition 151, 152; data not 
shown). Model fitness was not significantly improved based on OFV values and diagnostic plots.  
Previous studies had reported that paroxetine was mainly metabolized by the high affinity 
enzyme CYP2D6 124, 130 and the low affinity enzyme e.g., CYP3A4 124, 129. Accordingly, models 
with linear, nonlinear, and combined linear and nonlinear elimination were evaluated. Results 
showed that the nonlinear elimination model improved the model fitness and significantly 
decreased the OFV value compared to the linear elimination model. However, the combined 
model with linear and nonlinear elimination did not provide further improvement in model 
fitness.   
Elderly subjects taking oral paroxetine had higher plasma concentrations than younger 
subjects.124, 131 Age was identified as a significant covariate on the PKs of another SSRI, 
citalopram. 10 Age was not a significant covariate on paroxetine PK in this study, although the 
Vm estimates in subjects aged 80 or older appeared to be lower than subjects younger than 80 
years. The small sample size in the MTLD-2 study may lead to a decreased ability to detect an 
age effect in this study.  
Race was determined to be a significant covariate in both the one and two-compartment 
PK models when CYP2D6 genotype information was not incorporated in the model. 153 One 
possible explanation was related to the correlation between race and genotypes. The frequency of 
*4, the most frequent null allele in CAs, was about 3 fold higher than in AAs.134, 143 The 
CYP2D6 *17 allele was an African and African-American specific allele found in previous 
studies and this study. 134, 154  CYP2D6 *2N was only found in CA subjects in this study.  When 
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CYP 2D6 genotype was incorporated, this race effect was no longer significant. The frequency 
of UMs in CA was 8%, which may be more reflective of Pittsburgh Caucasian population, since 
the frequency of UMs is higher in Southern Europe (10%) than that in North Europe (1-2%).134  
 
Conclusion 
The population PK model adequately described paroxetine PK parameters in subjects with 
late-life depression. The results suggest that weight, sex and genotype contribute to the 
variability in PK parameters, and that therefore, individuals of different sex or with a different 
genotype may need to be dosed differently from one another.  
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Table 1: Conditions of CYP2D6 genotyping study: including the specific primers, restriction 
enzyme, restriction pattern, and agarose gel.  
 
Table a. Long PCR for CYP2D6 genotype determination 
CYP2D6 Allele Specific Primers PCR product (kb) Agarose gels 
2D6 F: 5'-CCAGAAGGCTTTGCAGGCTTCA-3' 
R: 5'-ACTGAGCCCTGGGAGGTAGGTA-3' 
5.0 0.85% 
2D6-dup F: 5'-CCTGGGAAGGCCCCA TGGAAG-3' 
R: 5'-CAGTTA CGGCAGTGGTCAGCT-3' 
3.5 0.85% 
*5 (deletion) F: 5'-ACCAGGCACCTGTACTCCTCA-3' 
R: 5'-GCATGAGCTAAGGCACCCAGAC-3' 
3.5 0.9% 
 
 
Table b. Re-amplification reactions performed for CYP2D6 genotype determination 
CYP2D6 Allele 
(Mutation) 
Specific Primers Restriction 
enzyme 
Restriction pattern 
(bp) 
Agarose 
gels 
*2 (C2938T) F: 5'-AGGCCTTCCTGGCAGAGATGGAG-3' 
R: 5'-CCCCTGCACTGTTTCCCAGA-3' 
cfo I wt:260, 126 
mut: 386 
2.0% 
*4 (G1934A) F: 5'-TGCCGCCTTCGCCAACCACT-3' 
R: 5'-CTCGGTCTCTCGCTCCGCAC-3' 
Bst NI wt:292 
mut: 111, 181 
1.5% 
*10 (G4286C) F: 5'-GAGACAAACCAGGACCTGCCA-3' 
R: 5'-GCCTCAACGTACCCCTGTCTC-3' 
BstEII wt:860 
mut: 240, 620 
1.8% 
*17 (1111C) 
(wt) 
F: 5'-CCAAGGTTCAAATAGGACTA-3' 
R:5'-CCCGAAACCCAGGATCTGGG-3' 
 wt: 237 1.5% 
*17 (1111T) 
(mut) 
F: 5'-CCAAGGTTCAAATAGGACTA-3' 
R: 5'-CCCGAAACCCAGGATCTGGA-3' 
 mut: 237 1.5% 
 
 
* wt: wild type; mut: mutant; F: forward primer; R: reverse primer 
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Table 2: Genotype/Phenotype frequencies in Caucasian (CA) and African - American (AA) 
subjects in the MTLD-2 trial 
 
CA AA Allele 
status 
Assigned 
phenotype 
Genotype 
Frequency (%) n Frequency (%) n
0 PMs *0/*0 1.6 1 0 0
1 IMs IM/*0, IM/IM, EM/*0, EM/IM 39 25 75 3
2 EMs EM/EM 52 33 25 1
3 UMs UM/*X 7.8 5 0 0
 
 
* 0 = non-functional alleles (e.g *4, *5); 1 = one normal functional (EM: *1, *2) or reduced-functional 
allele (IM: *10, *17), plus a reduced or non-functional allele; 2 = two functional alleles or *XN allele 
plus other allele (UM). CA: Caucasian; AA: African - American.   
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 Table 3: Patient characteristics for the MTLD-2 study 
 
 
Demographics MEAN±SD  
(Range) 
Sample size 171 
 
# of observations 1970 
 
Age (years) 77.1±5.8 
(69-95) 
Weight (kg) 72.0±16.4 
(32.9-137.0) 
Gender  Male: 58 
Female: 113 
Race Caucasian: 156 
African-American: 15 
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 Table 4: CYP2D6 allele frequency in Caucasian and African - American patients 
 
CYP2D6 
allele 
N of CA Allele frequency 
in CA 
N of AA Allele frequency 
in AA 
*1 48 0.38 1.00 0.13 
*2 45 0.35 4.00 0.50 
*4 22 0.17 1.00 0.13 
*5 4 0.03 0.00 0.00 
*17 0 0.00 2.00 0.25 
*10 4 0.03 0.00 0.00 
*2x2 5 0.04 0.00 0.00 
  
CA: Caucasian; AA: African - American   
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 Table 5:  PK parameter estimates for the two-compartment model 
Parameters Base model Estimates SE% Parameters Final model Estimates     SE% 
Vm (µg/h) 208 32.5 Vm (µg/h) 474 19.3 
Km (µg/L) 157 83.4 Km (µg/L) 205 24.67
V2 (L) 254 6.70 V2 (L/ 75 kg WT) 230 8.60 
V3 (L) 2350 102.1 V3 (L) 900 81.1 
Q (L/h) 1.33 12.3 Q (L/h) 1.05 25.3 
Ka (/h) 9.24 8.8 Ka (/h) 9.81 28.0 
PM (θVm) N/A N/A PM (θVm) 125 
IM (θVm) N/A N/A IM (θVm) 182 
EM (θVm) N/A N/A EM (θVm) 454 
UM (θVm) N/A N/A UM (θVm) 3670 
WT(θV2) N/A N/A WT(θV2) 1.83 
Sex (θV2) N/A N/A Sex (θV2) 99.3 
ωVm% 155 168.8 ωVm% 90.0 
ωKm% 79 19.4 ωKm% 109 
ωv2% 134 245.3 ωv2% 77.8 
σ1% 40 14.0 σ1% 35.1 
σ2 (µg/L) 10.8 90.6 σ2 (µg/L) 8.60 103
 
48.8 
19.4 
49.5 
34.6 
50.1 
42.9 
57.3 
56.1 
18.2 
14.4 
 
 
 
Abbreviations: Vm=maximal rate, Km=Michaelis-Menten constant (concentration at half Vm), 
SE=standard error, WT=total body weight, V2=volume of distribution of central compartment, 
V3=volume of distribution of peripheral compartment, ω=coefficient of variation of inter-individual 
variability, σ=coefficient of variation of residual error, N/A: not available, Unit of weight=kg. 
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 Table 6: Population Pharmacokinetic Model Development (2-compartment with nonlinear 
elimination) 
Covariate  Model -2LL ∆-2LL P value 
1 Base model 17137.900   
2-1    
Vm    
CYP2D6 M1 16977.144 -160.76  < 0.005 
WT M2 17079.98 -57.92 0.005
AGE M3 17143.06 5.155 
RACE M4 17133.65 -4.25  < 0.05 
SEX M5 17070.42 -67.48 0.005
2-2    
V2    
CYP2D6 M6 17071.83 -66.07 < 0.005
WT M7 17068.262 -69.64 0.005
AGE M8 17134.346 -3.55 
RACE M9 17142.224 4.32 > 
SEX M10 17080.828 -57.07 0.005
3-1    
Vm, V2     
Vm(CYP2D6, WT) M11 16876.32 -100.82 < 0.005 
Vm(CYP2D6), V2(WT) M12 16900.59 -76.55 < 0.005 
Vm(CYP2D6), V2(SEX) M13 16892.90 -84.24 < 0.005 
Vm(CYP2D6, RACE) M14 16977.165 0.021 > 0.05 
3-2    
Vm and V2     
Vm(CYP2D6), V2(SEX, WT) M15 16861.53 -31.37 < 0.005 
Vm(CYP2D6, WT), V2(SEX) M16 16830.24  -62.66  < 0.005 
 
 
<  
> 0.05 
<  
 
 
 
<  
> 0.05 
0.05 
<  
 
 
  
* WT=weight; V2=volume of distribution of central compartment; ∆-2LL was objective 
function value (OFV) form covariate model minus base model; -2LL values in 2-1 and 2-2 
were compared with base model; -2LL values in 3-1 were compared with model M1; while 
values in 3-2 were compared with 3-1 M13 and M11. The incorporation of covariates was 
described in the methods section. 
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Figure 1: Frequency histogram showing the sampling distribution for paroxetine sampling 
measurements. The x-axis is broken into 1-hour bins. The y-axis is the proportion of samples 
taken in each interval. 
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Figure 2: Diagnostic plots of final PK model.  
Figure 2a: Plot of population predicted paroxetine concentrations versus observed paroxetine 
concentrations.  Individual data points were shown as dots and the unity line is shown as a solid 
line. 
Observed paroxetine concentrations (ng/mL)
Po
pu
la
tio
n 
pr
ed
ic
te
d 
pa
ro
xe
tin
e 
co
nc
en
tra
tio
ns
 (n
g/
m
L)
0 200 400 600 800
0
10
0
20
0
30
0
40
0
 
Figure 2b: Plot of individual population predicted paroxetine concentrations versus observed 
paroxetine concentrations. Individual data points were shown as dots and the unity line is shown 
as a solid line. 
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Figure 2c: Plot of weighted residual error (WRES) verse population predicted concentrations  
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Figure 2d: Plot of WRES verse time.  
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Figure 3: Boxplot of Vm estimates for each CYP2D6 phenotype group. Dots in each group were 
median values. Notches show approximate 95% confidence limits for the median.  
CYP2D6 genotype was classified into one of the four CYP2D6 phenotype groups based on the 
phenotype-genotype relationship. In this plot, PMs = poor metabolizers, IMs =Intermediate 
metabolizers, EMs = extensive metabolizers, UMs=ultra-rapid metabolizers. Missing = Subject 
was missing CYP2D6 phenotype information.  
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CHAPTER 5 EVALUATION THE CONSISTENCY OF EXPOSURE USING THE 
PREDICTED/OBSERVED CONCENTRATION RATIO 
 
 
 
 
 
 
 
This chapter is based on the following paper: 
Yan Feng, Marc Gastonguay, Robert. R. Bies. Evaluation the consistency of exposure using the 
predicted/observed concentration ratio. Journal of Pharmacokinetics and Pharmacodynamics, 
2006 (In preparation) 
 
Copyright is to be assigned to Journals Rights & Permissions Controller (Springer Publishing) if 
the manuscript is accepted for publication. Once the paper is accept in Journal of 
Pharmacokinetics and Pharmacodynamics, the copyright transfer form will be signed by us, 
which including the rights of using the full article in the thesis. 
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 Abstract    
Purpose: The aim of this study was to evaluate the stability and robustness of using the 
deviation between Nonlinear Mixed Effects PK model-predicted concentration and observed 
drug concentration as a measure of erratic drug exposure driven primarily by variable adherence. 
 
Background: Non-adherence is very common among subjects in the schizophrenia and 
depression treatment. Research has demonstrated that there is a higher probability of re-
hospitalization for poorly adherent schizophrenic subjects 155. The relationship between  the 
pattern of fluoxetine dose intake and the probability of positive response among subjects with 
major depressive disorder showed to be related not to the absolute adherence rate but rather the 
time to the first drug holiday in the treatment regimen 33. Therefore, measuring an individual’s 
specific adherence characteristics is potentially very important information in clinical trials, since 
non-response or adverse drug effect may be caused by the inconsistent intake of the drug.  
 
Methods: Population pharmacokinetic (PK) modeling in conjunction with dosage history 
information comprising the input to the PK model from the Medication Event Monitoring 
System (MEMS) was used to evaluate the consistency of exposure in the two simulated trials 
with atypical antipsychotic and antidepressants. Escitalopram (long half-life drug) and 
risperidone (short half-life drug) were selected as the representative drugs from the clinical trials. 
The observed adherence rate was calculated based on weekly and 2 days adherence pattern for 
MEMS data obtained from the clinical trial. The distribution of the deviation between the 
predicted and observed concentrations (Cpred/Cobs and Cipred/Cobs ratio) was evaluated across 
all adherence rate patterns under the situations when the subjects’ correct (negative control) or 
incorrect / assumed (positive control) dosing history was applied in population PK analysis. The 
relationship between this ratio and adherence rate was assessed under the conditions of the 
positive control. The adherence rate was then assigned based on the relationship described above 
and the classification error of this approach was calculated under each adherence condition. The 
bias and precision of the PK parameter estimates was also evaluated under both positive and 
negative control conditions. 
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Results: MEMS data showed that the adherence rates varied within subjects during 
treatment in the real clinical setting.  Concentrations tended to be over-predicted in the poorly 
adherent subjects and under-predicted in the highly adherent subjects. The relationship between 
rate and ratio was adequately described by exponential functions. The rate was well classified for 
the clinical events under extreme conditions, e.g., very high and very low adherence rates. The 
Cipred/Cobs ratio was found to be more differentiable than Cpred/Cobs ratio under positive 
control, which was suggested by the mean ratio between adherence rate conditions. It was also 
shown that the percentage of  correctly classified adherence rates was higher based on the 
relationship between Cipred/Cobs ratio and adherence rate than that based on the Cpred/Cobs 
ratio. For both long and short half-life drugs, the parameters tended to be more biased and less 
precisely estimated using the incorrect dosing history 
 
Conclusion: This simulation study demonstrated the usefulness of population PK 
modeling in combination with MEMS information in deriving a Predicted to Observed ratio 
metric that aimed to reflect the connection to the consistency of exposure.  The deviation 
between the individual model-predicted concentrations and concentration measurements could 
only adequately reflect the extremes in adherence conditions (i.e., >100% and <5%).   
Keywords: adherence, MEMS, dosing history, NONMEM, modeling and simulation 
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1. Introduction 
Mixed effect population pharmacokinetics (PK) is the study of the sources and correlates 
of variability in plasma concentrations between individuals, 36, 156 which is currently widely used 
in evaluation of drug safety and efficacy. Population PK analysis also shows great advantage of 
analyzing large scale clinical trials where only a few samples are available per subject.10  
Unfortunately, the drug dosing history is often poorly recorded and the extent of noncompliance 
is usually underestimated, which can cause biased estimation for a population PK analysis and 
may mislead the decision making in clinical trials and drug pharmacotherapy. 17-23 Vrijens 
reported that using the detailed records of the subjects’ dosing history helps to achieve 
convergence in model fitting under the sparse sampling measurement situation,157 explaining 
40% of residual variability in the plasma lopinavir concentrations and reduced the overall 
variability by 55%.158 Non-adherence is very common among subjects receiving treatment for 
schizophrenia or depression. Research also demonstrated that poorly adherent schizophrenic 
subjects had a higher risk of re-hospitalization.155 Another study demonstrated the relationship of 
the time to first drug holiday with fluoxetine treatment and the probability of response among 
subjects with major depressive disorder. 33 Therefore, measuring an individual’s specific 
adherence condition is a very important piece of information in clinical trials, as the non-
response or adverse drug effect may be caused by inconsistent drug intake.   
 
Many studies have shown 17-22 that inaccurate dosing history information biases estimates 
of PK and pharmacodynamic (PD) parameters in hierarchical Bayesian analyses. Utilization of a 
prior established PK/PD model may allow one to utilize these biases by evaluating the deviation 
between the prior model predicted and the observed drug concentrations (Cpred/Cobs and 
Cipred/Cobs ratio). This deviation may be used to infer consistency of exposure to drug. 
Brundage 32, 159 showed that the Cobs/Cpred ratio correlated with virologic escape in pediatric 
HIV patients, where the greater the number of Cobs/Cpred ratios outside a specified limit, and 
thus less consistent the exposure, the shorter time of the first viral rebounds. Based on the work 
by Brundage, 159we evaluated 23 whether the Cpred /Cobs ratio could discern erratic versus 
consistent drug exposure arising from good versus poor adherence to drug therapy by using 
model-based simulation approach.  In the study, the magnitude of the Cpred/Cobs ratio increased 
with decreasing adherence rates indicating that Cpred/Cobs could discriminate between good and 
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poor adherence rates. However, when adherence become very low, the ratio unexpectedly 
decreased although the magnitude remained higher than unity.23  This raises the question of 
utility of this ratio under conditions of extremely poor adherence. There are several possible 
explanations for this observed decrease in the magnitude of the Cpred/Cobs ratio under 
conditions of extremely low adherence. As patients become less and less adherence to drug 
therapy, this may result in a greater number of concentration measurements below the limit of 
quantitation (BLQ). Censoring of these observations in the analysis may result in a smaller 
number of ratios contributing to the calculation of the overall Cpred/Cobs ratio for that 
adherence group.  In addition, the ratios that would have resulted from extremely low 
concentrations, if they were not BLQ, would likely be very high and expand the overall mean 
Cpred/Cobs ratio for that group.  Since these values were missing, this may result in a lower 
overall Cpred/Cobs ratio.  The estimation of individual specific PK parameters for that particular 
group may become less efficient as information is lost (i.e., fewer usable concentration samples 
from these individuals) from that group in this way as well as no observations between the BLQ 
and zero (thus truncating where concentrations are actually declining for the model estimation). 
The other limitations for the previous study23 is that 1): the dosing history was simulated based 
on the study design and the adherence pattern was arbitrarily selected; 2): only one simulation 
was performed, the reference for the Cpred/Cobs ratio was unavailable.  
 
In this study, the MEMS based dosing history data from SPECTRUM clinical trial 
(Depression, the search for treatment-relevant phenotypes) was incorporated in the computer 
simulations. Adherence, including acceptance, execution and discontinuation phases, generally 
refers to the percentage of the prescribed doses actually taken correctly as the percentage of days 
of treatment period when the medication is taken appropriately. 160-162 In this study, adherence 
defined as the dose taking (number of the prescribe pills taken per day) and the timing of doses 
taken (pills was taken within a prescribed period). A 100% reliable indirect measure for 
adherence does not exit to date. The Medication Event Monitoring System (MEMS)34 is a 
microprocessor-based method for continuous monitoring of adherence, which provides more 
accurate information than other indirect adherence measurements (e.g., self-report, direct 
interrogations, tablet estimates or prescription count). Adherence has also be measured by 
evaluating the stability of plasma level / dose (L/D) ratios, however, these require the precise 
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timing and scheduling of dosage self administration by the patient and subsequent clinical visit to 
capture the true trough. 30, 35 Jonsson had suggested that exclusion the data suspected of arising 
from non-adherence using population PK modeling approach could improve parameter estimates. 
163 However, the information was lost since the excluded data had a high probability to link to 
the observed clinical event due to their inconsistent drug exposure level. How the excluded data 
could help to identify the erratic adherence pattern and therefore link to the consequent clinical 
event has not been reported in the literature.  
 
The primary objective of this study is to assess the stability and robustness of using the 
ratio of Cpred/Cobs (i.e., model population predicted to observed concentration ratio) and 
Cipred/Cobs (model individual predicted to observed concentration ratio)in reflecting adherence 
patterns, by using simulation approaches incorporating design features selected from two clinical 
trials (SPECTRUM and CATIE). PK models of escitalopram (long half-life drug) and 
risperidone (short half-life drug) were used for simulation. The trials simulations are 1) the 
SPECTRUM (depression, the search for treatment – relevant phenotypes) trial that evaluates the 
use of escitalopram and / or interpersonal therapy (IPT) in depression by use of the SPECTRUM 
rating scale and 2) the controlled antipsychotic trials of intervention effectiveness (CATIE), 
which deals with the treatment using atypical anti-psychotics. We hypothesize that the ratios of 
Cpred/Cobs and/or Cipred/Cobs predicts adherence rate in clinical trial for both short and long-
half life drugs. The purposes of this study are a): to evaluate the distribution of the deviation 
between the model predicted concentrations and observed concentrations across the adherence 
rate patterns (high to extremely low adherence rates) for both long and short half-life drugs under 
the situation when the subjects’ correct dosing history is known (negative control) and when the 
correct dosing history is unknown (positive control); b): to evaluate the association between 
ratios and the adherence rates under the conditions of the positive control; c): to evaluate the bias 
and precision of parameter estimates under both positive and negative control conditions.  
 
 
2. Methods  
2.1 Study design and subjects 
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In order to assess the stability and robustness of the Cpred/Cobs ratio, the SPECTRUM 
and CATIE clinical trial designs specified below were simulated to generate PK samples under 
conditions for extremely low, low, intermediate and high adherence rates (see table 2). 
Adherence rate was defined as the % of tablets taken correctly in a specified period preceding the 
clinic visit and PK sample.  PK models for a representative long (escitalopram) and short 
(risperidone) half-life drug were used for the simulations.  
 
SPECTRUM clinical trial 
The SPECTRUM trial evaluated the use of escitalopram and / or interpersonal therapy 
(IPT) in depression by use of the SPECTRUM rating scale. Up to five concentrations per patients 
are proposed in the study. In the simulation study, the plasma samples were assumed taken at 
each clinical visit. The PK model was adapted from the literature,164, 165 which was then used as 
the basis of the escitalopram PK simulation model. SPECTRUM trial proposed using the MEMS 
cap as part of pharmacotherapy adherence monitoring. MEMS cap data included number of does 
taken (MEMS cap opening record) and the time of dose taken (MEMS cap opening time), which 
was considered as patients’ actual dosing history and was incorporated in the simulation study to 
generate ‘observed’ concentrations.  
 
CATIE clinical trial 
The CATIE study (NIMH #N01 MH90001) was two separate multi-site trials. It 
investigated the comparative effectiveness of atypical antipsychotics in up to 2,250 subjects with 
either Alzheimer disease (AD) or schizophrenia. One to six concentrations per subject are 
proposed to be provided for each antipsychotics (e.g., risperidone, olanzapine, and quetiapine). 
The risperidone concentration measurements obtained from CATIE-AD clinical trial were used 
to build the population PK model, and then used in the simulation study. MEMS data is 
unavailable in CATIE study.   
 
2.2 Simulation Study 
2.2.1. Analysis Platform  
Non-linear Mixed Effects Modeling is applied to perform population PK analysis using 
NONMEM computer program (Version V, GloboMax, Hanover, MD).40, 166 The models 
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consisted of a structural model that describe the disposition of the drug following oral 
administration, and a pharmaco-statistical model that describes the inter- and intra-individual 
variability. NONMEM is also utilized for performing the model-based simulations. ‘Virtual 
subjects’ datasets simulation, graphics and post-processing of NONMEM outputs are performed 
using S-PLUS (Version 6.2.1, Insightful, Seattle, WA). Perl (version.5.6) is used for scripts of 
data-extraction and simulation routines. 
 
2.2.2. Simulations and Estimation Step 
Simulation - MEMS cap data provided the actual dosing history (dose and time of dose 
taken) for subjects in SPECTRUM study. This information is unavailable for CATIE trial.  The 
MEMS data from SPECTRUM was adapted to provide the dosing history information for 
CATIE (see below for detail). Subjects recruited in both clinical trials had chronic psychiatric 
disorders. Depression is a mood disorder that frequently co-exists with schizophrenia, therefore 
we assumed that subjects in CATIE had similar adherence pattern as those in the SPECTRUM 
study. Since subjects received BID risperidone in CATIE trial, while QD escitalopram in 
SPECTRUM trial, it is also assumed that if subjects took one dose, he should take the other dose 
12 hour later with standard deviation of 1 hour.    
 
S-PLUS was applied to simulate datasets, which composed of ‘virtual subjects’ with a 
unique virtual concentrations time profile under sampling conditions outlined in CATIE and 
SPECTRUM studies. The simulated dataset included information of the actual PK sampling time 
at each clinical visit (negative control) and incorrectly-reported dosage history (nominal dose and 
dose taking time) and recorded PK sampling time (positive control). The simulated datasets 
provide individual PK parameters and concentration measurements for each virtual subject. The 
‘observed’ concentrations for subjects at each clinical visit were generated using the NONMEM 
simulation option. A PK sample was assumed to be taken at each clinic visit during the clinic 
opening time. The actual dosing taken time and number of dose taken was provided from MEMS 
data. The actual PK sampling time was selected between 8:00 am to 6:00 pm within clinical 
opening period using a random uniform distribution. The selected erroneous nominal time of 
dose taken  (incorrect dosing) was 9:00 pm, with an SD of 1 hour from the selected erroneous 
nominal time. The reported PK sampling time was erroneously reported with an SD of 15 min 
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from the actual PK sampling time. 100% of adherence was assumed for the positive control. The 
detailed description of simulation scenarios for SPECTRUM and CATIE trial were summarized 
in Table 1, e.g., numbers of subjects, PK sampling per subject, simulation replicates, etc. 
Subjects with MEMS data in SPECTRUM study were bootstrapped (n=100) to provide reference 
intervals.  
 
Estimations - The estimated concentrations from the virtual patient’s dataset were 
obtained under two conditions: 1): given correct dosage history (MEMS cap data) and actual 
sampling time, considered the negative control for this experiment, to confirm that there was 
enough information to build a model with relatively accurate individual specific predictions if all 
of the information was known correctly, 2): given incorrect (nominal) dosage history and 
reported sampling time, the positive control for this experiment, evaluated the nature of the 
Cpred/Cobs ratio in relation to the dosing history; and 3): The association between ratio and 
adherence rate under the positive control was assessed and their relationship(s) were applied for 
rate prediction and rate classification. The estimations were done by using the first-order analysis 
with POSTHOC option in NONMEM. 166 
 
PK Model - Risperidone was selected as a representative short half-life drug from the 
CATIE trial and escitalopram was selected as a representative long half-life drug from the 
SPECTRUM trial. The one-compartment with additive and proportional residual error model 
was developed using risperidone data from CATIE study and the two-compartment model with 
additive and proportional residual error models was adapted from the literature report for 
escitalopram.164, 165 The models were then used to generate a unique set of PK parameters for 
each patient using NONMEM program (one-compartment: ADVAN2 TRANS2 and two-
compartment: ADVAN4 TRANS4). In the risperidone model, the population mean (inter-
individual variance) of oral clearance (CL), volume of distribution (V), and absorption rate 
constant (Ka) were 16.6 L/h (123%), 214 L (114%) and 2.5 h-1 respectively. In the escitalopram 
model, the population mean (inter-individual variance) of CL, volume of distribution of central 
compartment (V2), volume of distribution of peripheral compartment (V3), inter-compartment 
clearance (Q) and Ka were 24.4 L/h (50%), 357 L (35%), 35.7 L/h (30%), 575 L (30%) and 0.16 
h-1 respectively. The covariance structure was established between clearance and volume, since 
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they were typically dependent. We proposed to evaluate the use of the “deviation” of a predicted 
concentration value from the observed, when the PK model is anchored with an established 
Bayesian prior PK model. The observed concentrations were generated by the simulation of the 
virtual patients. The concentrations obtained by the NONMEM estimation and PK parameters 
for each individual at each PK sampling measurement were used to create the model predicted 
concentration at the sampling time and thus serve as the basis of the derivation of the 
Cpred/Cobs and Cipred/Cobs ratio. The ratios under the conditions of the negative (known doing 
history) and positive controls (unknown dosing history) were calculated for each patient and 
were tested to evaluate the consistency of the exposure in the positive control.  
 
2.2.3 Evaluation of the overall distribution of the derivation of the ratio 
measurement across the adherence rates in long and short half-life drugs 
2.2.3.1 CATIE and SPECTRUM clinical trial  
According to the CATIE protocol, up to 350 patients are expected to enter each arm of 
the study. According to the SPECTRUM protocol, the 288 subjects are expected to enter into the 
study, 178 subjects are expected to provide plasma concentrations. Study design and simulation 
steps have been described in our previous report. 23 The strategy of simulating the virtual 
subjects for both clinical trials was modified based on the purpose of this study.  
 
Sample size - One of the objectives of this study was to assess the distribution of the 
derivation of the Cpred/Cobs ratio measurements across all adherence patterns. Data from 
SPECTRUM trial was bootstrapped to create 100 replicates.  
 
Dosage and PK sampling – In the CATIE study, subjects are assumed to take their 
medications twice a day. In the SPECTRUM study, 90% of subjects are assumed to take their 
medication in the evening and 10% in the morning. The MEMS cap data from the SPECTRUM 
study was applied to the negative control and was considered as the actual dosing history. In the 
positive control, subjects were assumed to take 2 mg risperidone twice a day in CATIE study and 
10 mg escitalopram once a day. Since MEMS data is not available for CATIE study, we assumed 
that the subjects in CATIE trial (2 mg BID risperidone) had similar adherence pattern as those in 
SPECTRUM (10 mg QD escitalopram) trial, and it was also assumed that if there was one dose 
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taken record, there should be a 2nd dose record 12 hours after the 1st dose with a standard 
deviation of 1 hour. For both studies, the dosing time of 9:00 PM were selected as mean 
(nominal) administration time with normal distribution and a standard deviation of 1 hour. The 
plasma samples were taken from 11 to 21 hours in subjects taking the dose. The actual sampling 
time was modeled as a random uniform distribution with the open times through the full 9 hours 
from 8AM to 6PM. The reported sampling time was erroneous, with a standard deviation of 15 
min from the actual sampling time.  
 
Adherence rate – The adherence rate was calculated based on different patterns, e.g., 
weekly and 2 days, where rate equal to the total number of MEMS cap opening record (total 
number of dosing actually taken) divided by total number of doses prescribed. Some literature 
classified rates into groups as:  ‘good’ (75-100% of dosage intake), ‘fair’ (25-75% of dosage 
intake) and ‘poor’ (<25% of dosage intake). The dosage intake over 100% is defined as ‘hyper-
compliance’, often relates to the belief that this may accelerate the onset of action or enhance 
drug’s efficacy. In this study, the adherence rate was categorized into weekly and 2-day 
adherence rate patterns, as shown in Table 2 and Table 3. The ratios at each adherence rate 
pattern were assessed under the conditions of the negative and positive control. 
 
2.2.3.2 Evaluate the overall distribution of the derivation of the ratio measurement  
In order to assess the distribution of the Cpred/Cobs ratio measurement across all 
adherence patterns, box-whisker plots were generated for all the adherence rates in SPLUS for 
both short and long half-life drugs. The box itself contains the middle 50% of the ratio values at 
each adherence rate level. If the median value within the box is not equidistant from the upper 
edge (75th percentile) and lower edge (25th percentile), then the data value was skewed. From the 
boxplot, we can examine the consistency of the Cpred/Cobs ratio in reflecting erratic adherence 
patterns (extremely low to high adherence rates). The ratio of predicted and observed 
concentrations should equal to one under the ideal situation (negative control). Under the 
positive control, concentrations were expected over-predicted if the adherence rate was assumed 
to be 100% while it was actually less than 100%, and under-predicted if the actual adherence rate 
over 100% was assumed to be 100%. Thus the systematic deviations between the differences 
between observed and predicted concentrations could be reflected by the shift of the median ratio 
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value with adherence rate level change. These plots allowed us to examine whether or not there 
were systematic deviations in the difference between observed and predicted concentrations, and 
how these central tendencies of the deviations (ratios) shifted with the erratic drug taking pattern 
(adherence rate) change for both short and long half-life drugs. 
 
2.2.3.3 Evaluate the BLQ impact on the derivation of the Cpred/Cobs ratio measure 
under the extremely low adherence condition  
The impact of BLQ on the ratio distribution was assessed, with a focus on the subjects 
with extremely low adherence rate. As mentioned above, the Cpred/Cobs ratio was found 
unexpectedly decreased in our previous study.23 Several possible explanations / hypothesis have 
been discussed above. Since for the poorly adherent subjects, they are likely produce 
concentrations measurements that are BLQ. Thus, fewer ratios are calculable directly from the 
measured data.  This may change the nature of the ratio, perhaps reducing its explanatory power 
under conditions of extreme non-adherence. In order to test the unexpected reduced ratio under 
extremely low adherence condition was more related to the unnatural truncation of the 
distribution caused by censoring concentrations BLQ rather than due to the model performance. 
Different levels of limit of quantitation (LOQ) were tested under negative control, and the 
percentage of the censored concentrations BLQ and the corresponding median ratio were 
calculated under the extremely low adherence rate condition for both long and short half-life 
drug.  
 
2.2.4 Evaluate the association between ratio and the adherence rate  
The central tendency of the ratio (mean) at each adherence rate was calculated. The 
association between the mean ratio and its corresponded observed adherence rate (weekly and 2 
days rate pattern) was assessed using NONMEM program. The relationship was then used to 
predict adherence rate at a given Cpred/Cobs or Cipred/Cobs ratio. The predicted adherence rate 
was classified based on minimum Euclidean distance classification criteria, 167  where the 
differences between the predicted rate and each observed adherence rate was calculated. The rate 
was assigned to be one of the observed adherence rate if the minimal difference between the 
predicted rate and the observed adherence rate was achieved. The percentage of the correct 
assigned rate was calculated for both weekly and 2 days adherence rate pattern.  
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 2.2.5 Evaluate the bias and precision of parameter estimates under positive and 
negative control  
The true parameter values were obtained from the simulation step, where all the correct 
dosing history was known. The parameter estimates under negative control (correct dosage 
history and actual sampling time) and positive control (incorrect dosage history and reported 
sampling time) were obtained from the estimation step. The bias and precision of the parameter 
estimates under each condition were evaluated using percentage prediction error (% PE) as 
shown below: 
%100% ×−=
true
trueestPE θ
θθ
 
Where θest is the estimated parameter values under negative or positive conditions 
obtained from the estimation step, and θtrue is the true parameter values obtained from the 
simulation step. The %PE was calculated from the 100 simulation replicates under each 
condition. The mean and standard deviation (SD) of %PE was calculated at each adherence rate, 
which was used as bias and precision measurement. The cutoff value for bias and precision was 
set to be 15% and 35%, 168 respectively, which was considered  a threshold for good prediction..  
 
3. Results  
3.1 Subjects  
A total of 65 patients’ MEMS data were available from the ongoing SPECTRUM clinical 
trial during the first 6 month, which had 863 clinical visit records.  The adherence rate was 
calculated for each clinical visit event (PK sampling), which was then grouped into different 
patterns, e.g., weekly, and 2 days adherence rate. The adherence rate was found to be varying 
within subject during the treatment. In the weekly adherence rate pattern, there were 9.7 % of the 
events with more than 7 doses taken record (rate >100%) before the clinical visit, 52.5 % of 
events with 6 to 7 doses taken record (rate: 85 to 100 %), 19.0 % of events with 3 to 5 doses 
record (rate: 30 to 85% ), 4.3 % of events with 1 to 2 doses record (rate: 0 to 30%), and 14.5 % 
of events without any dose taken record before the visit.  
 
3.2 Overall distribution of the derivation of the ratio across the adherence rates 
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The boxplots were generated for both long and short half-life drug under both positive 
and negative control. In the negative control, where the estimation was based on the subject with 
correct dosing history, the log median of Cpred/Cobs and Cipred/Cobs ratios was approximately 
to zero under each adherence rate condition, as shown in Figure 1a and Figure1b for the long 
half-life drug and Figure 2a and Figure 2b for the short half-life drug.  
 
As suggested by plots under negative conditions that the concentrations were under-
estimated under the extremely low adherence rate condition (0%), causing the Cpred/Cobs ratios 
less than one. As discussed above, there’re several possible reasons contributing to the reduced 
magnitude of the Cpred/Cobs ratio under the extremely low adherence condition. The impact of 
the different levels of LOQ on the magnitude of the Cpred/Cobs ratio was tested for escitalopram. 
In 0% adherence rate condition, the median value of the Cpred/Cobs ratio decreased with LOQ 
increase. The median (SD) ratio was 0.79 (1.14e+29) if LOQ is 0 ng/ml (without censoring), 
decreasing to 0.35 (20.3) if LOQ is 0.001ng/ml, and 0.16 (0.44) if LOQ is 1ng/ml. Censoring of 
the observed concentrations BLQ significantly reduced the number of ratios contributing to the 
overall Cpred/Cobs ratio calculation. If the LOQ was set to be 1ng/ml, 90.6% of the observed 
concentrations under the 0% weekly adherence rate condition were censored, and 57.8% was 
censored if LOQ was set to be 0.001ng/ml. For the results above, it suggested that the 
unexpected under-predicted concentrations under extremely low adherence condition were more 
caused by the high percentage of the censored concentrations BLQ than due to the model 
performance for long half-life drug. 
 
For the short half-life drug, without censoring BLQ, the median Cpred/Cobs ratios under 
the extremely low adherence rate condition were 0.005 (weekly rate pattern) and 0.2 (2 days 
adherence rate pattern). In the 2 days adherence rate pattern, 73.8% of the individual ratios were 
censored if LOQ was set to be 0.05ng/ml and 65.2% was censored if LOQ was set to be 
0.005ng/ml. Since the ratio under very low adherence rate conditions was significantly lower 
than 1, even without censoring any concentrations BLQ. The other possible explanations for this 
observation could be the model artifact. One compartment model was developed using highly 
sparse data from CATIE-AD study, while 2-compartment model had been reported for 
risperidone.169  Higher inter-individual variability (IIV) was evaluated using the highly sparse 
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data from CATIE-AD trial. Trying to evaluate the impact of model structure, PK parameters and 
IIV on the ratio under extremely low adherence conditions, The additional study was conducted 
using the 2-compartment PK model with reported PK parameters and IIV from our previous 
study.23 Similar BLQ effect on the ratio was found for the short half-life drug based on the 
previous model, where the Cpred/Cobs obtained from the extremely low adherence rate 
condition (2 days adherence rate pattern) become 0.7 without censoring (LOQ=0) BLQ and 
reduced to 0.5 if LOQ was set to be 0.005ng/ml and 0.2 if LOQ was set to be 0.2ng/ml. Under 
the weekly adherence rate patter, 100% of the concentrations were censored when LOQ was 
0.0005ng/ml. This was due to the nature of elimination processes for the short half-life, where 
the concentrations should be extremely low if the sample measuring time after dose is greater 
than 5 times half-life.   
For the results above, it suggested that if the model developed under highly sparse 
sampling data was used in simulations, the unexpected under-predicted concentrations under 
extremely low adherence condition were related to both the model performance and the censored 
concentrations BLQ for short half-life drug. Due to these observations for short half-life drug, 
Cipre/Cobs ratio was considered for assessing its relationship with rate for the short half-life 
drug. 
 
In the positive control, the estimation was based on the subjects with unknown dosing 
history. The median of Cpred/Cobs and Cipred/Cobs ratios increased with adherence rate 
decreasing as shown in Figure 1c and Figure 1d for the long half-life drug and Figure 2c and 
Figure 2d for the short half-life drug. The differences of the Cipre/Cobs ratio tended to be more 
differentiable among adherence rate groups than that of Cpred/Cobs ratio.  
 
3.3 Evaluation of the association between ratio and the adherence rate pattern 
The mean value of Cipred/Cobs ratio was obtained and its relationship with the observed 
weekly adherence rate was modeled. Bi-exponential and tri-exponential functions adequately 
described the relationship between Cipred/Cobs ratio and the weekly adherence rate for long and 
short half-life drug, respectively. The population predicted rate and the observed rate versus 
Cipred/Cobs ratio were shown in Figure 3a (long half-life drug) and Figure 3b (short half-life 
drug). The exponential relationship between Cipred/Cobs ratio and rate were shown below: 
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Long half-life drug:  RatioRatio eeRate ×−×− += 6.076.3 194396
Short half-life drug:  RatioRatioRatio eeeRate ×−×−×− ++= 6.0521.00827.0 5.171759.89
 
The exponential relationship developed above was then applied for rate prediction at each 
ratio obtained under positive control, and then classified into weekly and 2 days adherent rate 
pattern. The predicted rate classification was based on the minimum Euclidean distance 
classification criteria. 167  At a given Cipred/Cobs ratio, the distance between the predicted rate 
and the observed rate was calculated using equation: d= obspred RateRate −  and the predicted 
adherence rate was assigned to the class (observed rate) for which the distance "d" was minimum. 
The assigned rates were then grouped based on weekly adherence pattern as described in the 
methods section. The result of the correct rate classification at each rate groups was shown in 
Table 2 (weekly adherence rate classification) and Table 3 (2 days adherence rate classification). 
The result of weekly adherence rate condition showed that the correct assigned rate in PK 
samples measured under very high adherence rate condition (i.e., hypercompliant) for long and 
short half-life drug were 73.8% and 89.1%, respectively. In PK samples measured under 
extremely low adherence rates (0% in the last week)  the correct classification was 64.0% for 
long half-life drug and 39.9% for short half-life drug. The rates were better classified in PK 
samples measured under extremely low (0%) and extremely high adherence rate condition 
(>100%) than that under other adherence rate conditions. Two days adherence rate patterns were 
also evaluated. The relationship between 2 days adherence rate and Cipred/Cobs ratio was 
adequately described using a mono-exponential and bi-exponential function as shown below:  
Long half-life drug:   RatioeRate ×−= 05.2834
Short half-life drug:  RatioRatio eeRate ×−×− += 713.0069.0 4827.83
Similar as the results obtained from weekly adherence pattern, the rates were well 
classified for the event under extremely high (rate >100%) and extremely low (rate=0%) rate 
condition. The correct classified rates in the 2 days adherence rate pattern (Table 2 and 3) for 
long and short half-life drug were 80.8% and 91.8% under extremely high and 87.6% and 
35.81% under extremely low rate condition, respectively.  
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For the long half-life drug, the overall rates of correct adherence classification based on 
Cipred/Cobs ratios were: 42.3% for weekly adherence rate pattern and 50.2% for the 2 days 
adherence rate pattern. For short half-life drug, the total correct assigned rate based on 
Cipred/Cobs ratio was 15.8% in weekly adherence rate pattern and 19.3% in 2 days adherence 
rate pattern. 
 
The association of Cpred/Cobs ratio with adherence rate was also evaluate for long half-
life drug, following the same procedure as above. The total correct assigned rate based on 
Cpred/Cobs ratio were 26.4% in weekly adherence rate pattern and 29.9% in 2 days adherence 
rate pattern, which was lower than the correct assignment based on the Cipred/Cobs ratio. The 
correct assigned rate in PK samples measured under very high and very low adherence rate 
condition for long half-life drug were 75.4% and 54.6% under weekly rate pattern, and 79.8% 
and 69.8% under 2 days rate pattern.  
 
3.4 Evaluation of the bias and precision of parameter estimates  
The bias and precision of parameter estimates under negative and positive control was 
shown in Table 4/Figure 4a and Figure 4b for long half-life drug and Table 5/Figure 5a and 
Figure 5b for short half-life drug. Generally, all individual PK parameters for long half-life drug 
were well estimated under both positive and negative conditions, with mean %PE less than 15% 
and standard deviation (SD) of %PE less than 35% (except V2 and Q estimate under positive 
control). The parameter estimates tend to be more biased and less precise under positive control 
conditions where the subjects’ correct dosing history was assumed. The precision (SD of %PE) 
of clearance estimate was approximately 4 fold higher under negative control than that under the 
positive control. For the short half-life drug, estimates of individual oral clearance and Ka were 
unbiased, while volume of distribution estimates was biased. Most of the parameter estimates 
had SD of %PE over 35%, and the parameter estimates tend to be less precise under positive 
control where the subjects’ incorrect dosing history was used than that in negative control. The 
biased and less precise parameter estimates results could due to the high IIV of PK parameters 
estimated from CATIE-AD study, and the substantial variability was then contributed to the 
parameter estimates in simulation and estimation steps. The estimates of variability for clearance 
and volume of distribution were 123% and 114%, respectively.  An additional study were 
 108 
preformed to assess the impact of the variability on the parameter estimates, using the 2-
compartment PK model, reported PK parameters and IIV from our previous study.23 The 
parameters were well estimated under both negative control and positive control with bias (%PE) 
less than 15% and precision (SD of %PE) less than 35%, except the less precise KA estimate 
(%PE SD: 49.3% in negative control and 119.9% in positive control). Thus the bias and precise 
parameter estimates for short half-life drug was related to the model structure and the lower IIV.  
 
4. Discussion 
Many studies have demonstrated that non-adherence is very common in subjects with 
schizophrenia and depression.33, 126, 155  In the clinical trials, it was reported that the average 
adherence rate is only 43-78% among subjects during chronic treatment. 24, 25 There are many 
other similar terminologies used in the literature to describe adherence such as compliance, 
concordance, alliance.26, 27 In this article, adherence is defined in two ways: the percentage of 
prescribed doses taken; and the percentage of days of therapy when the medication was taken 
appropriately.  Thus, we focus on the continuous middle “execution” phase of drug taking (these 
patients have all initiated therapy-acceptance phase) and we are looking at patterns that occurred 
prior to discontinuation, the dichotomous end. 170   The inconsistency of drug exposure caused by 
variable adherence to the prescribed therapy was suggested to be a single largest source of 
variance to the drug response. 158 Therefore, adherence plays an important role in the 
pharmacotherapy efficacy assessment, since the dosage adjustments may not be relevant if the 
subject is inconsistently receiving the prescribed medicine. Population PK analysis showed many 
advantages over traditional PK analysis, especially for the larger clinical trial where only a few 
sample were available per subject. 10 The aim of this study was to identify erratic adherence 
pattern using modeling and simulation approach. This is the first study to evaluate the ability of 
using the deviation between the predicted versus observed concentrations in reflecting the erratic 
adherence rate, by using population PK modeling combined with MEMS data from a target 
population. We also assessed the relationship between adherence rate and the ratio of 
Cipred/Cobs and Cpred/Cobs and assigned the adherence rate based on their relationship. 
 
As demonstrated in many studies, adherence is related to the clinical outcomes. 29-33 Our 
simulation study suggested that the population PK model with incorporation MEMS data could 
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be used to detect erratic exposure and thus reflect the subject specific adherence pattern 
(extremely high and extremely low adherence patterns) for both long and short half-life drugs. 
The predicted weekly and 2 days adherence rate pattern was well classified under the extremely 
high adherence condition and extremely low adherence conditions.  Two days adherence rate 
pattern had a higher percentage of correct assignment than that of weekly adherence pattern for 
the extreme high and extremely low adherence conditions. Since the Cipred/Cobs was more 
differentiable than Cpred/Cobs for long half-life drug, the percentage of the correct weekly 
adherence rate assignment was approximately 1.5 fold higher if using Cipred/Cobs as the rate 
indicator than that if using Cpred/Cobs as the rate indicator. Diaz155 demonstrated that the 
adherence rates in subjects with schizophrenia decreased from 63% in the 1st month to 45% over 
the following 5 month. Subjects with adherence rate lower than 50% were experienced a higher 
probability of re-hospitalization. This was also true in the depression study, where an index 
representing adherence was associated with the poor response or non-response clinical event.33 
Therefore, identifying the subjects with extremely low or high adherence conditions, is important 
for any dosage adjustment during treatment, since the non-response could due to the poor 
adherence and adverse side effect could due to the extremely high adherence condition, 
especially when the clinical event is concentration dependent. There were only about 10% 
correctly assigned high, intermediate, and low adherence rates for short half-life drug and about 
20% for long half-life drug, which suggested that the drug monitoring may be necessary under 
these conditions, since these types of inconsistency of drug taken could lead to moderate adverse 
side effect which may be less severe than those under extreme adherence conditions.    
 
In this study, we didn’t find the reduced magnitude of Cpred/Cobs ratio under the 
extremely low adherence rate condition for positive control (using incorrect dosing history) as 
reported in our previous study. 23 However, the concentrations were unexpectedly under-
predicted in the extreme condition for negative control, where the correct dosing history was 
known for the population PK analysis. The results suggested that the unexpectedly decreased 
ratio was caused by the greater number of the censored concentrations BLQ as well as a 
disproportion number of measurement which is close for but above BLQ, for long half-life drug. 
This may bias the ratio distribution under extremely low adherence pattern. The higher the BLQ, 
the more concentration measurements was censored and then more likely the concentrations 
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were under-predicted. However, for the short half-life drug, even without censoring any 
concentrations BLQ, the concentrations were still under-predicted, although less severely than 
that with concentrations censored BLQ .. The other possible explanation for the reduced ratio 
could be the PK model structure and IIV. The risperidone PK model used in the simulation and 
estimation steps was developed using sparse data from CATIE-AD study. One compartment was 
found to be adequately described the data, however some studies suggested that two-
compartment model best fitted the risperidone data. 171  The results from the 2-compartment 
study for short half-life drug suggested that the reduced Cpred/Cobs under extremely low 
adherence condition was not only related to the censored concentrations BLQ, but also related to 
the model structure, IIV and the method for adherence rate pattern calculation (e.g., weekly 
versus 2 days). In general, since the Cpred/Cobs and Cipred/Cobs ratios for both long and short 
half-life drugs was estimated to be approximate to one (Figure 1 and Figure 2), except in the 
most extreme situation, suggesting that there was enough information to build the model with 
relative accurate individual specific predictions.  
 
Correct subjects dosing history is very important for a PK model not only for the 
parameter estimates 22, 163 but also for model convergence.157 It also can explain much of the 
residual variability. 158  In our study, the bias and precision of parameter estimates under both 
positive and negative conditions were evaluated. For long half-life drug, all the parameters were 
well estimated with %PE (bias) less than 15%. The parameter estimates were more precise under 
negative control than that in positive control, especially for clearance. For the short half-life drug, 
the clearance and Ka were unbiased estimated. The %PE for V under positive condition was 
approximately 5 fold higher than that in the negative condition; however the %PE was over 15% 
under both conditions. It was also found that %PE SD were higher than 35% for all parameters 
under both conditions, except KA under negative control. Since the PK model was developed 
using the sparse data from the CATIE-AD trial, high IIV was obtained with IIV on CL and V 
were 151% and 130% respectively. The high IIV was suspected to be contributing to the less 
precise parameter estimates. Additional studies (data not shown) were performed using the PK 
model and parameter values including population mean value and IIV, from our previous 
study.23 The result showed that all the parameters were estimated precisely and accurately, with 
%PE SD less than 35% and %PE less than 15% under both negative and positive control, except 
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Ka estimate. Thus the IIV on PK parameters had a higher impact on the parameter estimates than 
the incorrect dosing history. The other interesting finding was that using the model developed 
using hyper-sparse data resulted in biased and imprecise parameter estimates, but did not reduce 
the ability for the rate assignment based on ratio under the extreme adherence conditions (Table 
2 and Table 3).  
 
 
5. Conclusion 
The simulation study demonstrated that the combination of the population PK model with 
MEMS information could be used to detect erratic exposure and thus reflect the subject with 
extremely low or high adherence conditions for both long and short half-life drugs. Since both of 
the extremely high and extremely low adherence rate conditions can be well reflected by the 
Cipred/Cobs and Cpred/Cobs ratio, which provides a basis where the magnitude and consistency 
of exposure can be examined in conjunction with the maintenance response of subjects in a 
future study as response data become available.  
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Table 1: The detailed description of simulation scenarios for long half-life drug and short half-
life drug  
 
Simulation Profile  simulation scenarios  
Sample size for each 
simulation replicate 
65 
 
Dose (mg) Escitalopram: 10  
Risperidone: 2 
N of Clinical visit 
record per subject 
18 (2 to 43 record) 
Time for dose 
administration 
Actual: MEMS cap opening time  
Nominal: 21:00  (normal distribution, SD=1h) 
PK sampling time  Actual: 8:00 AM to 6:00 PM (uniform distribution) 
Nominal: Actual sampling time + reported time error (normal 
distribution, SD=15min) 
Adherence rate (%) 1: Weekly and 2 days actual rate  
2: Adherence rate groups (very high, high, inter-mediate, low and 
extremely low) based on weekly and 2 days pattern 
Simulation replicates 100 
Simulation 
conditions  
Time: actual dosage time and actual PK sampling time 
 
Estimation 
conditions for 
negative control 
Time: actual dosage time and actual sampling time 
Number of dose taking was reflected by adherence rate as shown 
above 
Estimation 
conditions for 
positive control 
Time: nominal dosage time and reported sampling time 
Adherence rate assumed in the estimation step: 100% for all of the 
simulation sets 
 
* SD: standard deviation 
 
 
 
 
 113 
Table 2 The Correct classified rate at weekly adherence rate condition for long half-life drug and 
short half-life drug 
 
Adherence rate  n of dose 
taken 
Long half-life drug 
n of event  % correct classification 
Short  half-life drug 
n of event    % correct classification 
Group 1  >7 8014 73.82 3593 89.06 
Group 2 6,7 45319 39.19 21939 5.98 
Group 3 3,4,5 15972 36.65 7035 9.05 
Group 4 1,2 2733 25.72 1252 9.03 
Group 5 0 1128 64.01 353 39.94 
 
* Group 1: very high adherence rate condition (>100%); group 2: high adherence rate condition (85-
100%); group 3: intermediate adherence rate condition (30-85%); group 4: low adherence rate condition 
(0-30%) and group 5: extremely low adherence rate condition (0%). 
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Table 3 The Correct classified rate at 2 days adherence rate condition for or long half-life drug 
and short half-life drug 
 
Adherence 
rate  
n of dose 
taken 
Long half-life drug 
n of event     % correct classification 
Short  half-life drug 
n of event      % correct classification 
Group 1  >2 8437 80.75 3935 91.82 
Group 2 2 43653 44.69 21677 6.64 
Group 3 1 17396 41.25 7496 15.62 
Group 4 0 3680 87.58 1064 35.81 
 
* Group 1: very high adherence rate condition (>100%); group 2: high adherence rate condition (100%); 
group 3: intermediate adherence rate condition (50%); group 4: low adherence rate condition (0%) and 
group. 
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Table 4 The overall bias and precision of parameter estimates under positive and negative control 
for long half-life drug  
PE (%) 
 
Negative control 
MEAN        SD 
Positive control 
MEAN       SD 
CL/F -1.9 5.7 3.4 24 
V2 3.0 29.1 10.5 39.3 
V3 3.9 26.7 6.0 32.8 
Q 5.4 31.8 8.4 35.8 
KA 0.6 6.4 -3.3 7.1 
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Table 5 The overall bias and precision of parameter estimates under positive and negative control 
for short half-life drug  
 
PE (%) 
 
Negative control 
MEAN            SD 
Positive control 
MEAN           SD 
CL/F -3.7 53.3 -0.38 83.2 
V 37.9 327.6 206.1 893.5 
KA -1.86 23.4 -0.69 53.5 
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Figure 1 Boxplot of the overall all ratio distribution at each adherence rate condition for long half-life 
drug (escitalopram). Dots in each group were median values. 
Figure 1a Boxplot of the log Cpred/Cobs ratio under negative control 
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Figure 1b Figure1b: Boxplot of the log Cipred/Cobs ratio under negative control 
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Figure1c: Boxplot of the log Cpred/Cobs ratio under positive control 
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Figure1d: Boxplot of the log Cipred/Cobs ratio under positive control. 
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Figure 2 Boxplot of the overall all ratio distribution at each adherence rate condition for short 
half-life drug (risperidone). Dots in each group were median values 
Figure 2a Boxplot of the log Cpred/Cobs ratio under negative control 
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Figure 2b Boxplot of the log Cipred/Cobs ratio under negative control 
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Figure 2c Boxplot of the log Cpred/Cobs ratio under positive control 
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Figure 2d Boxplot of the log Cipred/Cobs ratio under positive control. 
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 Figure 3 The association between Cipred/Cobs ratio and adherence rate in long half-life drug 
(Figure 3a) and in short half-life drug (Figure 3b). Dots represented the median values of 
Cipre/Cobs ratio at each observed adherence rate conditions. The line represented the model 
predicted rate at given Cipred/Cobs ratios.   
Figure 3a 
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Figure 4: Bias and precision of parameter estimates under negative and positive control. 
Figure 4a: Bias of parameter estimates for long half-life drug; Figure 4b: Precision pf parameter estimates 
for long half-life drug 
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Figure 4c: Bias of parameter estimates for short half-life drug; Figure 4d: Precision of parameter 
estimates for short half-life drug. 
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CHAPTER 6 OVERALL SUMMARY AND FUTURE DIRECTIONS 
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 6.1 Overall summary  
Population PK analysis is an important technique used to explore and define sources of 
variation in drug exposure in a target population. The purpose of the thesis work was to explore 
the usefulness of the mixed effect modeling approach in analysis sparse sampling measurements 
in large-scale clinical settings, including understanding variability among outpatients/inpatients 
with mental disorder, dose optimization and evaluation the consistency of drug exposure. 
 
To meet these goals, the following were carried out: 1): the study performed to evaluate 
age effect in subjects with major depressive disorder receiving citalopram using highly sparse 
data measurements; 2): the first study conducted to evaluate CYP2D6 genotypes impact on 
paroxetine disposition in late-life depression; 3): the first study to optimize dosage strategy for 
intensive care and general medical unit patients receiving enoxaparin by continuous intravenous 
infusion; and 4): the first study to evaluate the usefulness of population PK modeling with 
MEMS in evaluating the consistency of exposure. The conclusions from each study were shown 
as below: 
 
Elderly patients are not easily studied using the traditional PK analysis approaches, where 
intensive sampling measurements are needed for analysis. In the study, the data from two clinical 
trials were combined and analyzed. Age and weight were found to be significant covariates on 
clearance and volume of distribution. After the corrections include weight effect, age was a 
significant covariate across the entire age range (22-93 years). The study was able to extend 
these findings by demonstrating a continuous relationship between age and clearance of 
citalopram, as well as simultaneously accounting for the contribution of weight to citalopram 
pharmacokinetics. Clearance declined by 0.23 L/h per year of age and increased by 0.14 L/h per 
kg of body weight. The results also are important in understanding the magnitude and variability 
of drug exposure, as well as the specific factors that contributed to the inter-individual 
differences in the exposure.  
 
Late-life depression is a prevalent disorder that causes significant suffering and disability. 
Paroxetine, mainly metabolized by CYP2D6, is widely used in the treatment of depression. The 
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association between CYP2D6 genetics and paroxetine PKs in geriatric subjects after chronic 
paroxetine treatment is still unknown. In our study, it was found that the order of magnitude for 
Vm by CYP2D6 phenotype was: UMs>EMs>IMs>PMs. The other interesting finding in the 
study was that race was a significant covariate when CYP2D6 was not included in the model. 
One possible explanation for this observation is related to the correlation between race and 
CYP2D6 genotypes. When the CYP2D6 genotypes were incorporated, the race effect was no 
longer significant.  
 
Modeling and simulation can facilitate dosage strategies for the target populations. The 
target populations in our study were the general medical unit and intensive care unit subjects 
who received CII enoxaparin. Enoxaparin is mainly metabolized by the kidney. CrCL and weight 
were the significant covariates on clearance and central volume of distribution. The study 
showed that the dose of CII enoxaparin should be individualized based on the subjects’ renal 
function and weight. It is also suggested that subjects in the ICU appears to have higher exposure 
than those in general medical unit, even though the ICU patients are likely to receive slightly 
lower doses.  
 
Inconsistency of drug exposure caused by non-adherence is very common among 
subjects with schizophrenia or depression. Our studies examined the usefulness of population PK 
modeling combined with MEMS data in reflecting the consistency of exposure. Simulations 
showed that the deviation of model-predicted and observed concentrations adequately reflected 
subjects under the extremely high and extremely low adherence rate conditions. This 
methodology developed was very important in evaluation of individual specific adherence 
characteristics, and thus for understanding the clinical outcomes in the clinical trial, since the 
non-response or adverse drug effect may be caused by the inconsistency drug intake and it may 
be possible to get a sparse concentration sample for an individual rather than provide electronic 
monitoring to every individual assessed. 
 
6.2 Future directions 
Evaluate the impact of adherence on Escitalopram response in SPECTRUM study 
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The non-adherence is very common among schizophrenic and depressed patients during 
chronic treatment. The future study will be focused on examining the impact of the inconsistent 
escitalopram exposure driven by the erratic adherence rate during the treatment on the clinical 
response, including both safety and efficacy clinical outcomes from SPECTRUM study. 
Moreover, we will examine the ability of rate classification based on the relationship between 
ratio and adherence rate, when the actual concentrations are available.  
 
Paroxetine Pharmacodynamic study 
Evaluate the relationship between paroxetine response and serotonin genetics   
Reducing or at least capturing the immense variability in drug concentration is the first 
step towards optimizing power in pharmacodynamic studies. In the MTLD-2 study, we have 
demonstrated the impact of CYP2D6 genotypes on paroxetine pharmacokinetic parameters. In 
addition, the ability of capturing the magnitude of individual specific drug exposure over time 
provides a basis where the magnitude of exposure can be evaluated in conjunction with the 
maintenance response. Future work in MTLD-2 clinical study is focusing on understanding the 
variability of disease recurrence for similarly exposed subjects in the maintenance phase. There 
are two descriptors for the return of depressive symptoms.  The first is a relapse of the disease 
which is defined as a new episode of major depression occurring within 16 weeks of the initial 
treatment response.  The second is recurrence, and this is defined as the new episode of major 
depression at least 16 weeks after initial resolution of depression.  A new episode of major 
depressive disorder is defined by SCID/DSM-IV criteria in addition to HAMD score equal or 
greater than 15.  
 
The causes of depression are complex. One of the hypotheses is related to serotonergic 
activity, which suggests that decreased levels of serotonin at the synapse are factor causing 
depression. The initial site of action for SSRI (e.g., paroxetine) is the 5-HT transporter 
(SLC6A4); accordingly, the majority of studies to date have examined polymorphisms in or near 
the gene coding for the transporter. The association of the serotonin transporter promoter 
polymorphism with the speed or degree of a response or side effects of SSRI treatment is 
showing considerable promise. 172, 173 Therefore, the differences in the level or function of 
serotonin receptors, enzymes involved in synthesis (THP1) or metabolism (MAOA) of 5-HT 
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may also influence response. Genes correlated with antidepressant response are also believed to 
contribute to the high level of response variability. After the determination of the paroxetine 
exposure, the relationship between these 5-HT related genes and the probability of having 
recurrence will be examined. The results will help to understand the sources of variability related 
to depression recurrence, thus potentially providing for the individualization of dosage in the 
target populations. 
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APPENDIX A 
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LIST OF ABBREVIATION& NOMENCLATURE 
ABW   Adjusted body weight 
AIC   Akaike information criterion 
AUCss   Area under the curve at steady state 
CII   Continuous intravenous infusion 
CL   Clearance 
BMI   Body mass index 
BSA   Body surface area 
CrCL   Creatinine clearance 
Css   Steady state concentration 
DV   Observed concentrations 
DVT   Deep vein thrombosis 
EDTA   Ethylene diamine tetraacetic acid 
EMs   Extensive metabolizers 
F1   Bioavailability 
FO   First order 
FOCE   First order conditional estimate 
FOCEI   First order conditional estimate with interaction 
HAMD-17  Hamilton rating scale for depression 
Ka   Absorption rate constant 
IBW   Ideal body weight 
ICU   Intensive care unit 
IMs   Intermediate metabolizers 
IIV   Inter-individual variability 
IPRED   Individual predicted concentration 
LBW   Lean body weight 
LMWHs  Low molecular weight heparins 
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MI   Multiple imputation 
MMSE  Mini-mental state exam 
MTLD-2  Maintenance therapies in late-life depression 
OBJ   Objectve function 
OFV   Objective function value 
PCR   Polymerase chain reaction 
PE   Pulmonary embolus 
PD   Pharmacodynamics 
PI   Predicted interval 
PK   Pharmacokinetics 
PMs   Poor metabolizers 
PRED   Population predicted concentrations 
SC   Subcutaneous 
SSRIs   Selective serotonin reuptake inhibitors 
TS   Two-stage approach 
UFH   Unfractionated heparin 
UMs   Ultra-rapid metabolizers 
V   Volume of distribution 
V2 &Vc  Volume of distribution of central compartment 
V3 &Vp  Volume of distribution of peripheral compartment 
Vm   Maximal velocity 
WRES   Weighted residual error 
WT   Weight 
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APPENDIX B.1 PREDICTION OF CREATININE CLEARANCE FROM SERUM 
CREATININE 
1: Cockcroft & Gault equation to predict creatinine clearance from stable serum creatinine  
In male 
)/(72
)140(min)/(
dLmgScr
IBWagemLCLcr ×
×−=   
In female 
85.0
)/(72
)140(min)/( ××
×−=
dLmgScr
IBWagemLCLcr  
Ideal Body Weight (IBW) 
Male: IBW (kg) = 50 + (2.3 × Height in inches over 5 feet) 
Female: IBW (kg) = 45.5 + (2.3 × Height in inches over 5 feet) 
 
2: Brater equation to predict creatinine clearance from unstable serum creatinine  
In male 
wt
ScrScr
daytime
ScrScr
ScrScrage
mLCLcr ×+×
−×++×−×−
=
)(70
)(
)(49
)](0168.0035.1][03.2293[
min)/(
21
21
21
 
In female 
86.0
)(70
)(
)(49
)](0168.0035.1][03.2293[
min)/(
21
21
21
××+×
−×++×−×−
= wt
ScrScr
daytime
ScrScrScrScrage
mLCLcr  
Scr1 and Scr2 are the 1st and 2nd measured values of serum creatinine (mg/dL) 
respectively; time is the interval between Scr1 and Scr2 measurements in days, wt is the weight 
in kilogram unit.  
 
* Unstable Scr defined as the two separate determinations of serum creatinine obtained at 
least 12 hours apart have values within 0.2 mg/dL.  
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APPENDIX B.2 RELEVANT PART OF THE NONMEM CODE FOR ENOXAPARIN 
COVARIATE MODEL 
 
$SUBROUTINES ADVAN4 TRANS4 
 
$PK 
 
     BMI=WT/(HT*HT/10000)  ;Body mass index 
     BSA=SQRT(HT*WT/3600)  ;Body surface area 
     IBW=45.5+0.89*(HT-152.4)+4.5*SEX ;Ideal body weight 
 
     IF (SEX.EQ.1) THEN 
        LBW=1.1*WT-0.0128*BMI*WT ;Lean body weight 
     ELSE 
        LBW=1.07*WT-0.0148*BMI*WT  
     END IF 
     ABW=IBW+0.4*(WT-IBW)   ;Adjusted body weight 
     PIBW=WT*100/IBW    ;Percentage IBW 
 
     IF (SEX.EQ.1) THEN 
        PNWT=1.57*WT-0.0183*BMI*WT-10.5 ;Predicted normal weight 
     ELSE 
        PNWT=1.75*WT-0.0242*BMI*WT-12.6 
     END IF 
 
IF (GFR.EQ.0) THEN 
         TVCL=THETA(7) 
ELSE 
         TVCL=THETA(1)+(GFR/4.8)*THETA(6) 
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END IF 
 
      CL=TVCL*EXP(ETA(1)) 
      TVV2=THETA(2)*(WT/70) 
      V2=TVV2*EXP(ETA(2))  
      TVV3=THETA(3) 
      V3=TVV3 
      TVQ=THETA(4) 
      Q=TVQ   
      KA=THETA(5)      
      K    = CL/V2   
      F1=THETA(8)         
      S2=V2 
 
$ERROR 
     IPRED=F 
     IRES =F-DV 
IF (LO.EQ.0) THEN 
     Y = F*(1+ERR(1))+ERR(2) 
ELSE 
     Y = F*(1+ERR(3)) 
END IF 
 
 
$THETA 
   (0.229,FIXED)  ;Non-renal clearance component 
   (0,30)   ;Volume of central compartment distribution 
   (0.1,1.5)   ;Volume of peripheral compartment distribution 
   (0.1,1.5,200)  ;Inter-compartmental clearance 
   (0,0.5)   ; KA  
   (0,0.5)   ;Renal clearance component 
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   (0,1,5)   ;CL for missing situation 
   (0,0.8,1)   ;F1 
 
$OMEGA  
0.2  ; between subject variability of CL  
0.2  ; between subject variability of V2  
     
$SIGMA  
0.1  ; initial estimate of proportional residual error for ward patients   
130  ; initial estimate of additive residual error for ward patients   
0.1  ; initial estimate of proportional residual error for ICU patients   
 
$ESTIMATION  MAXEVAL=5000  PRINT=10 METHOD=1 INTERACTION 
SIGDIG=3 POSTHOC  
 
$COV 
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 APPENDIX B.3 RELEVANT PART OF THE NONMEM CODE FOR CITALOPRAM 
COVARIATE MODEL (1-COMPATMENT MODEL USING FOCEI METHOD) 
 
$SUB ADVAN2 TRANS2 
$PK 
   
        TVCL1 = THETA(1)*(WT/80)**THETA(5) 
        TVCL =TVCL1*(AGE/60)**THETA(4) 
        CL   = TVCL*EXP(ETA(1)) 
        TVV = THETA(2) 
        V   = TVV*EXP(ETA(2)) 
        TVKA  = THETA(3) 
        KA    = TVKA*EXP(ETA(3))    
       S2   = V 
       K    = CL/V 
     
$THETA 
    (0,10)   ;CL 
    (0,2000);V   
    (0,0.5);KA 
    (,-0.5,) ;AGE   
    (,2,) ;WT 
 
$ERROR 
     IPRED=F 
     IRES =F-DV 
     Y = F*(1+ERR(1))+ERR(2) 
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$OMEGA  
     0.1 
     0.1 
     1 FIXED 
    
$SIGMA 
     0.1 
     3 
 
$EST METH=1 INTERACTION MAX=9999 PRINT=5 NOABORT POSTHOC SLOW 
MSFO=c1aw4.msf 
 
$COV 
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APPENDIX B.4 CYP2D6 GENOTYPING PROTOCOL 
The CYP2D6 genotyping study has been briefly presented in the submitted manuscript in chapter 
4, including specific primers, restriction enzyme, restriction pattern and agarose gel. The other 
detail method information and related results in the CYP2D6 genotyping study, which wasn’t 
included in the manuscript, are shown below:  
 
1: DNA Extraction 
After separating lymphocytes from whole blood using BD Vacutainer CPTTM tubes, 
DNA is extracted using the standard procedure.138, 139 In brief, thawed lymphocyte pellets are 
resuspended in cell lysis buffer (0.01 M Tris-HCl pH 7.4, 0.32 M sucrose, 5 mM MgCl2, 1% 
Triton X100). The tubes are centrifuged at 3300 g for 20 min at 4°C. The supernatant is 
discarded and each pellet of cell nuclei is resuspended in nuclei lysis buffer (0.4 M Tris-HCl pH 
8.0, 0.06 M EDTA, 400 mM NaCl). Next, the cell lysates are digested overnight at 37°C by 
adding 200 µl of 10% sodium dodecyl sulfate (SDS) and 500 µl of proteinase-K solution (2 mg 
protease K in 1 % SDS and 2 mM EDTA). Then 1 ml of 6 M NaCL is added and sample is 
centrifuged at 2500 g for 15 min. Supernatant containing DNA is transferred to a polypropylene 
tube. DNA is ethanol precipitated and resuspended in 200 – 1000 µl Tris-EDTA buffer (pH 8.0). 
Genomic DNA fractions are stored at -20°C. 
 
2: CYP2D6 alleles’ Amplification  
A polymerase chain reaction (PCR)-based allele-specific analysis described before,140 
will be used. To determine whether individuals are carrying duplicated CYP2D6 genes, long 
PCR will be used to amplify a fragment spanning the potential crossing-over sites.140, 141   
Amplification reactions are performed on a MJ PCR System in 0.2 ml thin-walled tubes. 
The 25 µl PCR mix for CYP2D6 allele’s amplification (CYP2D6 *4, *5, *10, *17, and 
CYP2D6*XN) is shown in Table 4.1.a. The PCR conditions for each allele’s amplification are 
provided below: 
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Table B4.1: PCR mix (25µl) for CYP2D6 allele amplifications 
Long PCR 2D6 (5kb)  Nest PCR *2, *4, *10 *17  Long PCR *5 and 
*XN 
 1 x (µl)   1 x (µl)    1 x (µl) 
dNTP 4  dNTP 4 4  dNTP 4
5ΧBuffer  5  10ΧBuffer  2.5 2.5  5ΧBuffer  5
50 mM Mg2+ -  50 mM Mg2+ 0.5 0.375  50 mM 
Mg2+ 
-
5M GC 2.5  5M GC - -  5M GC 2.5
H2O 6  H2O 13.8 13.9  H2O 5.5
DNA 
template 
(MTLD-2 
sample) 
4  DNA template 
(long PCR 
product) 
1 1 1 DNA 
template 
(MTLD-2 
sample) 
4
GC rich Taq  0.5  Invitro Taq  0.2 0.2  GC rich 
Taq  
1
Primer F 1.5  Primer F 1.5 1.5  Primer F 1.5
Primer R 1.5  Primer R 1.5 1.5  Primer R 1.5
  
CYP2D6 (5kb), CYP2D6*XN (gene duplication) and CYP2D6*5 (deletion) allele 
Amplification reactions are performed on a MJ PCR System. The PCR conditions include 
initial denaturation at 95 °C for 4 min, followed by 39 PCR cycles of denaturation at 94.8 °C for 
30 s, annealing at 54.5 °C for 30 s, synthesis at 72 °C for 4.5 min. The program ends with a final 
extension at 72°C for 5 min.  
 
CYP2D6*2 (C2938T), *4 (G1934A), *10 (G4268C) and *10 (C188T) allele 
*2 and *4: Amplification reactions are performed on a MJ PCR System. The PCR 
conditions include initial denaturation at 95 °C for 3 min, followed by 39 PCR cycles of 
denaturation at 94.8 °C for 30 s, annealing at 56 °C for 30 s, synthesis at 72 °C for 30 s. The 
program ends with a final extension at 72°C for 1 min. 
 
*10 (G4268C): Amplification reactions are performed on a MJ PCR System. The PCR 
conditions include initial denaturation at 95 °C for 3 min, followed by 38 PCR cycles of 
denaturation at 94.8 °C for 30 s, annealing at 58 °C for 30 s, synthesis at 72 °C for 30 s. The 
program ends with a final extension at 72°C for 1 min. 
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*10 (C188T): Amplification reactions are performed on a MJ PCR System. The PCR 
conditions include initial denaturation at 95 °C for 3 min, followed by 38 PCR cycles of 
denaturation at 94.8 °C for 30 s, annealing at 58.5 °C for 30 s, synthesis at 72 °C for 30 s. The 
program ends with a final extension at 72°C for 1 min. 
 
CYP2D6*17 allele specific PCR 
*17: Amplification reactions are performed on a MJ PCR System. The PCR conditions 
include initial denaturation at 95 °C for 3 min, followed by 27 PCR cycles of denaturation at 
94.8 °C for 30 s, annealing at 57.5 °C (wt) or 58 °C (mut) for 30 s, synthesis at 72 °C for 30 s. 
The program ends with a final extension at 72°C for 1 min. 
 
3: Nest PCR product digestion  
The digestion buffer for each CYP2D6 allele is presented in Table 4.1.b. Mixing 7 µl 
Digestion buffer with15 µl DNA products and followed by overnight digestion. Then load on gel 
after mixing with 4 µl orange dye.  
Table B4.2. Digestion Buffers for CYP2D6 alleles 
 CYP2D6 Allele  
 (Mutation)  
*2 
 (C2938T) 
*4 
(G1934A) 
*10 
 (C188T) 
*10 
(G4268C) 
cfo I or Hha I Bst NI HphI BstEII 
0.225 0.23 0.6 0.23 
 Restriction enzyme  Name 
                                 Volume (µl) 
                               Activity (KU/ml) 20  10  5  10  
 Temperature (°C) 37 60 37 60 
 Buffer 2.25 (Buf4) 2.25 (Buf2) 2.25 (NEB4) 2.25 
 BSA 0.23 0.23 - - 
 H2O 5.02 4.8 4.62 5.02 
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APPENDIX B.5 RELEVANT PART OF THE NONMEM CODE FOR PAROXETINE 
COVARIATE MODEL 
$SUBROUTINES ADVAN9 TOL=5 
$MODEL COMP=(GUT, DEFDOS), COMP=(CENTRAL, DEFOBS), 
COMP=(PERIPH) 
 
$PK 
IF (GENO.EQ.0) TVVM=THETA(1) ;Vm for subjects with missing 2D6 genotype 
information 
IF (GENO.EQ.1) TVVM=THETA(7) ;Vm for PMs 
IF (GENO.EQ.2) TVVM=THETA(8) ;Vm for IMs 
IF (GENO.EQ.3) TVVM=THETA(9) ;Vm for EMs 
IF (GENO.EQ.4) TVVM=THETA(10)  ;Vm for UMs 
 
   TVVM1=TVVM*(WT/75)**THETA(11)  
   VM=TVVM1*EXP(ETA(1)) 
   KM=THETA(2)*EXP(ETA(2)) 
   TVV21=THETA(3) 
   TVV2=TVV21+(1-SEX)*THETA(12)   
   V2=TVV2*EXP(ETA(3)) 
   V3=THETA(4) 
   Q=THETA(5) 
    S2=V2 
   KA=THETA(6) 
   
$DES 
   CON=A(2)/V2 
   CL=VM/(KM+CON) 
   DADT(1)=-KA*A(1) 
   DADT(2)=KA*A(1)-A(2)*CL/V2-A(2)*Q/V2+A(3)*Q/V3 
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   DADT(3)=-A(3)*Q/V3+A(2)*Q/V2 
 
$ERROR 
        IPRED=F 
        IRES=DV-IPRED 
       Y=F*(1+ERR(1)) + ERR(2) 
 
$THETA 
    (0,200,3000);VM 
    (0,20);KM 
    (20,200);V2 
    (20,200);V3 
    (0,20);Q 
    (0,10);KA  
    (0,10);PM 
    (0,10);IM 
    (0,10);EM 
    (0,10);UM 
    (0,0.5);WT 
    (,10,);SEX 
 
$OMEGA   
0.1  ; between subject variability of Vm   
0.1   ; between subject variability of Km 
0.6  ; between subject variability of V2 
 
$SIGMA  
0.1  ; initial estimate of proportional residual error  
10  ; initial estimate of additive residual error 
 
$COV 
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$EST SIG=3 MAX=9999 PRINT=10 NOABORT METHOD=0 POSTHOC 
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APPENDIX B.6 RELEVANT S SCRIPT FOR ADHERENCE RATE CALCULATION 
#  Below is the S code for weekly adherence rate pattern calculation  
 
# Total subjects 
subj.vec <- unique(df11$ID) 
nsubj <- length(subj.vec) 
 
# Calculate weekly adherence rate pattern (7 days) 
rate <- 7  
for (isubj in 1:nsubj){  
#  isubj <- 1 
 ###Extract data for isubj## 
 TF.subj<-df11$ID==subj.vec[isubj] 
 tmp.df<-df11[TF.subj,] 
 # Total rows for the isubj 
 nEV <-nrow(tmp.df)  
  
# Temp variables 
j <- x <- 1 
for (iEV in j:nEV){ 
   # Record for each PK sample (MDV=0) 
 if(any(tmp.df$MDV[iEV]==0)){ 
      # Calculate total rows within one week before PK sample (Clinical visit) 
       nDV.tmp <- iEV-x 
  # T.dose is used to calculate total dose within each time frame 
       T.dose <- 0 
        # Select the time frame before each PK sample (one week) 
       Time.df <- tmp.df$Time1.tmp[iEV]-rate 
  for (iDV.tmp in 1:nDV.tmp){ 
   TF.ad1 <- tmp.df$Time1.tmp[iEV-iDV.tmp]>Time.df 
      if(any(TF.ad1)){ 
            # Total MEMS opening: could be more than 7 
      T.dose <- tmp.df$MDV[iEV-iDV.tmp]+T.dose  
       }  
     } 
         # Calculate weekly adherence rate pattern  
   tmp.df$ADH7[iEV] <- T.dose/rate #  
       # Change to the next searching point (next PK sampling)  
   j <- x <- iEV+1  
 } 
  } 
 df11[TF.subj, ]<- tmp.df 
 } 
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